Document:

Form of Series BB Preferred Stock Warrant of the Registrant

 Exhibit 4.4B 
 FORM OF COMMON STOCK WARRANT 
 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH
SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

			
	Warrant No.: BB-            	  	Number of Shares:             
	Date of Issuance: March 12, 2008	  	(subject to adjustment)

 JAZZ PHARMACEUTICALS, INC. WARRANT NO. BB-__ 
 Common Stock Warrant 
 This
Warrant No. BB-             (this “Warrant”) of Jazz Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for value received, hereby
certifies that             , the holder of this Warrant, or its registered assigns (the “Registered Holder”), is entitled, subject to the terms set forth below, to
purchase from the Company, at any time after the date hereof and on or before the Expiration Date (as defined in Section 6 below), up to              shares of Common Stock of
the Company (“Common Stock”), at a purchase price of $20.36 per share. The shares purchasable upon exercise of this Warrant and the purchase price per share, as adjusted from time to time pursuant to the provisions of this Warrant,
are hereinafter referred to as the “Warrant Stock” and the “Purchase Price,” respectively. 
 This Warrant
was part of a series of warrants to purchase in the aggregate 8,695,652 shares of the Company’s Series BB Preferred Stock (the Warrant together such other warrants collectively referred to herein as the “Series BB Warrants”)
originally issued pursuant to that certain Senior Secured Note and Warrant Purchase Agreement, dated June 24, 2005, by and among the Company and the initial holders of the Series BB Warrants (the “Purchase Agreement”). On
June 6, 2007, the Company completed an initial public offering of shares of Common Stock (the “IPO”). In connection with the IPO, (a) the Company completed a 1-for-11.06701 reverse stock split of its Common Stock and
Preferred Stock and (b) all shares of the Company’s Preferred Stock were converted into shares of Common Stock immediately prior to the closing of the IPO (the “Adjustment Events”). As a result of the Adjustment Events,
the Series BB Warrants became exercisable for an aggregate of 785,728 shares of Common Stock at a purchase price of $20.36 per share (the Series BB Warrants, as so adjusted, collectively referred to herein as the “Common Stock
Warrants”). In connection with the issuance of this Warrant to the Registered Holder, this Warrant has been appropriately modified from the form of the original Series BB Warrants to give effect to the Adjustment Events. 

 1. Exercise. 
 (a) Manner of Exercise. This Warrant may be exercised by the Registered Holder, in whole or in part, by surrendering this
Warrant, with the exercise form appended hereto as Exhibit A duly executed by such Registered Holder, at the principal office of the Company, or at such other office or agency as the Company may designate, accompanied by payment in full
of the Purchase Price payable in respect of the number of shares of Warrant Stock purchased upon such exercise unless exercised pursuant to the Net Issue Exercise provisions of Section 1(c) below. The Purchase Price may be paid by cash, check,
or wire transfer. 
 (b) Effective Time of Exercise. Each exercise of this Warrant shall be deemed to have been
effected immediately prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 1(a) above. At such time, the person or persons in whose name or names any certificates for
Warrant Stock shall be issuable upon such exercise as provided in Section 1(d) below shall be deemed to have become the holder or holders of record of the Warrant Stock represented by such certificates. 
 (c) Net Issue Exercise. 
 (i) In lieu of exercising this Warrant in the manner provided above in Section 1(a), the Registered Holder may elect to receive shares equal to the value of this Warrant (or the portion of this Warrant being
canceled) by surrender of this Warrant at the principal office of the Company together with notice of such election on the exercise form appended hereto as Exhibit A duly executed by such Registered Holder, in which event the Company shall
issue to such Registered Holder a number of shares of Warrant Stock computed using the following formula: 
  

			
		  	 X = Y (A-B)
       A

		
	 Where
	  	X = The number of shares of Warrant Stock to be issued to the Registered Holder.
		
		  	Y = The number of shares of Warrant Stock purchasable under this Warrant (at the date of such calculation).
		
		  	A = The fair market value of one share of Warrant Stock (at the date of such calculation).
		
		  	B = The Purchase Price (as adjusted through the date of such calculation).

 (ii) For purposes of this Section 1(c), the fair market value of Warrant Stock
on the date of calculation shall mean with respect to each share of Warrant Stock: 
 (A) if the Common Stock is traded on a
securities exchange, including The NASDAQ Stock Market, the fair market value shall be deemed to be the closing price on the date of calculation (or, if there are no sales for such date, then on the last date on which there were sales); or

  

 B-1 

 (B) if the Common Stock is actively traded over the counter, the fair market value shall
be deemed to be the closing bid or sales price (whichever is applicable) on the date of calculation (or, if the date of calculation is not a trading day, the last trading day prior to the date of calculation); or 
 (C) if neither (A) nor (B) is applicable, the fair market value of Warrant Stock shall be determined in good faith by the
Company’s Board of Directors. 
 (d) Delivery to Registered Holder. As soon as practicable after the
exercise of this Warrant in whole or in part, and in any event within ten (10) days thereafter, the Company at its expense will cause to be issued in the name of, and delivered to, the Registered Holder, or as such Registered Holder (upon
payment by such Registered Holder of any applicable transfer taxes) may direct: 
 (i) a certificate or certificates for the
number of shares of Warrant Stock to which such Registered Holder shall be entitled, and 
 (ii) in case such exercise is in
part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on the face or faces thereof for the number of shares of Warrant Stock equal (without giving effect to any adjustment therein) to the number of such
shares called for on the face of this Warrant minus the number of such shares purchased by the Registered Holder upon such exercise as provided in Section 1(a) or 1(c) above. 
 2. Adjustments. 
 (a) Stock Splits and Dividends. If the outstanding shares of Warrant Stock shall be subdivided into a greater number of shares or a dividend in Warrant Stock shall be paid in respect of Warrant Stock, the Purchase Price in
effect immediately prior to such subdivision or at the record date of such dividend shall simultaneously with the effectiveness of such subdivision or immediately after the record date of such dividend be proportionately reduced. If outstanding
shares of Warrant Stock shall be combined into a smaller number of shares, the Purchase Price in effect immediately prior to such combination shall, simultaneously with the effectiveness of such combination, be proportionately increased. When any
adjustment is required to be made in the Purchase Price, the number of shares of Warrant Stock purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (i) an amount equal to the number of shares
issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase Price in effect immediately after such adjustment.

 (b) Reclassification, Etc. In case there occurs any reclassification or change of the outstanding securities
of the Company or of any reorganization of the Company (or any other corporation the stock or securities of which are at the time receivable upon the exercise of this Warrant) or any similar corporate reorganization on or after the date hereof, then
and in each such case the Registered Holder, upon the exercise hereof at any time after the consummation of 

  

 B-2 

 
such reclassification, change, or reorganization, shall be entitled to receive, in lieu of the stock or other securities and property receivable upon the
exercise hereof prior to such consummation, the stock or other securities or property to which such Registered Holder would have been entitled upon such consummation if such Registered Holder had exercised this Warrant immediately prior thereto, all
subject to further adjustment pursuant to the provisions of this Section 2. 
 (c) Adjustment Certificate.
When any adjustment is required to be made in the Warrant Stock or the Purchase Price pursuant to this Section 2, the Company shall promptly mail to the Registered Holder a certificate setting forth (i) a brief statement of the facts
requiring such adjustment, (ii) the Purchase Price after such adjustment and (iii) the kind and amount of stock or other securities or property into which this Warrant shall be exercisable after such adjustment. 
 3. Transfers. 
 (a) Unregistered Security. Each holder of this Warrant acknowledges that this Warrant and the Warrant Stock have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and
agrees that in no event will it dispose of all or any portion of this Warrant or the Warrant Stock unless and until (a) it has complied with the provisions of Section 3(b) below, and (b) if reasonably requested by the Company, the
Registered Holder shall have furnished the Company with an opinion of counsel reasonably satisfactory in form and substance to the Company and the Company’s counsel to the effect that (x) such disposition will not require registration
under the Securities Act and (y) appropriate action necessary for compliance with the Securities Act and any applicable state, local, or foreign law has been taken. Without limiting the foregoing, the Registered Holder, by accepting this
Warrant, agrees that it may transfer this Warrant (or any portion hereof) only to one of its Affiliates (as defined in the Purchase Agreement) or to any other person or entity that is acceptable to the Company, provided that, in the case of any
transfer, the applicable transferee must agree in writing to be subject to the terms of this Warrant and the Investor Rights Agreement (as such terms are defined below); provided, however, that, except with respect to transfers to its
Affiliates, the Registered Holder hereby covenants not to effect such transfer if such transfer either would invalidate the securities laws exemptions pursuant to which this Warrant was originally offered and sold or would itself require
registration and/or qualification under the Securities Act or applicable state securities laws. Each certificate evidencing this Warrant transferred as provided above shall bear an appropriate restrictive legend substantially to the foregoing
effect. 
 For purposes of this Warrant, “Investor Rights Agreement” means that certain Third Amended and Restated Investor
Rights Agreement, dated as of June 6, 2007, by and among the Company, the investors in the Company’s Series A Preferred Stock, Series B Preferred Stock and Series B Prime Preferred Stock, the holders of the Common Stock Warrants (and any
shares issued upon exercise of such warrants) and certain other holders of Common Stock. 
 (b) Transferability.
Subject to the provisions of this Section 3 and the provisions of Section 5, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of the Warrant with a properly executed assignment in the form of
Exhibit B hereto at the principal office of the Company. Any purported transfer of all or any portion of this Warrant in violation of the provisions of this Warrant shall be null and void. 
  

 B-3 

 (c) Warrant Register. The Company will maintain a register containing the
names and addresses of the Registered Holders of this Warrant and all other Common Stock Warrants. Until any transfer of this Warrant is made in the warrant register, the Company may treat the Registered Holder of this Warrant as the absolute owner
hereof for all purposes; provided, however, that if this Warrant is properly assigned in blank, the Company may (but shall not be required to) treat the bearer hereof as the absolute owner hereof for all purposes, notwithstanding any
notice to the contrary. Any Registered Holder may change such Registered Holder’s address as shown on the warrant register by written notice to the Company requesting such change. 
 4. Representations and Warranties of the Registered Holder. The Registered Holder hereby represents and warrants to the Company that:

 (a) Authorization. The Registered Holder has full power and authority to enter into, and perform its
obligations under, this Warrant. This Warrant, when executed and delivered by the Registered Holder, will constitute a valid and legally binding obligation of the Registered Holder, enforceable in accordance with its terms, except as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of
specific performance, injunctive relief, or other equitable remedies. 
 (b) Purchase Entirely for Own Account.
This Warrant is issued to the Registered Holder in reliance upon the Registered Holder’s representation to the Company, which by the Registered Holder’s acceptance of this Warrant, the Registered Holder hereby confirms, that the Warrant to
be acquired by the Registered Holder and the Warrant Stock (collectively, the “Securities”) will be acquired for investment for the Registered Holder’s own account, not as a nominee or agent, and not with a view to the resale
or distribution of any part thereof, and that the Registered Holder has no present intention of selling, granting any participation in, or otherwise distributing the same. By accepting this Warrant, the Registered Holder further represents that the
Registered Holder does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Securities. The Registered
Holder has not been formed for the specific purpose of acquiring the Securities. 
 (c) Disclosure of
Information. The Registered Holder has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions of the offering of the Securities with the Company’s management and has had an
opportunity to review the Company’s facilities. The Registered Holder understands that such discussions, as well as any written information delivered by the Company to the Registered Holder, were intended to describe the aspects of the
Company’s business which it believes to be material. 
 (d) Restricted Securities. The Registered Holder
understands that the Securities have not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide
nature of the investment intent and the accuracy of the Registered Holder’s representations as expressed herein. The Registered Holder understands that 

  

 B-4 

 
the Securities are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Registered
Holder must hold the Securities indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The
Registered Holder acknowledges that the Company has no obligation to register or qualify the Securities for resale. The Registered Holder further acknowledges that if an exemption from registration or qualification is available, it may be
conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the Registered Holder’s control, and which
the Company is under no obligation and may not be able to satisfy. 
 (e) Accredited Investor. The Registered
Holder is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 
 5.
Market Standoff. 
 (a) Market Standoff. The Registered Holder hereby agrees that, if so requested
by the Company and the Underwriter’s Representative (as defined below), if any, the Registered Holder shall not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of this Warrant or other
securities of the Company (“Market Standoff”) without the prior written consent of the Company and the Underwriter’s Representative for such period of time (a) not to exceed one hundred eighty (180) days following the
effective date of a Registration Statement of the Company filed under the Securities Act in the case of the IPO or (b) commencing with the date the Company provides notice to the Registered Holder of a proposed follow-on offering and ending 90
days after the effective date of the Registration Statement or, in the event of a shelf registration, the date of the prospectus for such follow-on offering, as may be requested by the Underwriter’s Representative; provided, however, that the
Registered Holder shall not be required to agree to a Market Standoff for a period of time that commences less than thirty (30) days after the expiration of another period of time during which the Registered Holder has agreed to a Market
Standoff. The obligations of the Registered Holder under this Section 5 shall be conditioned upon similar agreements being in effect with each other stockholder of the Company who is an officer, or director or, with respect only to the
Company’s initial public offering, greater than 1% stockholder of the Company prior to such initial public offering. For purposes of this Warrant, the “Underwriter’s Representative” is the representative the underwriter or
underwriters selected for the underwriting of a public offering of the Company’s securities. 
 (b) Stop-Transfer
Instructions. In order to enforce the covenants set forth in Section 3 and Section 5(a), the Company may impose stop-transfer instructions with respect to the securities of the Registered Holder (and the securities of every other
person subject to the restrictions in Section 3 and Section 5(a)). 
  

 B-5 

 6. Termination. This Warrant (and the right to purchase securities upon exercise hereof)
shall terminate on June 24, 2012 (the “Expiration Date”). 
 7. Notices of Certain Transactions. In the
event that the Company shall propose at any time to: 
 (a) declare any dividend or distribution upon the Common Stock,
whether in cash, property, stock, or other securities, whether or not a regular cash dividend and whether or not out of earnings or earned surplus; 
 (b) offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; 
 (c) effect any reclassification or recapitalization of the Common Stock or Preferred Stock outstanding involving a change in the Common
Stock or Preferred Stock; 
 (d) merge or consolidate with or into any other partnership, corporation, business trust, joint
stock company, trust, unincorporated association, joint venture, governmental authority or other entity of whatever nature; or 
 (e) sell, lease, or convey all or substantially all its assets, property or business, or to liquidate, dissolve, or wind up the Company; then, in connection with each such event, the Company shall send to the Registered Holder (in
accordance with the provisions of Section 23): 
 (i) at least twenty (20) days’ prior written notice of the
date on which a record shall be taken for such dividend, distribution or subscription rights (and specifying the date on which the holders of Common Stock shall be entitled thereto) or for determining rights to vote in respect of the matters
referred to in (c), (d) and (e) above; and 
 (ii) in the case of the matters referred to in (c), (d) and
(e) above, at least 20 days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property
deliverable upon the occurrence of such event or the record date for the determination of such holders if such record date is earlier). 
 8.
Reservation of Stock. The Company will at all times reserve and keep available, solely for the issuance and delivery upon the exercise of this Warrant, such shares of Warrant Stock and other stock, securities and property, as from time
to time shall be issuable upon the exercise of this Warrant. 
 9. Exchange of Warrants. Upon the surrender by the Registered
Holder of any Warrant or Warrants, properly endorsed, to the Company at the principal office of the Company, the Company will, subject to the provisions of Section 3 hereof, issue and deliver to or upon the order of such Registered Holder, at
the Company’s expense, a new Warrant or Warrants of like tenor, in the name of such Registered Holder, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock called for on the face or faces of the Warrant
or Warrants so surrendered. 
  

 B-6 

 10. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company,
or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 
 11. No Rights as Stockholder. Until the exercise of this Warrant, the Registered Holder of this Warrant shall not have or exercise any rights by virtue hereof as a stockholder of the Company. 

12. Additional Rights. Upon exercise of this Warrant, the Registered Holder shall have and be entitled to exercise the rights granted to
the signatories who are holders of the Common Stock issued upon conversion of the Company’s Series BB Preferred Stock under the Investor Rights Agreement. By its receipt of this Warrant, the Registered Holder agrees to be bound by the Investor
Rights Agreement. 
 13. No Fractional Shares. No fractional shares of Common Stock will be issued in connection with any
exercise hereunder. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the fair market value of one share of Common Stock on the date of exercise, as
determined in good faith by the Company’s Board of Directors. 
 14. Amendment or Waiver. Any term of the Common Stock
Warrants may be amended or waived only by an instrument in writing signed by the Company and the holders of Common Stock Warrants covering at least sixty-five percent (65%) of the number of shares of Common Stock subject to Common Stock
Warrants outstanding at the time of such amendment or waiver. 
 15. Headings. The headings in this Warrant are for purposes of
reference only and shall not limit or otherwise affect the meaning of any provision of this Warrant. 
 16. Governing Law. This
Warrant shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law. 
 17. Survival of Representations. Unless otherwise set forth in this Warrant, the warranties, representations and covenants of the Company and the Purchasers contained in or made pursuant to this Warrant
shall survive the execution and delivery of this Warrant. 
 18. Transfer; Successors and Assigns. The terms and conditions of
this Warrant shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties provided that they have complied with the terms and conditions herein. Nothing in this Warrant, express or implied, is
intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Warrant, except as expressly provided in this Warrant.

 19. Counterparts. This Warrant may be executed in two or more counterparts, each of which shall be deemed an original and
all of which together shall constitute one instrument. 
  

 B-7 

 20. Attorney’s Fees. If any action at law or in equity (including arbitration) is
necessary to enforce or interpret the terms of any of this Warrant, the prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.

 21. Severability. If one or more provisions of this Warrant are held to be unenforceable under applicable law, the parties
agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be excluded from this Warrant, (b) the balance
of this Warrant shall be interpreted as if such provision were so excluded and (c) the balance of this Warrant shall be enforceable in accordance with its terms. 
 22. Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Warrant, upon any breach or default of any other party under this Warrant, shall
impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring;
nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or
default under this Warrant, or any waiver on the part of any party of any provisions or conditions of this Warrant, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this
Warrant or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 23. Notices. All notices
required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient,
or if not, then on the next business day; (iii) one day after deposit with a nationally (or internationally) recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices to the Company shall be
sent to the Company’s principal place of business. All notices to the Registered Holder shall be sent to the address as set forth on the signature page of this Warrant or at such other address as the Registered Holder may designate pursuant to
Section 3(c) by ten (10) days’ advance notice to the Company. 
 24. Entire Agreement. This Warrant and the
documents and agreements referred to herein (including the Investor Rights Agreement) constitute the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to
the subject matter hereof existing between the parties hereto are expressly canceled. 
  

 B-8 

			
	JAZZ PHARMACEUTICALS, INC.
		
	By:	 	 
	Name:	 	 
	Title:	 	 
	Address:	 	 3180 Porter Drive
 Palo Alto, CA
94304

		
	Fax Number:	 	 (650) 496-3781

  

			
	Accepted and Agreed:
	
	REGISTERED HOLDER
	
	 
		
	By:	 	 
		 	Name:
		 	Title
	Address:	 	

 [Signature Page to Common Stock Warrant] 
  

 B-9 

 EXHIBIT A 
 EXERCISE FORM 
  

			
	 To:   Jazz Pharmaceuticals, Inc.
	 	Dated:
                                        
    

 The undersigned, pursuant to the provisions set forth in the attached Warrant No. BB-16, hereby
irrevocably elects to (a) purchase              shares of Common Stock covered by such Warrant and herewith makes payment of
$            , representing the full purchase price for such shares at the price per share provided for in such Warrant, or (b) exercise such Warrant for
             shares purchasable under the Warrant pursuant to the Net Issue Exercise provisions of Section 1(c) of the Warrant. 
 The undersigned acknowledges that it has reviewed the representations and warranties contained in Section 4 of the Warrant and by its signature
below hereby makes such representations and warranties to the Company as of the date hereof. 
  

			
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 
		
	Name of Entity:	 	 

 EXHIBIT B 
 ASSIGNMENT FORM 
 FOR VALUE RECEIVED,
                                        
                                        
         hereby sells, assigns and transfers all of the rights of the undersigned transferor under the attached Warrant with respect to the number of shares of Common Stock covered thereby set forth below,
unto: 
  

					
	 Name of Assignee
	 	 Address/Fax Number
	 	 No. of Shares

  
 The undersigned transferor
represents that it has complied with all of the provisions of the attached Warrant governing the transfer of such Warrant, including without limitation the provisions of Section 3 thereof, and acknowledges that any purported transfer of all or
any part of such Warrant in violation of the terms of the attached Warrant shall be null and void. 
  

									
				
	Dated:
                                        
                    	 		 	By:	 	 
					
		 		 		 	Name:	 	 
					
		 		 		 	Title:	 	 

 The undersigned transferee of the attached Warrant acknowledges the limitations on transfer of the
attached Warrant, including without limitation those contained in Section 3 thereof, agrees to be bound by the terms of the attached Warrant and the Investor Rights Agreement (as defined in the attached Warrant) to the same extent as if the
undersigned transferee were the initial holder of the attached Warrant, and shall deliver to the Company together with this assignment form a counterpart signature page to the Investor Rights Agreement. 
  

									
				
	Dated:
                                        
                        	 		 	By:	 	 
					
		 		 		 	Name:	 	 
					
		 		 		 	Title:Senior Secured Note and Warrant Purchase Agreement

 Exhibit 4.5A 
 EXECUTION COPY 
  
  
  
 JPI COMMERCIAL, LLC 
 $150,000,000 
 15% Senior Secured Notes due
June 24, 2011 
 GUARANTEED AND ACCOMPANIED WITH WARRANTS
ISSUED BY 
 JAZZ PHARMACEUTICALS, INC. 
  
  
 SENIOR SECURED NOTE AND WARRANT PURCHASE AGREEMENT 
  
  
 Dated as of March 14, 2008 
  
  
  
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 Table of Contents 
  

					
	 	  	 	  	Page
	 SECTION 1.
	  	Authorization, Sale and Issuance of Notes and Warrants	  	2
			
	 Section 1.1
	  	Authorization	  	2
	 Section 1.2
	  	Sale and Purchase of the Notes and Warrants	  	2
	 Section 1.3
	  	Closings	  	4
	 Section 1.4
	  	Payment Terms of the Notes	  	5
			
	 SECTION 2.
	  	Company Guaranty	  	5
			
	 Section 2.1
	  	Background	  	5
	 Section 2.2
	  	Company Guaranty	  	5
	 Section 2.3
	  	No Fraudulent Conveyance	  	6
	 Section 2.4
	  	Unconditional Guaranty	  	6
	 Section 2.5
	  	Waiver	  	7
	 Section 2.6
	  	Authorization	  	7
	 Section 2.7
	  	Responsibility	  	8
	 Section 2.8
	  	Consent	  	8
	 Section 2.9
	  	Transfer	  	8
	 Section 2.10
	  	Continuation	  	8
	 Section 2.11
	  	Subrogation	  	9
	 Section 2.12
	  	Subordination	  	9
			
	 SECTION 3.
	  	Security Interests	  	9
	 Section 3.1
	  	Grant of Security Interests	  	9
	 Section 3.2
	  	Perfection of Security Interests	  	10
	 Section 3.3
	  	Possession of Collateral and Related Matters	  	11
	 Section 3.4
	  	Continuing Security Interest; Termination	  	11
			
	 SECTION 4.
	  	Conditions to Closing	  	11
			
	 Section 4.1
	  	Conditions to Initial Closing	  	11
	 Section 4.2
	  	Conditions to the Subsequent Closing	  	12
	 Section 4.3
	  	Conditions to Each Closing	  	13
			
	 SECTION 5.
	  	Representations and Warranties of the Company and the Borrower	  	13
			
	 Section 5.1
	  	Organization; Power and Authority	  	13
	 Section 5.2
	  	Authorization, Etc.	  	14
	 Section 5.3
	  	Disclosure	  	14
	 Section 5.4
	  	Capitalization; Subsidiaries	  	14
	 Section 5.5
	  	Financial Statements	  	15
	 Section 5.6
	  	Compliance with Laws, Other Instruments, Etc.	  	15
	 Section 5.7
	  	Governmental Authorizations, Etc.	  	16
	 Section 5.8
	  	Litigation; Observance of Agreements, Statutes and Orders	  	16

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 i

					
	 Section 5.9
	  	Taxes	  	16
	 Section 5.10
	  	Title to Property; Leases	  	17
	 Section 5.11
	  	Intellectual Property, Licenses, Permits, Etc.	  	17
	 Section 5.12
	  	Compliance with ERISA	  	17
	 Section 5.13
	  	Private Offering by the Company	  	18
	 Section 5.14
	  	Use of Proceeds	  	19
	 Section 5.15
	  	Existing Indebtedness; Future Liens	  	19
	 Section 5.16
	  	Foreign Assets Control Regulations, Etc.	  	19
	 Section 5.17
	  	Status under Certain Statutes	  	19
	 Section 5.18
	  	Environmental Matters	  	20
	 Section 5.19
	  	Names	  	20
	 Section 5.20
	  	Locations; FEIN	  	20
	 Section 5.21
	  	Solvency	  	20
	 Section 5.22
	  	Status of Security Interest	  	21
	 Section 5.23
	  	Compliance with Settlement Agreements	  	21
			
	 SECTION 6.
	  	Representations of the Purchasers	  	21
			
	 Section 6.1
	  	Representations to the Borrower and the Company	  	21
	 Section 6.2
	  	Exculpation of the Purchasers	  	23
			
	 SECTION 7.
	  	Information as to the Company	  	23
			
	 Section 7.1
	  	Financial and Business Information	  	23
	 Section 7.2
	  	Officer’s Certificate	  	26
	 Section 7.3
	  	Inspection	  	26
	 Section 7.4
	  	Executive Management Access	  	26
			
	 SECTION 8.
	  	Prepayment of the Notes	  	26
			
	 Section 8.1
	  	Required Prepayments	  	26
	 Section 8.2
	  	Optional Prepayments with Make-Whole Amount	  	27
	 Section 8.3
	  	Contingent Required Redemption	  	28
	 Section 8.4
	  	Maturity, Surrender, Etc.	  	28
			
	 SECTION 9.
	  	Affirmative Covenants	  	28
			
	 Section 9.1
	  	Compliance with Law	  	28
	 Section 9.2
	  	Insurance	  	28
	 Section 9.3
	  	Maintenance of Properties	  	29
	 Section 9.4
	  	Payment of Taxes and Claims	  	29
	 Section 9.5
	  	Corporate or Limited Liability Company Existence, Etc.	  	29
	 Section 9.6
	  	Minimum Cash Balance	  	30
	 Section 9.7
	  	Subsidiary Documentation	  	30
	 Section 9.8
	  	Perfection and Maintenance of Security Interests	  	31
	 Section 9.9
	  	Collateral Locations	  	31
	 Section 9.10
	  	Compliance with Settlement Agreements	  	32

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 ii

					
	 SECTION 10.
	  	Negative Covenants	  	32
			
	 Section 10.1
	  	Limitations on Indebtedness	  	32
	 Section 10.2
	  	Mergers, Consolidations and Dispositions	  	34
	 Section 10.3
	  	Limitation on Liens	  	36
	 Section 10.4
	  	Restricted Payments	  	36
	 Section 10.5
	  	Subsidiaries, Acquisitions and Investments	  	37
	 Section 10.6
	  	Transactions with Affiliates	  	37
	 Section 10.7
	  	JPI Commercial License Agreements	  	37
	 Section 10.8
	  	Corporate Documents	  	38
	 Section 10.9
	  	Settlement Agreements	  	38
	 Section 10.10
	  	Orphan	  	38
			
	 SECTION 11.
	  	Events of Default	  	38
			
	 SECTION 12.
	  	Remedies on Default, Etc.	  	41
			
	 Section 12.1
	  	Acceleration	  	41
	 Section 12.2
	  	Other Remedies	  	41
	 Section 12.3
	  	Certain Remedies as to Collateral	  	41
	 Section 12.4
	  	Appointment of Attorney-in-Fact	  	42
	 Section 12.5
	  	Limitation on Duty of the Collateral Agent with Respect to Collateral	  	43
	 Section 12.6
	  	Application of Proceeds	  	43
	 Section 12.7
	  	License of Intellectual Property	  	43
	 Section 12.8
	  	No Waivers or Election of Remedies, Expenses, Etc.	  	44
	 Section 12.9
	  	Revocation of Jazz Commercial License Agreements	  	44
			
	 SECTION 13.
	  	Registration; Transfer; Substitution of Notes	  	44
			
	 Section 13.1
	  	Registration of Notes	  	44
	 Section 13.2
	  	Transfer of Notes	  	44
	 Section 13.3
	  	Replacement of Notes	  	45
	 Section 13.4
	  	Securitization	  	45
			
	 SECTION 14.
	  	Payments on Notes	  	45
			
	 Section 14.1
	  	Place of Payment	  	45
	 Section 14.2
	  	Home Office Payment	  	45
			
	 SECTION 15.
	  	Expenses, Etc.	  	46
			
	 Section 15.1
	  	Fees; Transaction Expenses	  	46
	 Section 15.2
	  	Survival	  	46
			
	 SECTION 16.
	  	Survival of Representations and Warranties; Entire Agreement	  	46
			
	 SECTION 17.
	  	Amendment and Waiver	  	47
			
	 Section 17.1
	  	Requirements	  	47
	 Section 17.2
	  	Solicitation of Holders of Notes	  	47
	 Section 17.3
	  	Binding Effect, Etc.	  	48

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 iii

					
	 Section 17.4
	  	Notes Held by Company, Etc	  	48
			
	 SECTION 18.
	  	Notices	  	48
			
	 SECTION 19.
	  	Reproduction of Documents	  	49
			
	 SECTION 20.
	  	Confidential Information	  	49
			
	 SECTION 21.
	  	The Collateral Agent	  	50
			
	 Section 21.1
	  	Appointment; Nature of Relationship	  	50
	 Section 21.2
	  	Powers	  	50
	 Section 21.3
	  	General Immunity	  	51
	 Section 21.4
	  	No Responsibility for Loans, Creditworthiness, Collateral, Recitals, Etc	  	51
	 Section 21.5
	  	Action on Instructions of Purchasers	  	51
	 Section 21.6
	  	Employment of Collateral Agents and Counsel	  	51
	 Section 21.7
	  	Reliance on Documents; Counsel	  	52
	 Section 21.8
	  	The Collateral Agent's Reimbursement and Indemnification	  	52
	 Section 21.9
	  	Rights as a Purchaser	  	52
	 Section 21.10
	  	Successor Collateral Agent	  	52
	 Section 21.11
	  	Collateral Documents	  	53
			
	 SECTION 22.
	  	Miscellaneous	  	54
			
	 Section 22.1
	  	Successors and Assigns	  	54
	 Section 22.2
	  	Payments Due on Non-Business Days	  	54
	 Section 22.3
	  	Headings	  	54
	 Section 22.4
	  	Severability	  	54
	 Section 22.5
	  	Construction	  	54
	 Section 22.6
	  	Counterparts	  	54
	 Section 22.7
	  	Governing Law	  	54
	 Section 22.8
	  	Waiver of Jury Trial	  	54
	 Section 22.9
	  	Indemnity	  	55

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 iv

					
	SCHEDULE A	  	—	  	Information Relating To Purchasers
			
	SCHEDULE B	  	—	  	Defined Terms
			
	SCHEDULE C	  	—	  	Material Adverse Events
			
	EXHIBIT A - 1	  	—	  	Form of 15% Senior Secured Tranche A Note due June 24, 2011
			
	EXHIBIT A - 2	  	—	  	Form of 15% Senior Secured Tranche B Note due June 24, 2011
			
	EXHIBIT B	  	—	  	Form of Warrant to Purchase Common Stock
			
	EXHIBIT C	  	—	  	Form of Xyrem License Agreement
			
	EXHIBIT D	  	—	  	Form of Antizol License Agreement
			
	EXHIBIT E	  	—	  	Form of LUVOX® CR License Agreement
			
	EXHIBIT F	  	—	  	Certain Antizol Contracts
			
	EXHIBIT G	  	—	  	Certain LUVOX® CR Contracts
			
	EXHIBIT H	  	—	  	Certain Xyrem Contracts
			
	EXHIBIT I	  	—	  	Form of Orphan Asset Transfer Agreement
			
	EXHIBIT J	  	—	  	Form of Registration Rights Agreement
			
	EXHIBIT K	  	—	  	Form of Agreement of Merger
			
	EXHIBIT 4.1(a)	  	—	  	List of Closing Deliverables for Initial Closing
			
	EXHIBIT 4.2(a)	  	—	  	List of Closing Deliverables for Subsequent Closing

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 v

 Dated as of March 14, 2008 
 TO EACH PURCHASER LISTED ON THE ATTACHED 
     SCHEDULE A WHO IS A SIGNATORY HERETO (COLLECTIVELY WITH
THEIR RESPECTIVE 
     SUCCESSORS AND ASSIGNS,
THE “PURCHASERS”): 
 Ladies and Gentlemen: 
 THIS SENIOR SECURED NOTE AND WARRANT PURCHASE
AGREEMENT (this “Agreement”) is hereby entered into by and among the Purchasers, JAZZ PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and
JPI COMMERCIAL, LLC, a Delaware limited liability company (the “Borrower”), with reference to the following: 
  

	 	 A.
	 The Company has organized the Borrower, a wholly owned Subsidiary of Company, to acquire the Transferred Orphan Assets
from Orphan Medical, LLC (“Orphan”), a wholly owned Subsidiary of the Company, and to acquire and hold the LUVOX® CR Intellectual Property. 

  

	 	 B.
	 The Purchasers have agreed, subject to the terms and conditions hereof, to furnish debt financing to the Borrower by way
of the purchase of the Borrower’s senior secured notes in order to provide the Company with funds (1) for the acquisition of the LUVOX® CR Assets and the marketing and
distribution of LUVOX® CR in the United States, (2) to enable the Company to refinance certain Indebtedness of Orphan owing to the holders of the Orphan Notes, which Indebtedness is
guaranteed by the Company and secured by, among other things, certain of the Transferred Orphan Assets, and (3) for general corporate purposes. 

  

	 	D.	Certain capitalized terms used in this Agreement are defined in Schedule B; references to a “Schedule” or an “Exhibit” are, unless otherwise
specified, to a Schedule or an Exhibit attached to this Agreement. 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 1

 NOW THEREFORE, the Purchasers, the Company and the Borrower hereby agree as
follows: 
 SECTION 1. AUTHORIZATION, SALE AND ISSUANCE OF NOTES
AND WARRANTS. 
 Section 1.1 Authorization. 
 (a) The Borrower has authorized the issue and sale of up to $150,000,000 aggregate principal amount of its 15% Senior Secured Notes (the
“Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13 of this Agreement) due June 24, 2011, which shall be comprised of up to $70,000,000 of Tranche A Notes (the
“Tranche A Notes”) and $80,000,000 of Tranche B Notes (the “Tranche B Notes” and, together with the Tranche A Notes, the “Notes”). The Tranche A Notes shall be substantially in the form set forth on
Exhibit A-1 and the Tranche B Notes shall be substantially in the form set forth in Exhibit A-2. 
 (b) The
Company has further authorized the issuance and sale to each Purchaser of Warrants (the “Warrants”, such term to include any such warrants issued in substitution therefor pursuant to the terms thereof) to purchase common stock, par
value $0.0001 per share, of the Company (“Common Stock”), each substantially in the form set forth in Exhibit B. 
 Section 1.2 Sale and Purchase of the Notes and Warrants. Subject to the terms and conditions of this Agreement: 
 (a) (i) The Borrower hereby agrees to issue and sell to each Purchaser signatory hereto at the Initial Closing, and each such Purchaser agrees to purchase from the Borrower, at the Initial Closing, a Tranche A Note in the aggregate
principal amount of Tranche A Notes to be purchased set forth opposite such Purchaser’s name on Schedule A attached hereto under the heading “INFORMATION RELATING TO PURCHASERS AT INITIAL CLOSING”, in each case at a purchase
price of 100% of the aggregate principal amount of such Tranche A Note. The Borrower further hereby agrees to issue to each such Purchaser a Tranche B Note, and each such Purchaser agrees to acquire from the Borrower, at the Initial Closing, a
Tranche B Note in the aggregate principal amount of Tranche B Notes to be exchanged set forth opposite such Purchaser’s name on Schedule A attached hereto under the heading “Purchasers at Initial Closing”, in each case in
exchange for an identical aggregate principal amount of Orphan Notes, which shall be all of the Orphan Notes held by such Purchaser. The aggregate principal amount of all Tranche A Notes issued and sold at the Initial Closing shall not exceed
$40,000,000. 
 (ii) The Borrower shall have the right, but not the obligation, to issue and sell, and the Purchasers set
forth on Schedule A under the heading “INFORMATION RELATING TO PURCHASERS AT SUBSEQUENT CLOSING”, or Affiliate(s) of such Purchasers designated thereby and reasonably acceptable to the Borrower, agree to purchase from the Borrower,
at the Subsequent Closing, Tranche A Notes in an aggregate principal amount (determined by the Borrower) not to exceed $30,000,000, at a purchase price of 100% of the aggregate principal amount of such Tranche A Notes. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 2

 (iii) Each Purchaser’s obligation hereunder is several and not joint with the other
Purchasers’ obligations such that no Purchaser shall have any obligation or liability to any Person for the performance or nonperformance by any other Purchaser hereunder. 
 (b) As further consideration for the purchase of the Tranche A Notes by the Purchasers pursuant to Section 1.2(a), and with
the Company’s express acknowledgement of its direct and indirect benefit received in connection with such financial accommodations, the Company agrees to issue and deliver at the applicable Closing to each Purchaser then purchasing a Tranche A
Note, a Warrant to purchase the number of shares of the Common Stock as determined as follows: 
 (i) with respect to the
Initial Closing, that number of shares of the Common Stock set forth opposite such Purchaser’s name on Schedule A attached hereto under the heading “INFORMATION RELATING TO PURCHASERS AT INITIAL CLOSING”; and 
 (ii) with respect to the Subsequent Closing, that number of shares of the Common Stock as shall equal the quotient obtained by dividing
(a) 20% of the principal amount of the Tranche A Note purchased by such Purchaser at the Subsequent Closing by (b) the Subsequent Closing Exercise Price (as defined below), and rounding down the resulting quotient to the nearest whole
share of Common Stock. 
 In the case of the Warrants issued at the Initial Closing, the exercise price per share of such Warrants shall be
$14.23. In the case of the Warrants issued at the Subsequent Closing, the exercise price per share shall be the greater of (i) $2.00 or (ii) the product of 1.2 times the volume weighted average closing price (as based on price
quotations published by a nationally recognized stock quotation service reasonably agreed upon by the Borrower, the Company and the applicable Purchaser) of the Company’s Common Stock for the period of 30 consecutive days ending on the date
notice of the Subsequent Closing is given pursuant to Section 1.3(a) (the “Subsequent Closing Exercise Price”). 
 (c) The Borrower, the Company and each Purchaser hereby acknowledge and agree that the Tranche A Notes and Warrants issued in accordance with this Agreement constitute an “investment unit” for the purposes of
Section 1273(c)(2)(A) of the Code. In accordance with Sections 1273(c)(2)(A) and 1273(b)(2) of the Code, the issue price of the investment unit is 100% of the aggregate principal amount of the Tranche A Note set forth opposite each such
Purchaser’s name on Schedule A. Allocating that issue price between the Tranche A Note and Warrant issued at the Initial Closing based on their relative fair market values, as required by Section 1273(c)(2)(B) of the Code and
Treasury Regulation Section 1.1273-2(h)(1), results in (i) the Tranche A Note having an 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 3

 
issue price of 95.06% of the aggregate principal amount of such Note and (ii) the Warrant having a purchase price of 4.94% of the aggregate principal
amount of such Tranche A Note. The allocation of the issue price for Tranche A Notes and Warrants issued at the Subsequent Closing shall be as reasonably agreed by the Borrower, the Company and the applicable Purchaser at the time of the Subsequent
Closing. The Borrower, the Company and each Purchaser agree to prepare their respective federal income tax returns in a manner consistent with the foregoing agreement. 
 Section 1.3 Closings. (a) The issuance and sale of the Tranche A Notes and the exchange of the Tranche B Notes, in each case pursuant to Section 1.2(a)(i), and the issuance and delivery of the
accompanying Warrants, shall occur at a closing (the “Initial Closing”) to be held at the offices of the Company, 3180 Porter Drive, Palo Alto, California 94304, at 10:00 a.m. local time, on March 17, 2008. The issuance and
sale of the Tranche A Notes pursuant to Section 1.2(a)(ii) (if any), and the issuance and delivery of the accompanying Warrants, shall occur at a closing (the “Subsequent Closing” and, together with the Initial Closing,
the “Closings”) to be held at the such offices of the Company, at 10:00 a.m. local time, on a Business Day determined by the Borrower and the Company and specified in a notice from the Borrower and the Company to the Purchaser of
such Tranche A Notes that the Borrower intends to issue and sell such Tranche A Notes and Warrants on such date, which in any case shall be not less than three Business Day after the date of delivery of such notice. Notwithstanding the foregoing,
the Initial Closing or the Subsequent Closing may be held at such other place and time as may be agreed upon by the Borrower, the Company, and all of the applicable Purchasers, except that the Subsequent Closing shall in no event occur after
January 31, 2009. For the avoidance of doubt, the Closings described in this Section 1.3 shall be subject in all cases to satisfaction of the conditions set forth in Section 4 hereof. 
 (b) At the Initial Closing, the Borrower will deliver to, or at the direction of, each Purchaser purchasing a Tranche A Note and/or
exchanging Tranche B Note at the Initial Closing a Tranche A Note in the form of a single Tranche A Note and/or a Tranche B Note in the form of a single Tranche B Note, as applicable, in each case dated the date of the Initial Closing and registered
in such Purchaser’s name, against (i) in the case of Tranche A Notes, delivery by such Purchaser to the Borrower of immediately available funds in the amount of the purchase price therefor by wire transfer to the account of the Borrower,
identified in writing by the Borrower prior to such Initial Closing, and (ii) in the case of Tranche B Notes, delivery of Orphan Notes in the aggregate principal amount of the Tranche B Notes to be exchanged therefor; provided that the Borrower
and any holder of Orphan Notes that is unable to deliver such Orphan Notes at the Initial Closing agree that, pending subsequent delivery of such Orphan Notes, such exchange shall for all purposes of this Agreement be deemed to have occurred at the
Initial Closing and the Borrower shall hold the Tranche B Notes to which such holder is entitled in trust for, and deliver the same to, such holder upon receipt of such Orphan Notes. It is expressly acknowledged and agreed by all of the parties to
this Agreement that (y) upon consummation of the issuance and sale of the Tranche A Notes and accompanying Warrants and the exchange (or deemed exchange) of the Tranche B Notes for Orphan Notes at the Initial Closing, all outstanding Orphan
Notes shall be continued as Tranche 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 4

 
B Notes hereunder and the Lien of the Collateral Agent on behalf of the holders of Orphan Notes shall be continued as security for the obligations of the
Credit Parties under this Agreement, the Notes, and the other Related Documents, and (z) all Orphan Notes (including any such Orphan Notes to be subsequently delivered as agreed pursuant to this paragraph (b)) shall be cancelled and no longer
be outstanding and the Orphan Note Purchase Agreement and the Related Documents (as defined in the Orphan Note Purchase Agreement) (other than the Warrants (as defined in the Orphan Note Purchase Agreement)) shall terminate and have no further force
or effect, except those provisions that are expressly stated to survive such termination or the payment of the Orphan Notes or expressly continued under the Related Documents (as defined herein). 
 (c) At the Subsequent Closing, the Borrower will deliver to or at the direction of the Purchaser purchasing a Tranche A Note at the
Subsequent Closing a Tranche A Note in the form of a single Tranche A Note, dated the date of the Subsequent Closing and registered in such Purchaser’s name, against delivery by such Purchaser to the Borrower of immediately available funds in
the amount of the purchase price therefor by wire transfer to the account of the Borrower, identified in writing by the Borrower prior to such Closing. 
 (d) At each Closing, the Company will deliver to or at the direction of each Purchaser purchasing a Tranche A Note at such Closing a Warrant dated the date of such Closing and registered in the name of such Purchaser,
and evidencing the right of such Purchaser to purchase that number of shares of the Company’s Common Stock as determined in accordance with the provisions of Section 1.2(b). 
 Section 1.4 Payment Terms of the Notes. The Notes shall bear interest, in the amounts and payable at the times set forth therein, and shall be due
and payable in full on the maturity date set forth therein or as otherwise provided for under this Agreement without defense, set off or counterclaim of any sort. All payments required to be made under the Notes shall be made in the manner and to
the account of each Purchaser as set forth in the Notes. 
 SECTION 2. COMPANY GUARANTY. 
 Section 2.1 Background. The Company hereby acknowledges and affirms that, as the sole beneficial owner of all of the membership interests of the
Borrower, it will directly or indirectly receive certain benefits from the credit accommodations provided for under this Agreement and is therefore willing to guaranty the prompt payment and performance of the Obligations of the Borrower, on the
terms set forth in this Section 2. 
 Section 2.2 Company Guaranty. For value received and in consideration for the
Purchasers’ execution of this Agreement and the purchase of the Notes, the Company unconditionally guarantees (a) the full and prompt payment when due, whether at maturity or earlier, by reason of acceleration or otherwise, and at all
times thereafter, of all of the indebtedness and obligations of every kind and nature of the Borrower to each Purchaser, or any permitted assignee of any Purchaser, pursuant to the terms of this Agreement and the other Related Documents, howsoever
created, arising or evidenced, whether direct or indirect, absolute 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 5

 
or contingent, joint or several, now or hereafter existing, or due or to become due, and howsoever owned, held or acquired by such Purchaser, whether through
discount, premium, purchase, direct loan or as collateral or otherwise, and whether principal, interest, fees, costs, expenses or otherwise (including without limitation any interest, Make-Whole Amount, fees or expenses accruing following the
commencement of any insolvency, receivership, reorganization or bankruptcy case or proceeding relating to the Borrower, whether or not a claim for post-petition interest, Make-Whole Amount, fees or expenses is allowed in such case or proceeding);
and (b) the prompt, full and faithful discharge by the Borrower of each and every term, condition, agreement, representation and warranty now or hereafter made by the Borrower to the Purchasers under this Agreement and the other Related
Documents (all such indebtedness and obligations listed in (a) and (b) of this sentence being hereinafter referred to as the “Obligations”). The Company further agrees to pay all reasonable out-of-pocket costs and
expenses, including, without limitation, all court costs and reasonable attorneys’ fees paid or incurred by any Purchaser in collecting all or any part of the Obligations from, or in prosecuting or defending any action against, the Company. All
amounts payable by the Company under this Section 2 shall be payable upon demand and shall be made in lawful money of the United States, in immediately available funds. 
 Section 2.3 No Fraudulent Conveyance. It is intended that the Company’s guaranty under this Section 2 (the “Company
Guaranty”), and any Liens granted by the Company to secure the Company Guaranty, do not constitute a “Fraudulent Conveyance” (as hereinafter defined). Consequently, the Company agrees that if the Company Guaranty, or any Liens
securing the Company Guaranty, would, but for the application of this sentence, constitute a Fraudulent Conveyance, the Company Guaranty and each such Lien shall be valid and enforceable only to the maximum extent that would not cause the Company
Guaranty or such Lien to constitute a Fraudulent Conveyance, and the Company Guaranty or the other Related Documents providing for such Lien shall automatically be deemed to have been amended accordingly at all relevant times. For purposes hereof,
“Fraudulent Conveyance” means a fraudulent conveyance under Section 548 of the Bankruptcy Code or a fraudulent conveyance or fraudulent transfer under the provisions of any applicable fraudulent conveyance or fraudulent
transfer law or similar law of any state, nation or other governmental unit, as in effect from time to time. 
 Section 2.4 Unconditional
Guaranty. The Company hereby agrees that its obligations under the Company Guaranty shall be unconditional, irrespective of (i) the validity or enforceability of the Obligations or any part thereof, or of any Notes, Related Documents or
other document evidencing all or any part of the Obligations, (ii) the absence of any attempt to collect from the Borrower or any other guarantor of all or any part of the Obligations or other action to enforce the same, (iii) the waiver
or consent by any Purchaser with respect to any provision of any instrument evidencing the Obligations, or any part thereof, or any other agreement heretofore, now or hereafter executed by the Borrower or any other guarantor of all or any part of
the Obligations, and delivered to such Purchaser, (iv) failure by any Purchaser or the Collateral Agent to take any steps to perfect and maintain its security interest in, or to preserve its rights to, any security or collateral for the
Obligations or any guaranty, (v) the existence or nonexistence of any defenses which may be available to the Borrower or any other guarantor of 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 6

 
all or any part of the Obligations, (vi) the institution of any proceeding under Chapter 11 of Title 11 of the United States Code (11 U.S.C. § 101
et seq.), as amended (the “Bankruptcy Code”), or any similar proceeding, by or against the Borrower or any other guarantor, or any Purchaser’s election in any such proceeding of the application of Section 1111(b)(2) of the
Bankruptcy Code, (vii) any borrowing or grant of a security interest by the Borrower, as debtor-in-possession, under Section 364 of the Bankruptcy Code (or use of cash collateral under Section 363 of the Bankruptcy Code),
(viii) the disallowance, under Section 502 of the Bankruptcy Code, of all or any portion of the Purchasers’ claim(s) for repayment of the Obligations, or (ix) any other circumstance which might otherwise constitute a legal or
equitable discharge or defense of a guarantor other than the indefeasible payment in full of all Obligations. 
 Section 2.5 Waiver.
The Company hereby waives diligence, presentment, demand of payment, filing of claims with a court in the event of receivership or bankruptcy of the Borrower or other guarantors, protest or notice with respect to the Obligations and all demands
whatsoever, and covenants that the Company Guaranty will not be discharged, except by complete and indefeasible payment and performance of the Obligations. The Company further waives notice of (i) acceptance of the Company Guaranty,
(ii) the existence or incurring from time to time of any Obligations guarantied hereunder, and (iii) the existence of any Default or Event of Default, the making of demand, nonpayment, or the taking of any action by any Purchaser or the
Collateral Agent, under this Agreement or any of the other Related Documents. At any time that the Notes become due and payable, whether by maturity or acceleration, any holder of a Note may, in its sole election (regardless of whether the liability
of Borrower or any other guarantor of all or any part of the Obligations has matured or may then be enforced), proceed directly and at once, without notice, against the Company to collect and recover the full amount or any portion of the
Obligations, without first proceeding against the Borrower or any other guarantor, or against any security or collateral for the Obligations. The Company agrees that the Company Guaranty constitutes a guarantee of payment when due and not of
collection. 
 Section 2.6 Authorization. The Purchasers and the Collateral Agent are hereby authorized, without notice or demand and
without affecting the liability of the Company hereunder, at any time and from time to time to (i) renew, extend, accelerate or otherwise change the time for payment of, or other terms relating to, the Obligations or otherwise modify, amend or
change the terms of this Agreement, any Note or any other Related Document (subject to the terms hereof and thereof), now or hereafter executed by the Borrower, the Company or any other guarantor and delivered to any of the Purchasers;
(ii) accept partial payments on the Obligations; (iii) take and hold security or collateral for the payment of the Obligations guaranteed hereby, or for the payment of the Company Guaranty, or for the payment of any other guaranties of the
Obligations, and exchange, enforce, waive and release any such security or collateral; (iv) apply such security or collateral and direct the order or manner of sale or other disposition thereof as in its discretion it may determine; and
(v) settle, release, compromise, collect or otherwise liquidate the Obligations and any security or collateral therefor in any manner, without affecting or impairing the obligations of the Company hereunder. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 7

 Section 2.7 Responsibility. The Company hereby assumes responsibility for keeping itself informed
of the financial condition of the Borrower and any and all endorsers and/or other guarantors of any instrument or document evidencing all or any part of the Obligations and of all other circumstances bearing upon the risk of nonpayment of the
Obligations or any part thereof, and the Company hereby agrees that neither the Purchasers nor the Collateral Agent shall have any duty to advise the Company of information known to any Purchaser or the Collateral Agent regarding such condition or
any such circumstances or to undertake any investigation. If any of the Purchasers or the Collateral Agent, each in their respective discretion, undertakes at any time or from time to time to provide any such information to the Company, such
Purchaser or the Collateral Agent, as applicable, shall be under no obligation to update any such information or to provide any such information to the Company on any subsequent occasion. The Company further acknowledges that the Company has
examined or had the opportunity to examine this Agreement and the other Related Documents, and waives any defense which may exist resulting from the Company’s failure to receive or examine at any time this Agreement or the other Related
Documents. 
 Section 2.8 Consent. The Company consents and agrees that none of the Purchasers or the Collateral Agent shall be under
any obligation to marshal any assets in favor of the Company or against or in payment of any or all of the Obligations. The Company further agrees that, to the extent that the Borrower, the Company or any other Person makes a payment or payments to
the Purchasers, or any Purchaser receives any proceeds of collateral, which payment or payments or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside and/or required to be repaid to the Borrower, its
estates, trustees, receivers or any other Person, including, without limitation, the Company, under any bankruptcy law, state or federal law, common law or equitable theory, then to the extent of such payment or repayment, the Obligations or the
part thereof which has been paid, reduced or satisfied by such amount, and the Company’s obligations hereunder with respect to such portion of the Obligations, shall be reinstated and continued in full force and effect as of the date such
initial payment, reduction or satisfaction occurred. 
 Section 2.9 Transfer. Subject to the provisions of Section 13, any
Purchaser may sell or assign the Obligations or any part thereof, or grant participations therein, pursuant to the terms of this Agreement and in any such event, each and every immediate or remote assignee or holder of, or participant in, all or any
of the Obligations shall have the right to enforce the Company Guaranty, by suit or otherwise, for the benefit of such assignee, holder or participant, as fully as if herein by name specifically given such right, but each Purchaser shall have an
unimpaired right, prior and superior to that of any such assignee, holder or participant, to enforce the Company Guaranty for the benefit of such Purchaser, as to any part of the Obligations retained by such Purchaser. 
 Section 2.10 Continuation. The Company Guaranty shall continue in full force and effect (and may not be revoked or terminated), and the Purchasers
shall be entitled to purchase the Notes on the faith hereof, until such time as all of the Obligations have been indefeasibly paid and satisfied in full. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 8

 Section 2.11 Subrogation. Any and all rights of any nature of the Company to subrogation,
contribution, reimbursement or indemnity and any right of the Company to recourse to any assets or property of, or payment from, the Borrower or any other guarantor of all or any part of the Obligations as a result of any payments made or to be made
hereunder for any reason, are hereby unconditionally waived by the Company, and the Company shall not at any time exercise any of such rights unless and until all of the Obligations have been indefeasibly paid and satisfied in full. Any payments
received by the Company in violation of this Section 2.11 shall be held in trust for, and immediately remitted to, the Purchasers. 
 Section 2.12 Subordination. The payment of any and all of indebtedness, liabilities and obligations of Borrower to the Company of every kind or nature, whether joint or several, due or to become due, absolute or contingent, now
existing or hereafter arising, and whether principal, interest, fees, costs, expenses or otherwise (collectively, the “Subordinated Debt”), is expressly subordinated to the Obligations. So long as an Event of Default exists, no
payment of any kind (by voluntary payment, prepayment, acceleration, setoff or otherwise) of any portion of the Subordinated Debt may be made by Borrower or received or accepted by the Company at any time. Until such time as the Obligations have
been indefeasibly paid and satisfied in full, the Company will not (i) obtain any Lien on any property of the Borrower to secure the Subordinated Debt, or (ii) commence any lawsuit, action or proceeding of any kind against the Borrower to
recover all or any part of the Subordinated Debt. Any payments received by the Company in violation of this Section 2.12 shall be held in trust for and immediately remitted to the Purchasers. 
 SECTION 3. SECURITY INTERESTS. 
 Section 3.1 Grant of Security Interests. To secure the full and prompt payment and performance of the Obligations and the Company Guaranty, including all renewals, extensions, restructurings and refinancings of any or all of the
foregoing, each of the Borrower and the Company hereby grants to the Collateral Agent, for the benefit of the holders of the Notes, a continuing Lien in and to all right, title and interest of Borrower and the Company in the following property,
respectively, of the Borrower and the Company, whether now owned or existing or hereafter acquired thereby or arising and regardless of where located, including the products and proceeds thereof (all being collectively referred to as the
“Collateral”): 
  

	 	i)	Accounts; 

  

	 	ii)	Deposit Accounts (as defined in the UCC); 

  

	 	iii)	Documents of Title; 

  

	 	iv)	Equipment; 

  

	 	v)	General Intangibles; 

  

	 	vi)	Inventory; 

  

	 	vii)	Investment Property; and 

  

	 	viii)	Other Collateral; 

 provided, however, that notwithstanding
any of the other provisions set forth in this Section 3, this Agreement shall not constitute a grant of a security interest in (a) any ownership interests of any Foreign Subsidiary or (b) any property to the extent that such
grant of a security interest is prohibited by any requirements of law of a Governmental Authority, requires a consent not obtained of any Governmental Authority pursuant to such requirement of law or is prohibited by, or constitutes a breach or
default under or results in the termination of or requires any consent 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 9

 
not obtained under, any contract, license, agreement, instrument or other document evidencing or giving rise to such property or any applicable shareholder
or similar agreement, except to the extent that such requirement of law or the term in such contract, license, agreement, instrument or other document or shareholder or similar agreement providing for such prohibition, breach, default or termination
or requiring such consent is ineffective under applicable law. 
 Section 3.2 Perfection of Security Interests. Each of the Borrower
and the Company hereby authorizes the Collateral Agent to prepare and file such financing statements or amendments thereof (including financing statements and amendments thereof describing the Collateral as “all assets” or “all
personal property” or words to that effect) as the Collateral Agent or the Purchasers may from time to time deem necessary or appropriate in order to perfect and maintain the security interests granted hereunder in accordance with the UCC or
the Uniform Commercial Code of any applicable jurisdiction. Each of the Borrower and the Company shall, at the Collateral Agent’s request, at any time and from time to time, execute and deliver to the Collateral Agent within ten
(10) Business Days of such request, such documents and other agreements and instruments (and pay the cost of filing or recording the same in all public offices deemed reasonably necessary or desirable by the Collateral Agent or the Purchasers)
and do such other acts and things as the Collateral Agent may deem necessary or desirable in order to establish and maintain a valid, attached and perfected security interest in the Collateral in favor of the Collateral Agent for the benefit of the
Purchasers (free and clear of all other liens, claims and rights of third parties whatsoever, whether voluntarily or involuntarily created, except as otherwise permitted by Section 10.3) to secure payment of the Obligations, and in order
to facilitate the collection of the Collateral. Each of the Borrower and the Company irrevocably hereby makes, constitutes and appoints the Collateral Agent (and all Persons designated by the Collateral Agent for that purpose) as the Borrower’s
and the Company’s respective true and lawful attorney and agent-in-fact to file such financing statements and other similar documents, agreements and instruments as may be necessary to preserve and perfect the Collateral Agent’s security
interest in the Collateral. Each of the Borrower and the Company acknowledges and agrees that the Collateral is intended to encompass all assets and property of Borrower and the Company (subject to the terms and conditions of this Agreement) and if
at any time Borrower or the Company acquires any interest in any assets or property a security interest in which cannot be perfected by the filing of a financing statement in the appropriate jurisdiction or any assets or property a security interest
in which can be perfected by the filing of a financing statement in the appropriate jurisdiction but that are not covered by the security interest grant set forth above (e.g., commercial tort claims, it being certified by Borrower or the Company
that it has no interest in any commercial tort claims as of the Initial Closing), then the Borrower or the Company, as appropriate, will, if reasonably requested by the Collateral Agent, cause such assets or property to become part of the Collateral
and take such reasonable steps as the Collateral Agent or the Purchasers may require in accordance with this Section 3.2. Each of the Borrower and the Company hereby agree to give the Collateral Agent prompt notice of any commercial tort
claim filed by the Company or any of its subsidiaries. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 10

 Section 3.3 Possession of Collateral and Related Matters. Until an Event of Default has occurred
and is continuing, both of the Borrower and the Company shall have the right, except as otherwise provided in this Agreement, to (a) sell or lease any of their Inventory normally held thereby for any such purpose, (b) use and consume any
raw materials, work in process or other materials normally held thereby for such purpose and (c) dispose of any assets to the extent permitted under Section 10.2. If any Inventory is in the possession or control of any warehouseman
or the Company’s or the Borrower’s, as applicable, agents or processors, then the Borrower or the Company, as applicable, shall, upon the Collateral Agent’s request, notify such warehouseman, agent or processor of the Collateral
Agent’s security interest in such Inventory and, upon the Collateral Agent’s request, instruct them to hold all such Inventory for the Collateral Agent’s account and subject to the Collateral Agent’s instructions. 
 Section 3.4 Continuing Security Interest; Termination. 
 (a) This Section 3 creates a continuing security interest in the Collateral and shall (i) remain in full force and effect
until the payment or satisfaction in full of the Obligations (other than any contingent indemnity obligations), (ii) be binding upon the Borrower and the Company, and their respective successors and assigns and (iii) except to the extent
that the rights of any transferor or assignor are limited by the terms of this Agreement, inure, together with the rights and remedies of the Collateral Agent, to the benefit of the Collateral Agent and the holders of Notes. The Borrower’s and
the Company’s successors and assigns shall include, without limitation, a receiver, trustee or debtor-in possession thereof or therefor. 
 (b) Upon the payment in full in cash of the Obligations (other than any contingent indemnity obligations), the security interests granted pursuant to this Section 3 shall terminate and all rights to the
Collateral shall revert to the Borrower and the Company, as applicable. Upon any such termination of the security interests hereunder, the Borrower and the Company shall each be entitled to the return, upon its request and at its expense, of such of
the Collateral held by the Collateral Agent as shall not have been sold or otherwise applied pursuant to the terms hereof and the Collateral Agent will, at the Borrower’s and the Company’s expense, execute and deliver to the Borrower or
the Company, as applicable such other documents as they shall reasonably request to evidence such termination. In connection with any transfers, sales or other dispositions of assets permitted under this Agreement or any other release of Collateral
that may be required in connection with any other action which is permitted by this Agreement, the Collateral Agent will release and terminate the Liens granted under this Agreement with respect to such assets. 
 SECTION 4. CONDITIONS TO CLOSING. 
 Section 4.1 Conditions to Initial Closing. Each Purchaser’s obligation to purchase, pay for, and exchange the Notes to be purchased and/or exchanged at the Initial Closing is subject to the fulfillment to
such Purchaser’s reasonable satisfaction, prior to or at the Initial Closing, of the following conditions: 
 (a)
Closing Deliveries. Such Purchaser shall have received, in form and substance reasonably satisfactory to it, all documents, instruments, agreements, opinions and certificates identified on Exhibit 4.1(a). 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 11

 (b) Consummation of the Orphan Merger and Orphan Asset Transfer. The Orphan Merger
shall have been consummated in accordance with the terms of the Orphan Merger Agreement, without any amendment, modification, or waiver that has not been agreed to by the Purchasers. All conditions necessary to consummate the Orphan Asset Transfer
under the Orphan Asset Transfer Agreement shall have been satisfied or waived (in a manner approved by the Purchasers), the parties to the Orphan Asset Transfer Agreement shall be prepared to and, simultaneously with the purchase and exchange of
such Notes shall, consummate the Orphan Asset Transfer and such Purchaser shall have received evidence of the foregoing reasonably satisfactory to it. 
 (c) Security Interests; Waivers and Consents. (i) Such Purchaser shall have received the results of recent lien, tax lien, judgment and litigation searches in each relevant jurisdiction with respect to the
Company, the Borrower, and Orphan and their respective Subsidiaries, and such searches shall reveal no Liens other than Permitted Liens or Liens that are being discharged on or prior to the consummation of the Initial Closing pursuant to
documentation reasonably satisfactory to such Purchaser. 
 (ii) All waivers, approvals or consents of Governmental
Authorities or other third parties as may be required by law or under contract to consummate the Orphan Asset Transfer and the transactions contemplated by this Agreement (including any necessary stockholder agreements, consents or waivers required
in connection with the issuance of the Warrants) shall have been obtained and shall be in full force and effect on such Closing Date, and such Purchaser shall have received evidence of the foregoing reasonably satisfactory to it. 
 (d) Fees and Expenses. The Company or the Borrower shall have paid (i) all invoiced fees and expenses of Pillsbury Winthrop
Shaw Pitman LLP, legal counsel to LB I Group Inc. in connection with the execution and delivery of this Agreement and the Closings, and (ii) to LB I Group Inc. all fees due and payable thereto under the Fee Letter. 
 Section 4.2 Conditions to the Subsequent Closing. The applicable Purchaser’s obligation to purchase and pay for the Notes to be sold thereto
at the Subsequent Closing is subject to the fulfillment to such Purchaser’s reasonable satisfaction, prior to or at the Subsequent Closing, of the following conditions: 
 (a) Consummation of the Initial Closing. The Initial Closing shall have occurred. 
 (b) Closing Deliveries. Such Purchaser shall have received, in form and substance reasonably satisfactory to it, all documents,
instruments, agreements, opinions and certificates identified on Exhibit 4.2(a). 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 12

 (c) Net Product Sales. The
Company shall have certified to such Purchaser, in a manner satisfactory to such Purchaser and with such supporting financial statements or other information as such Purchaser may reasonably request, that the year-to-date Net Product Sales for the
2008 fiscal year-to-date are greater than or equal to $[ * ], and the year-to-date Net Product Sales for LUVOX® CR for the 2008 fiscal year-to-date are greater than or equal to $[ * ].

 (d) Reservation of Additional Shares. The Company shall have reserved for issuance upon the exercise of the Warrants
to be issued at the Subsequent Closing the number of shares of its Common Stock which are purchasable upon such exercise. 
 Section 4.3
Conditions to Each Closing. In addition to the conditions set forth in Section 4.1 or Section 4.2, whichever is applicable, each Purchaser’s obligation to purchase and pay for the Notes to be sold thereto at any
Closing is subject to the fulfillment to such Purchaser’s reasonable satisfaction, prior to or at such Closing, of the following conditions: 
 (a) Representations and Warranties. The representations and warranties of the Company and the Borrower in this Agreement and the Related Agreements, which are qualified by their terms as to Materiality, shall
be correct, and all other representations and warranties of the Company and the Borrower in this Agreement and the Related Agreements shall be correct in all material respects, on and as of the date of such Closing (in the case of the Initial
Closing both before and after taking into account the effect of the Orphan Asset Transfer), except to the extent that such representations and warranties relate to an earlier date, in which case such representations and warranties shall be correct,
or correct in all material respects, as the case may be, as of such earlier date. 
 (b) Performance; No Default. Each
of the Company and the Borrower shall have performed and complied with all agreements and conditions contained in this Agreement required to be performed or complied with by it prior to or at the Closing, and after giving effect to the issue and
sale of the Notes (and the application of the proceeds thereof as contemplated by Schedule 5.14), the issue of the Warrants and the consummation of the Orphan Asset Transfer, no Default or Event of Default shall have occurred and be
continuing. 
 (c) No Material Adverse Effect. Except as set forth on Schedule C (it being understood and agreed
that the identification of an event on said schedule shall not be an admission or agreement that such event has in fact had, or could reasonably be expected to have, a Material Adverse Effect), nothing has occurred since December 31, 2006,
which could reasonably be expected to have a Material Adverse Effect. 
 SECTION 5. REPRESENTATIONS AND
WARRANTIES OF THE COMPANY AND THE BORROWER. 
 Each of the Company and the Borrower represents and warrants, jointly and severally, to the Purchasers that, as of the date hereof and at the Closing, both before and after giving effect to the Orphan Asset Transfer: 
 Section 5.1 Organization; Power and Authority. Each Credit Party is a corporation duly organized, validly existing and in good standing under the
laws of its jurisdiction of incorporation or formation, as applicable, and is duly qualified as a foreign corporation or limited liability company, as applicable, and is in good standing in each jurisdiction in which such qualification is required
by law, other than those jurisdictions as to which the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Each Credit Party has the corporate or
limited liability company power and authority, as the case may be, to own or hold under lease the properties it purports to own or hold under lease, to transact the business it transacts and proposes to transact, to execute and deliver this
Agreement and/or the other Related Documents to which it is a party, and to perform the provisions hereof and thereof. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 13

 Section 5.2 Authorization, Etc. This Agreement and the other Related Documents, and in the case of
the Borrower, the borrowing under the Notes, have been duly authorized by all necessary corporate or limited liability company action, as the case may be, on the part of each Credit Party signatory thereto, and this Agreement and such other Related
Documents each constitutes, and upon execution and delivery thereof, will constitute, a legal, valid and binding obligation of the each such Credit Party, as applicable, enforceable against such Credit Party, respectively, in accordance with its
terms, except as such enforceability may be limited by (a) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and (b) general principles of
equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
 Section 5.3 Disclosure. This
Agreement, the documents, certificates or other writings delivered to the Purchasers by or on behalf of the Company and the Borrower in connection with the transactions contemplated hereby and the financial statements listed in
Schedule 5.5, taken as a whole, do not contain any untrue statement of a material fact or omit to state any fact necessary to make the statements therein not materially misleading in light of the circumstances under which they were made.
Except as disclosed herein or therein, since December 31, 2006, there has been no change in the financial condition, operations, business or properties of the Company, the Borrower and any of their respective Subsidiaries, taken as a whole,
except changes that individually or in the aggregate would not reasonably be expected to have a Material Adverse Effect. There is no fact known to the Company or the Borrower that would reasonably be expected to have a Material Adverse Effect that
has not been set forth herein or in the other documents, certificates and other writings delivered to the Purchasers by or on behalf of the Company or the Borrower specifically for use in connection with the transactions contemplated hereby.

 Section 5.4 Capitalization; Subsidiaries. 
 (a) On the date of the Initial Closing, the authorized capital stock of the Company consists of: 
 (i) 20,000,000 shares of Preferred Stock, with a par value of $0.0001, none of which is issued or outstanding. 
 (ii) 150,000,000 shares of Common Stock, of which 24,620,829 shares have been duly and validly issued and are fully paid and
nonassessable. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 14

 (iii) The Company has reserved: (A) 562,192 shares of its Common Stock for issuance
upon the exercise of the Warrants issued at the Initial Closing; (B) 785,728 shares of its Common Stock for issuance upon the exercise of the Warrants (as defined in the Orphan Note Purchase Agreement); (C) 5,513,324 shares of Common Stock
for issuance under the Company’s 2003 Equity Incentive Plan and 2007 Equity Incentive Plan, of which 49,127 shares have been issued upon the exercise of options; (D) 630,325 shares of Common Stock for issuance under the Company’s 2007
Employee Stock Purchase Plan; and (E) 197,835 shares of Common Stock for issuance under the Company’s 2007 Non-Employee Directors’ Stock Option Plan. Options to purchase 3,405,633 shares of Common Stock have been granted under the
Company’s 2003 Equity Incentive Plan, 2007 Equity Incentive Plan, and 2007 Non-Employee Directors’ Stock Option Plan, and 115,898 shares of Restricted Units have been granted under such plans. Except as provided for under the Registration
Rights Agreement and that certain Third Amended and Restated Investor Rights Agreement dated as of June 6, 2007 by and among the Company, the investors party thereto, there are no outstanding rights of first refusal, preemptive rights, phantom
stock, stock appreciation rights or other rights, warrants, options, conversion privileges, subscriptions, or other rights or agreements, either directly or indirectly, to purchase or otherwise acquire or issue any equity securities of the Company.

 (b) On the date of the Initial Closing, the Company has no direct Subsidiaries other than the Borrower and Orphan. The
Company is the sole member of the Borrower and Orphan, and all of the outstanding membership interests of the Company in each of the Borrower and Orphan are owned by the Company free and clear of all Liens other than Permitted Liens. There are no
outstanding commitments or other obligations of the Borrower or Orphan to issue, and no options, warrants or other rights of any Person to acquire, any equity interests of the Borrower or Orphan. 
 Section 5.5 Financial Statements. The Company has delivered to each Purchaser copies of the financial statements of the Company and its
Subsidiaries listed on Schedule 5.5. All of said financial statements (including in each case the related schedules and notes) fairly present in all material respects the consolidated financial position of the Company and its
Subsidiaries as of the respective dates specified in such financial statements and the consolidated results of their operations and cash flows for the respective periods so specified and have been prepared in accordance with GAAP consistently
applied throughout the periods involved except as set forth in the notes thereto (subject, in the case of any interim financial statements, to normal year-end adjustments). 
 Section 5.6 Compliance with Laws, Other Instruments, Etc. The execution, delivery and performance by each Credit Party of the Related Documents to
which each such Credit Party is a party, including the Notes, in the case of the Borrower, and the Warrants, in the case of the Company, will not violate, contravene, result in any breach of, or constitute a default under, or result in the creation
of any Lien (other than Liens permitted by Section 10.3) in respect of any 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 15

 
property of such Credit Party under, (a) any indenture, mortgage, deed of trust, loan, purchase or credit agreement, lease, corporate charter or by-laws
or other organizational documents or constituent agreements, or any other agreement or instrument to which any Credit Party is bound or by which any Credit Party or any of their respective properties may be bound or affected, (b) any of the
terms, conditions or provisions of any order, judgment, decree, or ruling of any court, arbitrator or Governmental Authority applicable to any Credit Party or (c) any statute or other rule or regulation of any Governmental Authority applicable
to any Credit Party, in each case, except to the extent as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 Section 5.7 Governmental Authorizations, Etc. Except as disclosed in Schedule 5.7, no consent, approval or authorization of, or registration, filing or declaration with, or notice to any Governmental
Authority is required in connection with the execution, delivery or performance by each Credit Party of the Related Documents to which each such Credit Party is a party, including the Notes, in the case of the Borrower, and the Warrants, in the case
of the Company. 
 Section 5.8 Litigation; Observance of Agreements, Statutes and Orders. 
 (a) Except as disclosed in Schedule 5.8, there are no actions, suits or proceedings pending or, to the knowledge of the
Company or the Borrower, threatened against or affecting any Credit Party or the property of any Credit Party in any court or before any arbitrator of any kind or before or by any Governmental Authority that, individually or in the aggregate, could
reasonably be expected to have a Material Adverse Effect. 
 (b) No Credit Party is in default under any term of any agreement
or instrument to which it is a party or by which it is bound, or any order, judgment, decree or ruling of any court, arbitrator or Governmental Authority or is in violation of any applicable law, ordinance, rule or regulation (including without
limitation Environmental Laws) of any Governmental Authority, which default or violation, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 
 Section 5.9 Taxes. Each Credit Party has filed all tax returns that are required to have been filed by it in any jurisdiction, and has paid all
taxes shown to be due and payable on such returns and all other taxes and assessments levied upon it or its properties, assets, income or franchises, to the extent such taxes and assessments have become due and payable and before they have become
delinquent, except for any taxes and assessments (a) the amount of which is not individually or in the aggregate Material or (b) the amount, applicability or validity of which is currently being contested in good faith by appropriate
proceedings and with respect to which such Credit Party has established adequate reserves in accordance with GAAP. The charges, accruals and reserves on the books of the Borrower and the Company and their Subsidiaries in respect of Federal, state or
other taxes for all fiscal periods are adequate. Except as disclosed in Schedule 5.9, the Federal income tax liabilities of the Borrower, the Company and their respective Subsidiaries have been determined and paid for all fiscal years up to
and including the fiscal year ended December 31, 2006. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 16

 Section 5.10 Title to Property; Leases. The Credit Parties have good and sufficient title to their
respective properties that individually or in the aggregate are Material, including all such properties reflected in the most recent audited balance sheets referred to in Section 5.5 or purported to have been acquired by the Credit
Parties after said date (except as sold or otherwise disposed of in the ordinary course of business), in each case free and clear of Liens prohibited by this Agreement. All leases entered into by a Credit Party that individually or in the aggregate
are Material are valid and subsisting and are in full force and effect in all material respects. 
 Section 5.11 Intellectual Property,
Licenses, Permits, Etc. 
 (a) Schedule 5.11 sets forth, as of the date of the Initial Closing: 
 (i) all of the Credit Parties’ patents and patent applications, in-bound patent licenses, trademarks and trademark applications,
in-bound trademark licenses, copyrights and copyright applications and in-bound copyright licenses, including the description thereof, the name of the registered owner, the jurisdiction of such registration and the registration number; and

 (ii) with respect to the Antizol Assets, Xyrem Assets, LUVOX® CR Assets, Antizol Contracts, Xyrem Contracts and LUVOX® CR Contracts, all of the patents and patent applications, in-bound patent
licenses, trademarks and trademark applications, in-bound trademark licenses, copyrights and copyright applications and in-bound copyright licenses, including the description thereof, the name of the registered owner, the jurisdiction of such
registration and the registration number 
 (collectively, the “IP Rights”). 
 (b) Except as disclosed in Schedule 5.11, to the Knowledge of the Company: 
 (i) the Company and its Subsidiaries own or possess the IP Rights, without known conflict with the rights of others; 
 (ii) no Product of the Company or its Subsidiaries infringes in any Material respect any license, patent, copyright, service mark,
trademark, trade name or other intellectual property right owned by any other Person; and 
 (iii) there is no Material
violation by any Person of any right of the Company or any of its Subsidiaries with respect to any IP Rights. 
 Section 5.12 Compliance
with ERISA. 
 (a) The Company and each ERISA Affiliate have operated and administered each Plan in compliance with all
applicable laws except for such instances of noncompliance as have not resulted in and could not reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any ERISA Affiliate has incurred any liability pursuant to Title
I or IV of ERISA or the penalty or excise tax provisions of the 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 17

 
Code relating to employee benefit plans (as defined in Section 3 of ERISA), and no event, transaction or condition has occurred or exists that could
reasonably be expected to result in the incurrence of any such liability by the Company or any ERISA Affiliate, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate, in either case
pursuant to Title I or IV of ERISA or to such penalty or excise tax provisions or to Section 401(a)(29) or 412 of the Code, other than such liabilities or Liens as would not reasonably be expected to be, individually or in the aggregate,
Material. 
 (b) The present value of the aggregate benefit liabilities under each of the Plans (other than Multiemployer
Plans), determined as of the end of such Plan’s most recently ended plan year on the basis of the actuarial assumptions specified for funding purposes in such Plan’s most recent actuarial valuation report, did not exceed the aggregate
current value of the assets of such Plan allocable to such benefit liabilities. The term “benefit liabilities” has the meaning specified in Section 4001 of ERISA and the terms “current value” and “present value”
have the meaning specified in Section 3 of ERISA. 
 (c) The Company and its ERISA Affiliates have not incurred
withdrawal liabilities (and are not subject to contingent withdrawal liabilities) under Section 4201 or 4204 of ERISA in respect of Multiemployer Plans that remain unsatisfied or that, individually or in the aggregate, would reasonably be
expected to be Material. 
 (d) The expected post-retirement benefit obligation (determined as of the last day of the
Company’s most recently ended fiscal year in accordance with Financial Accounting Standards Board Statement No. 106, without regard to liabilities attributable to continuation coverage mandated by Section 4980B of the Code) of the
Company and its Subsidiaries is not Material. 
 (e) Assuming that the representations and warranties of the Purchasers set
forth in Section 6.1(e) are true and correct, the execution and delivery of this Agreement and the issuance and sale of the Notes hereunder will not involve any transaction that is subject to the prohibitions of Section 406 of ERISA
or in connection with which a tax could be imposed pursuant to Section 4975(c)(l)(A)-(D) of the Code. 
 Section 5.13 Private
Offering by the Company. Assuming that the representations and warranties of the Purchasers set forth in Section 6 are true and correct, the offering, issuance and delivery of the Notes, the Warrants and the shares of capital stock
issuable upon the exercise of the Warrants (collectively, the “Securities”) are exempt from the registration requirements of the Securities Act and the rules and regulations thereunder, and, except for the federal and state filings
set forth in Schedule 5.7, it is not necessary to make or obtain any filings, registrations, qualifications, notifications or consents or approvals of or with any Governmental Authority in connection therewith. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 18

 Section 5.14 Use of Proceeds. The Borrower
will apply the proceeds of the sale of the Notes to consummate the Orphan Asset Transfer, to make certain payments owing to Solvay Pharmaceuticals, Inc. (“Solvay”) under that certain License Agreement by and between Solvay and the Company
relating to LUVOX® CR dated January 31, 2007, to market and distribute LUVOX® CR and for general corporate purposes. No
Credit Party is engaged principally or as one of its activities, in the business of extending credit for the purpose of “purchasing” or “carrying” any “margin stock” as such terms are defined in Regulation U of the
Federal Reserve Board as now and from time to time hereafter in effect. None of the proceeds of the Notes will be used, directly or indirectly, for the purpose of purchasing or carrying any margin stock or for any other purpose which might cause any
of the Notes under this Agreement to be considered a “Purpose credit” within the meaning of Regulations T, U, or X of the Board of Governors of the Federal Reserve Board. 
 Section 5.15 Existing Indebtedness; Future Liens. 
 (a) Except as described therein, Schedule 5.15 sets forth a complete and correct list of all outstanding Indebtedness of each Credit Party as of the date of the Initial Closing. No Credit Party is in
default and no waiver of default is currently in effect, in the payment of any principal or interest on any Indebtedness of such Credit Party and no event or condition exists with respect to any Indebtedness of such Credit Party that would permit
(or that with notice or the lapse of time, or both, would permit) one or more Persons to cause such Indebtedness to become due and payable before its stated maturity or before its regularly scheduled dates of payment. 
 (b) Except as disclosed in Schedule 5.15, no Credit Party has agreed or consented to cause or permit in the future (upon the
happening of a contingency or otherwise) any of its property, whether now owned or hereafter acquired, to be subject to a Lien other than Permitted Liens. 
 Section 5.16 Foreign Assets Control Regulations, Etc. Neither the sale of the Notes by the Borrower hereunder nor its use of the proceeds thereof will violate the Trading with the Enemy Act, as amended, or any
of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling legislation or executive order relating thereto. Without limiting the foregoing, neither the Company nor
any of its Subsidiaries (a) is or will become a blocked person described in Section 1 of Executive Order 13224 of September 23, 2001 Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or
Support Terrorism (66 Fed. Reg. 49049 (2001)) or (b) engages or will engage in any dealings or transactions, or be otherwise associated, with any such person. 
 Section 5.17 Status under Certain Statutes. No Credit Party is an “investment company” registered or required to be registered subject
to regulation under the Investment Company Act of 1940, as amended, or is subject to regulation under the Public Utility Holding Company Act of 1935, as amended, or the Federal Power Act, as amended. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 19

 Section 5.18 Environmental Matters. Except as otherwise disclosed in Schedule 5.18:

 (a) the Company has no Knowledge of any claim, has received no notice of any claim, and no proceeding has been instituted
raising any claim against any Credit Party or any real properties now or formerly owned, leased or operated thereby, alleging any damage to the environment or violation of any Environmental Laws, except, in each case, such as would not reasonably be
expected to result in a Material Adverse Effect; 
 (b) the Company has no knowledge of any facts which would give rise to any
claim, public or private, of violation of Environmental Laws or damage to the environment emanating from, occurring on or in any way related to real properties now or formerly owned, leased or operated by any Credit Party or to other assets or their
use, except, in each case, such as would not reasonably be expected to result in a Material Adverse Effect; 
 (c) no Credit
Party has stored any Hazardous Materials on real properties now or formerly owned, leased or operated by any of them or has disposed of any Hazardous Materials in a manner contrary to any Environmental Laws in each case in any manner that would
reasonably be expected to result in a Material Adverse Effect; and 
 (d) all buildings on all real properties now owned,
leased or operated by any Credit Party are in compliance with applicable Environmental Laws, except where failure to comply could not reasonably be expected to result in a Material Adverse Effect. 
 Section 5.19 Names. Schedule 5.19 sets forth, as of the date of the Initial Closing, all names, trade names, fictitious names and business
names under which each Credit Party currently conducts its business or has at any time during the past five years conducted business. 
 Section 5.20 Locations; FEIN. Schedule 5.20 sets forth, as of the date of the Initial Closing, the state of organization of each Credit Party, location of each Credit Party’s chief executive office and principal place of
business, the location of all other offices of the Credit Parties, and all Collateral locations other than (a) locations of Inventory which has been delivered to clinical research organizations in connection with such Credit Party’s
clinical research or to physicians as a sample, in each case, in the ordinary course of such Credit Party’s business, or (b) locations of Equipment being used by employees and consultants of any Credit Party in the ordinary course of
business. Each Credit Party’s federal employer identification number and entity identification number in its respective state of incorporation, as of the date of the Initial Closing, is set forth on Schedule 5.20. 
 Section 5.21 Solvency. At each Closing, both before and after giving effect to the Orphan Asset Transfer and the transactions contemplated by this
Agreement and the other Related Documents, and, as of the date of this Agreement, each Credit Party: (a) owns assets the fair saleable value of which are (i) greater than the total amount of its liabilities (including contingent
liabilities) and (ii) greater than the amount that will be required to pay its probable liabilities as they mature; (b) has capital that is not unreasonably small in relation to its businesses as presently conducted or any contemplated or
undertaken transaction; and (c) does not intend to incur and does not believe that it will incur debts beyond its ability to pay such debts as they become due. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 20

 Section 5.22 Status of Security Interest. This Agreement creates in favor of the Collateral Agent
a legal, valid and enforceable security interest in the Collateral. When financing statements setting forth the Collateral and naming the Collateral Agent as the secured party and the Borrower and the Company, as the debtor, respectively, have been
filed with the Secretary of State of the State of Delaware against each of the Borrower and the Company, the Collateral Agent will have a fully perfected first priority Lien on, and security interest in, the Collateral in which a security interest
may be perfected by such filing, subject only to Permitted Liens. 
 Section 5.23 Compliance with Settlement Agreements. As of the
Initial Closing and the Subsequent Closing, both before and after giving effect to the Orphan Asset Transfer and the transactions contemplated by this Agreement and the other Related Documents, and, as of the date of this Agreement, each of the
Credit Parties and Orphan (a) is not, and at no previous time has been, in breach or default of any of its obligations under the (i) the Civil Settlement Agreement among the United States of America, Company and Orphan dated July 13,
2007 (the “Civil Settlement Agreement”), (ii) the Non-prosecution Agreement between the United States Attorney’s Office for the Eastern District of New York and Company dated July 13, 2007 (the
“Non-prosecution Agreement”), or (iii) the Plea Agreement between the United States Attorney’s Office for the Eastern District of New York and Orphan dated July 13, 2007 (the “Plea Agreement”), and
(b) is not, and at no previous time has been, in Material Breach or Default of any of its material obligations under the Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and
Company dated July 13, 2007 (the “Corporate Integrity Agreement” and, collectively with the Civil Settlement Agreement, the Non-prosecution Agreement and the Plea Agreement, the “Settlement Agreements”);
(c) has not received any notice of alleged breach, default, or non-compliance with respect to any provision of any of the Settlement Agreements; and (d) to the Company’s knowledge, has committed no act and has omitted to take no
action which would form, in whole or in part, a good faith basis for alleging that such Credit Party or Orphan is in breach or default (in the case of the Corporate Integrity Agreement, Material Breach or Default) of any of its obligations under the
Settlement Agreements. 
 SECTION 6. REPRESENTATIONS OF THE PURCHASERS. 
 Section 6.1 Representations to the Borrower and the Company. Each Purchaser represents and warrants to the Borrower and the Company, severally and
not jointly, with respect to its purchase of the Notes and, to the extent applicable, Warrants as follows: 
 (a) Purchaser is
purchasing the Note and Warrant for investment for Purchaser’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act. Purchaser is an
“accredited investor” as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and, in any case, has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and
risks of investing in the Securities. Purchaser has not been formed for the purpose of investing in the Securities. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 21

 (b) Purchaser understands that the Note and Warrant that Purchaser is purchasing have not
been registered under the Securities Act by reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Purchaser’s investment intent as expressed herein. 
 (c) Purchaser further acknowledges and understands that the Securities must be held indefinitely unless they are subsequently registered
under the Securities Act or an exemption from such registration is available and the Securities may be imprinted with a legend indicating such restrictions on the transferability thereof. 
 (d) Purchaser understands that the Securities are presently characterized as “restricted securities” under the federal
securities laws inasmuch as they are being acquired from the Company and the Borrower in a transaction not involving a public offering and that under such laws and applicable regulations, such securities may be resold without registration under the
Securities Act only in certain limited circumstances. In this connection, Purchaser represents that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 (e) Purchaser represents that at least one of the following statements is an accurate representation as to each source of
funds (a “Source”) to be used by such Purchaser to pay the purchase price of the Notes to be purchased by such Purchaser hereunder: 
 (i) if such Purchaser is an insurance company, the Source does not include assets allocated to any separate account maintained by you in which any employee benefit plan (or its related trust) has any interest, other
than a separate account that is maintained solely in connection with your fixed contractual obligations under which the amounts payable, or credited, to such plan and to any participant or beneficiary of such plan (including any annuitant) are not
affected in any manner by the investment performance of the separate account; or 
 (ii) the Source is either (i) an
insurance company pooled separate account, within the meaning of Prohibited Transaction Exemption (“PTE”) 90-1 (issued January 29, 1990), or (ii) a bank collective investment fund, within the meaning of the PTE 91-38
(issued July 12, 1991) and, except as Purchaser has disclosed to the Company in writing pursuant to this paragraph (b), no employee benefit plan or group of plans maintained by the same employer or employee organization beneficially owns more
than 10% of all assets allocated to such pooled separate account or collective investment fund; or 
 (iii) the Source
constitutes assets of an “investment fund” (within the meaning of Part V of the QPAM Exemption) managed by a “qualified professional asset manager” or “QPAM” (within the meaning of Part V of the QPAM Exemption), no
employee benefit plan’s assets that are included in such investment fund, when combined with the assets of all other employee benefit 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 22

 
plans established or maintained by the same employer or by an affiliate (within the meaning of Section V(c)(1) of the QPAM Exemption) of such employer or by
the same employee organization and managed by such QPAM, exceed 20% of the total client assets managed by such QPAM, the conditions of Part I(c) and (g) of the QPAM Exemption are satisfied, neither the QPAM nor a person controlling or
controlled by the QPAM (applying the definition of “control” in Section V(e) of the QPAM Exemption) owns a 5% or more interest in the Company and (x) the identity of such QPAM and (y) the names of all employee benefit plans whose
assets are included in such investment fund have been disclosed to the Company in writing pursuant to this paragraph (iii); or 
 (iv) the Source is a governmental plan; or 
 (v) the Source is one or more employee benefit plans, or a separate
account or trust fund comprised of one or more employee benefit plans, each of which has been identified to the Company in writing pursuant to this paragraph (v); or 
 (vi) the Source does not include assets of any employee benefit plan, other than a plan exempt from the coverage of ERISA. 
 As used in this Section 6.1, the terms “employee benefit plan,” “governmental plan,” “party in interest”
and “separate account” shall have the respective meanings assigned to such terms in Section 3 of ERISA. 
 Section
6.2 Exculpation of the Purchasers. Each Purchaser acknowledges that it is not relying upon any Person (including the Collateral Agent or any other Purchaser), other than the Company and its officers (acting in their respective capacities as
representatives of the Company), in deciding to invest and in making its investment in the purchase of the Notes and Warrants. Each Purchaser agrees that none of the Collateral Agent, the other Purchaser or any of their respective controlling
Persons, officers, directors, partners, agents or employees shall be liable to such Purchaser for any losses incurred by such Purchaser in connection with its purchase of the Notes and Warrants. 
 SECTION 7. INFORMATION AS TO THE COMPANY. 
 Section 7.1 Financial and Business Information. The Borrower and the Company, jointly and severally, agree to deliver to each holder of Notes:

 (a) Quarterly Statements. Within 45 days after the end of each quarterly fiscal period in each fiscal year of the
Company (other than the last quarterly fiscal period of each such fiscal year), copies of: 
 (i) a consolidated and, if
requested by the Majority Holders, consolidating balance sheet of the Company and its Subsidiaries as at the end of such quarter; and 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 23

 (ii) consolidated and, if requested by the Majority Holders, consolidating statements of
income, changes in stockholders’ equity and cash flows of the Company and its Subsidiaries for such quarter and (in the case of the second and third quarters) for the portion of the fiscal year ending with such quarter; 
 setting forth in each case in comparative form the figures for the corresponding periods in the previous fiscal year, all in reasonable detail, prepared
in accordance with GAAP applicable to quarterly financial statements generally, and certified by a Senior Financial Officer as fairly presenting, in all material respects, the financial position of the companies being reported on and their results
of operations and cash flows, subject to changes resulting from year-end adjustments. Filing of the Company’s quarterly reports on Form 10-Q under and in satisfaction of the Exchange Act shall, for purposes of this Section 7.1(a)
constitute delivery. 
 (b) Annual Statements. Within 90 days after the end of each fiscal year of the Company, copies
of, 
 (i) a consolidated and, if requested by the Majority Holders, consolidating balance sheet of the Company and its
Subsidiaries, as at the end of such year, and 
 (ii) consolidated and, if requested by the Majority Holders, consolidating
statements of income, changes in stockholders’ equity and cash flows of the Company and its Subsidiaries, for such year, 
 setting forth
in each case in comparative form the figures for the previous fiscal year, all in reasonable detail, prepared in accordance with GAAP, and accompanied by an opinion thereon of independent certified public accountants of recognized national standing,
which opinion shall state that such financial statements present fairly, in all material respects, the financial position of the companies being reported upon and their results of operations and cash flows and have been prepared in conformity with
GAAP, and that the examination of such accountants in connection with such financial statements has been made in accordance with generally accepted auditing standards, and that such audit provides a reasonable basis for such opinion in the
circumstances. Filing of the Company’s annual reports on Form 10-K under and in satisfaction of the Exchange Act shall, for purposes of this Section 7.1(b), constitute delivery. If requested by the Majority Holders, the reports in
this clause (b) shall be accompanied by any management letter prepared by the above-referenced accountants. 
 (c)
Notice of Default or Event of Default. Promptly, and in any event within five Business Days after a Responsible Officer becomes aware of the existence of any Default or Event of Default or that any Person has given any notice or taken any
action with respect to a claimed default hereunder or that any Person has given any notice or taken any action with respect to a claimed default of the type referred to in Section 11(f), a written notice specifying the nature and period
of existence thereof and what action the Company is taking or proposes to take with respect thereto; 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 24

 (d) ERISA Matters. Promptly, and in any event within five Business Days after a
Responsible Officer becomes aware of any of the following, a written notice setting forth the nature thereof and the action, if any, that the Company or an ERISA Affiliate proposes to take with respect thereto: 
 (i) with respect to any Plan (other than any Multiemployer Plan), any reportable event, as defined in Section 4043(b) of ERISA and
the regulations thereunder, for which notice thereof has not been waived pursuant to such regulations as in effect on the date hereof; or 
 (ii) the taking by the PBGC of steps to institute, or the threatening by the PBGC of the institution of, proceedings under Section 4042 of ERISA for the termination of, or the appointment of a trustee to
administer, any Plan (other than any Multiemployer Plan), or the receipt by the Company or any ERISA Affiliate of a notice from a Multiemployer Plan that such action has been taken by the PBGC with respect to such Multiemployer Plan; or 

(iii) any event, transaction or condition that could result in the incurrence of any liability by the Company or any ERISA Affiliate
pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit plans, or in the imposition of any Lien on any of the rights, properties or assets of the Company or any ERISA Affiliate pursuant to
Title I or IV of ERISA or such penalty or excise tax provisions, if such liability or Lien, taken together with any other such liabilities or Liens thereof then existing, could reasonably be expected to have a Material Adverse Effect; 
 (e) Notices of Certain Adverse Events. Promptly, and in any event within five Business Days after a Responsible Officer becomes
aware of any of the following, a written notice regarding: (i) the occurrence of any event or circumstance which has had or will likely have a Material Adverse Effect, (ii) the occurrence of any event or circumstance which is a matured and
un-waived material default under any third party agreement entered into by the Company or any of its Subsidiaries that is Material, (iii) the institution of any action, suit, proceeding, governmental investigation or arbitration which exposes
the Company or any of its Subsidiaries to a liability that is Material, and (iv) the receipt of any communications regarding potential or actual material defaults (whether waived or not) on any Indebtedness that is Material; and 
 (f) Requested Information. With reasonable promptness, such other materials, data and information relating to the business,
operations, affairs, financial condition, properties or prospects of the Company or any of its Subsidiaries as from time to time may be reasonably requested by any such holder of Notes in order to enable such holder to monitor the Borrower’s
and the Company’s progress in key areas; provided, however, that neither the Borrower nor the Company shall be obligated to provide such information as is comprised of privileged attorney client communications or that is particularly
sensitive confidential business material. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 25

 (g) Operating Plan and Budget. If requested by the Majority Holders, as soon as
available, and in any event within 30 days after the end of each fiscal year of the Company, a copy of the Company’s consolidated and, if so requested, consolidating budget for the such fiscal year, such budget to show the Company’s
projected consolidated and, if so requested by the Majority Holders, consolidating revenues, expenses, and balance sheet on a quarterly basis. 
 Section 7.2 Officer’s Certificate. Each set of financial statements delivered to a holder of Notes pursuant to Section 7.1(a) or Section 7.1(b) hereof shall be accompanied by a certificate of a Senior
Financial Officer setting forth a statement that such officer has reviewed the relevant terms hereof and has made, or caused to be made, under his or her supervision, a review of the transactions and conditions of the Company and its Subsidiaries
from the beginning of the quarterly or annual period covered by the statements then being furnished to the date of the certificate and that such review shall not have disclosed the existence of a Default or an Event of Default or, if any such
condition or event exists, specifying the nature and period of existence thereof and what action the Company shall have taken or proposes to take with respect thereto. 
 Section 7.3 Inspection. The Company shall, and shall cause each Subsidiary to, permit the representatives of each holder of Notes to visit and inspect any of the properties, books and financial records of the
Company and each Subsidiary, to examine and make copies (in reasonable quantities) of the books of accounts and other financial records of the Company and each Subsidiary thereof, and, with the consent of the Company if no Default or Event of
Default exists (such consent to not be unreasonably withheld), to discuss the affairs, finances and accounts of the Company and each Subsidiary with, and to be advised as to the same by the Company’s employees and independent public accountants
(and by this provision the Company authorizes such accountants to discuss with the Purchasers the finances and affairs of the Company and its Subsidiaries so long as consent has been given thereby when required by this Section 7.3), in
each case, at such reasonable times and reasonable intervals during normal business hours upon reasonable prior notice. 
 Section 7.4
Executive Management Access. The Company shall cause the Executive Chairman, the Chief Executive Officer and/or the Chief Financial Officer of the Company to meet with the Purchasers promptly upon the Purchasers’ reasonable request therefor
no less frequently than once per quarter. 
 SECTION 8. PREPAYMENT OF THE NOTES. 
 Section 8.1 Required Prepayments. In addition to paying the remaining outstanding principal amount and the interest due on the Notes on the
maturity date thereof or upon acceleration of the Notes pursuant to Section 12, all as guaranteed by the Company Guaranty, if a Mandatory Prepayment Event occurs, the Borrower and the Company each agree as follows: 
 (a) Promptly upon the consummation of such Mandatory Prepayment Event, the Borrower shall give the holders of the Notes written notice of
such Mandatory Prepayment Event with a description in reasonable detail of such Mandatory Prepayment Event including, the calculation of the Net Proceeds received in connection therewith and, for each holder of a Note, the amount of such
holder’s Pro Rata Portion of such Net Proceeds. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 26

 (b) The Net Proceeds received by the Company or any of its Subsidiaries in connection
with such Mandatory Prepayment Event shall be placed upon receipt thereof directly into a deposit or investment account pledged to the Collateral Agent for the benefit of the holders of the Notes as collateral security for the prompt and full
payment of the Notes and shall be applied to the outstanding principal balance of the Notes or released to the Company or its Subsidiaries as follows: 
 (i) Each holder of a Note shall have the option, exercised by written notice to the Borrower, prior the end of business on the date that is 21 days after receiving notice of the Mandatory Prepayment Event (the
“End Release Date”), to require that all or any portion of such holder’s Pro Rata Portion of the Net Proceeds, in such holder’s discretion, be applied as a prepayment in reduction of the outstanding principal balance of
the then outstanding Notes then held by such Holder. 
 (ii) If and to the extent that any holder of a Note declines to
require a mandatory prepayment or otherwise waives the provisions of this Section 8.1 in connection with any Mandatory Prepayment Event, in either case in a writing signed by such holder, or, if such holder fails to give notice prior to
the End Release Date requiring a full or partial prepayment of such holder’s Note or Notes pursuant to clause (i) above, then an amount equal to such holder’s Pro Rata Portion of the Net Proceeds shall be released from the collateral
account and freely available to the Company and its Subsidiaries for all legal purposes permitted by this Agreement. 
 Section 8.2
Optional Prepayments with Make-Whole Amount. The Borrower may, at its option, upon notice as provided below, prepay at any time all, or from time to time any part of the Notes, in a minimum amount not less than $5,000,000 and in increments of at
least $1,000,000 in excess of such minimum, in the case of a partial prepayment, at 100% of the principal amount so prepaid, together with interest accrued thereon to the date of such prepayment, plus the Make-Whole Amount, if any, determined for
the prepayment date with respect to such principal amount. The Borrower will give each holder of Notes written notice of each optional prepayment under this Section 8.2 not less than 5 days prior to the date fixed for such
prepayment. Each such notice shall specify such date, the aggregate principal amount of the Notes to be prepaid on such date, the principal amount of each Note held by such holder to be prepaid, and the interest and Make-Whole Amount, if any, to be
paid on the prepayment date with respect to such principal amount being prepaid, and shall be accompanied by a certificate of Senior Financial Officer specifying the computation of the Make-Whole Amount due in connection with such prepayment,
setting forth the details of such computation. In the case of 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 27

 
each partial prepayment of the Notes made pursuant to this Section 8.2, the principal amount of the Notes to be prepaid shall be allocated among
all of the Notes at the time outstanding in proportion, as nearly as practicable, to the respective unpaid principal amounts thereof not theretofore called for prepayment. 
 Section 8.3 Contingent Required Redemption. If, at any time after end of the calendar quarter in which [ * ], the Annualized Aggregate Net Product
Sales of the Company are less than $[ * ], then the Majority Holders may, by notice to the Company and the Borrower, require the Borrower to redeem up to $30,000,000 outstanding principal amount of the Notes at a redemption price equal to par plus
all accrued and unpaid interest on the Notes to be redeemed. Such redemption shall occur on a date fixed by the Borrower by notice to the Note holders not less than 30 and not more than 90 days after receipt of notice from the Majority Holders under
this Section, and shall be effected pro rata among all holders of Notes according to the aggregate principal amount of Notes held by each such holder. 
 Section 8.4 Maturity, Surrender, Etc. In the case of each prepayment or redemption of Notes pursuant to this Section 8, the principal amount of each Note to be prepaid shall mature and become due
and payable on the date fixed for such prepayment, together with interest on such principal amount accrued to such date and the applicable Make-Whole Amount, if any. From and after such date, unless the Borrower shall fail to pay such principal
amount when so due and payable, together with the interest and Make-Whole Amount, if any, as aforesaid, interest on such principal amount shall cease to accrue. Any Note paid or prepaid in full shall be surrendered to the Company and cancelled and
shall not be reissued, and no Note shall be issued in lieu of any prepaid principal amount of any Note. All such prepayments and redemptions shall be pro rata as among the Tranche A Notes and Tranche B Notes. 
 SECTION 9. AFFIRMATIVE COVENANTS. 
 Each of the Borrower and the Company covenants, jointly and severally, that so long as any of the Notes are outstanding: 
 Section 9.1 Compliance with Law. The Borrower will, and will cause each of its Subsidiaries to, and the Company will, and will cause each Subsidiary to, comply with all laws, ordinances or governmental rules or regulations to which
each of them is subject, including, without limitation, Environmental Laws, and to obtain and maintain in effect all licenses, certificates, permits, franchises and other governmental authorizations necessary to the ownership of their respective
properties or to the conduct of their respective businesses, in each case to the extent necessary to ensure that non-compliance with such laws, ordinances or governmental rules or regulations or failures to obtain or maintain in effect such
licenses, certificates, permits, franchises and other governmental authorizations could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 Section 9.2 Insurance. The Borrower will, and will cause each of its Subsidiaries to, and the Company will, and will cause each Subsidiary to,
maintain, with financially sound and reputable insurers, insurance with respect to their respective properties and businesses against such casualties and contingencies, of such types, on such terms and in such amounts (including 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 28

 
deductibles, co-insurance and self insurance, if adequate reserves are maintained with respect thereto) as is customary in the case of entities of
established reputations engaged in the same or a similar business and similarly situated. The Collateral Agent shall be named as “lender’s loss payee” on all insurance policies relating to any Collateral and as “additional
insured” under all liability policies (except Directors’ and Officers’ Insurance, automobile insurance, workers’ compensation, fiduciary liability and employment practices), in each case pursuant to appropriate endorsements in
form and substance reasonably satisfactory to the Collateral Agent. 
 Section 9.3 Maintenance of Properties. The Borrower will, and
will cause each of its Subsidiaries to, and the Company will, and will cause each Subsidiary to, maintain and keep, or cause to be maintained and kept, their respective properties in good repair, working order and condition (other than ordinary wear
and tear), so that the business carried on in connection therewith may be properly conducted at all times; provided that this Section shall not prevent the Company or any Subsidiary from discontinuing the operation and the maintenance of any
of its properties if such discontinuance is desirable in the conduct of its business and the Company has concluded that such discontinuance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 Section 9.4 Payment of Taxes and Claims. The Borrower will, and will cause each of its Subsidiaries to, and the Company will, and
will cause each Subsidiary to, file all tax returns required to be filed in any jurisdiction and to pay and discharge all taxes shown to be due and payable on such returns and all other taxes, assessments, governmental charges, or levies imposed on
them or any of their properties, assets, income or franchises, to the extent such taxes and assessments have become due and payable and before they have become delinquent and all claims for which sums have become due and payable that have or might
become a Lien (other than Liens permitted by Section 10.3) on properties or assets of the Company or any Subsidiary; provided that neither the Company nor any Subsidiary need pay any such tax or assessment or charge or claim if
(a) the amount, applicability or validity thereof is contested by the Company or such Subsidiary on a timely basis in good faith and in appropriate proceedings, and the Company or a Subsidiary has established adequate reserves therefor in
accordance with GAAP on the books of the Company or such Subsidiary or (b) the nonpayment of all such taxes, assessments, charges and claims in the aggregate could not reasonably be expected to have a Material Adverse Effect. 
 Section 9.5 Corporate or Limited Liability Company Existence, Etc. Subject to Section 10.2, the Borrower will, and will cause each of
its Subsidiaries to, and the Company will, and will cause each Subsidiary to, at all times preserve and keep in full force and effect its existence as a corporation or limited liability company, as the case may be, and the existence as a corporation
or limited liability company, as the case may be, of each of such Subsidiary and all rights and franchises of the Borrower, the Company and such Subsidiaries; provided, that this Section 9.5 shall neither apply to nor operate to
prevent the Borrower or the Company from failing to preserve the existence as a corporation or limited liability company, as the case may be, right or franchise of any Subsidiary if such failure would not impair the Collateral Agent’s rights in
any assets of such Subsidiary pledged as collateral for the payment of the Obligations and, in the good faith judgment of the Company, such failure would not be reasonably expected to have a Material Adverse Effect. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 29

 Section 9.6 Minimum Cash Balance. If at any time on or after the date on which financial
statements of the Company for the fiscal quarter ended March 31, 2009 are required to be delivered pursuant to Section 7.1, and for so long as, the Annualized Aggregate Net Product Sales of the Company are less than $[ * ] (on or
after such date), the Borrower shall maintain a minimum cash balance equal to 15% of the then outstanding principal amount on the Notes in a deposit or other similar demand investment account that is pledged to the Collateral Agent for the benefit
of the Purchasers as collateral security for the prompt and full payment of the Notes and which such account is subject to a control account agreement, in form and substance reasonably satisfactory to the Collateral Agent, between the applicable
financial intermediary where such account is held and the Collateral Agent. 
 Section 9.7 Subsidiary Documentation. In connection
with and within five Business Days of the creation, acquisition and/or capitalization by the Company or any Subsidiary of the Company of a new Subsidiary (a “New Subsidiary”) on or after the date hereof, the Borrower will, and will
cause each of its Subsidiaries to, and the Company will, and will cause each Subsidiary to, satisfy the following requirements: 
 (a) In the case of a New Subsidiary which is a Domestic Subsidiary, deliver to the Collateral Agent, the following documentation, instruments and agreements, in each case, evidencing a first priority perfected security interest and in form
and substance reasonably satisfactory to the Collateral Agent: 
 (i) a pledge agreement (substantially in the form of the
Pledge Agreement) executed by the Company or the Subsidiary which is the parent of such New Subsidiary together with the related stock certificates or certificates evidencing membership or equivalent equity interests, as the case may be, stock
powers or membership or equivalent equity interest powers and similar documentation reasonably required by the Collateral Agent to attach and perfect a security interest in 100% of the capital stock or similar ownership interests of the New
Subsidiary as collateral security for the prompt and full payment and performance of the Obligations; 
 (ii) a Guaranty
executed by the New Subsidiary guaranteeing the prompt and full payment of the Obligations; 
 (iii) a security agreement,
mortgage, deed of trust and/or intellectual property security agreement executed by the New Subsidiary as reasonably required by the Collateral Agent in order to properly attach and perfect (as applicable) a security interest in all of the property
of the New Subsidiary (other than property constituting ownership interests of a Foreign Subsidiary, which shall be subject to the provisions of Section 9.7(b) below) as collateral security for the prompt and full payment of the
Obligations; and 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 30

 (iv) authorization from the new Subsidiary to file any necessary UCC financing statements
and other similar documents or instruments required to perfect any security interests granted pursuant to the clause (iii) above. 
 (b) In the case of a New Subsidiary which is a Foreign Subsidiary, deliver to the Collateral Agent a pledge agreement or similar instrument or agreement executed by the parent of such New Subsidiary pursuant to which
65% of the outstanding ownership interests of such New Subsidiary is pledged as collateral security for the prompt and full payment of the Obligations. 
 Section 9.8 Perfection and Maintenance of Security Interests The Borrower will, and will cause each of its Subsidiaries to, and the Company will, and will cause each Subsidiary to, perform any and all steps
reasonably requested by the Collateral Agent to perfect, maintain and protect the Collateral Agent’s security interests in and against the Collateral granted or purported to be granted under this Agreement or any other Related Agreement,
including, without limitation, (a) authorizing the Collateral Agent to file financing or continuation statements, or amendments thereof, (b) delivering to the Collateral Agent all certificates, notes and other instruments representing or
evidencing Collateral, which certificates, notes and other instruments have been duly endorsed or are accompanied by duly executed instruments of transfer or assignment, all in form and substance reasonably satisfactory to the Collateral Agent,
(c) at the reasonable direction of the Collateral Agent, delivering to the Collateral Agent warehouse receipts covering that portion of the Collateral, if any, located in warehouses and for which warehouse receipts are issued, (d) after
the occurrence and during the continuance of an Event of Default, and only to the extent permitted by law, transferring Inventory and Equipment to warehouses designated by the Collateral Agent or taking such other steps as are deemed necessary by
the Collateral Agent to maintain its control of the Inventory and Equipment, and (e) executing and delivering all further instruments and documents, and taking all further action as the Collateral Agent may reasonably request. 
 Section 9.9 Collateral Locations. The Borrower will, and will cause each of its Subsidiaries to, and the Company will, and will cause each
Subsidiary to, keep the Collateral (other than (a) Inventory delivered, in the ordinary course of any Credit Party’s business, to clinical research organizations used in clinical research or to physicians as a sample and (b) Equipment
being used by employees and consultants of any Credit Party in the ordinary course of its business) at the locations specified on Schedule 5.20; provided, however, that the Borrower or the Company may amend
Schedule 5.20 so long as such amendment occurs by written notice to the Collateral Agent not less than thirty (30) days prior to the date on which such Collateral is moved. With respect to any new location (which in any event shall
be within the continental United States), Borrower and the Company will execute such documents and take such actions as the Collateral Agent deems reasonably requests to perfect and protect the security interests of the Collateral Agent in the
Collateral prior to the transfer or removal of any Collateral to such new location. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 31

 Section 9.10 Compliance with Settlement Agreements. The Borrower will, and will cause each of its
Subsidiaries to, and the Company will, and will cause each Subsidiary (including without limitation Orphan) to, (a) comply in a timely fashion with all of its respective obligations under the Settlement Agreements including without limitation
(i) making all payments required thereunder, (ii) providing all information, disclosures and certifications required thereunder, and (iii) making its reasonable best efforts to ensure that all Covered Persons comply with the Code of
Conduct and Policies and Procedures as set forth in the Settlement Agreements; and (b) provide immediate (i.e., within one (1) Business Day) notice to Collateral Agent in the event that it receives a notice of breach or default with
respect to any of the Settlement Agreements. 
 SECTION 10. NEGATIVE COVENANTS. 
 Each of the Borrower and the Company, jointly and severally, covenants that so long as any of the Notes are outstanding: 
 Section 10.1 Limitations on Indebtedness. 
 (a) The Borrower will not, and will not permit its Subsidiaries to, and the Company will not, and will not permit its Subsidiaries to, create, issue, assume, guarantee or otherwise incur or in any manner be or become
liable in respect of any Indebtedness, except: 
 (i) Indebtedness evidenced by the Notes; 
 (ii) unsecured Indebtedness incurred by the Company or any Domestic Subsidiary of the Company other than the Borrower (or any of the
Borrower’s Subsidiaries) so long as no principal of such Indebtedness is scheduled to mature prior to the stated maturity of the Notes; 
 (iii) (a) secured or unsecured purchase money Indebtedness (including Capital Leases) (such Indebtedness being referred to herein as “Permitted Purchase Money Indebtedness”) incurred by the Company or
any Domestic Subsidiary of the Company other than the Borrower (or any of the Borrower’s Subsidiaries) and (b) secured Indebtedness (such Indebtedness being referred to herein as “Permitted Receivables/Inventory
Indebtedness”) incurred by the Company or any Domestic Subsidiary of the Company other than the Borrower (or any of the Borrower’s direct Subsidiaries) secured by Accounts and Inventory, if all such Permitted Purchase Money
Indebtedness and Permitted Receivables/Inventory Indebtedness does not exceed, in the aggregate at any time outstanding, the lesser of (1) $15,000,000 and (2) 75% of Inventories and Receivables, as determined at such time using the
consolidated balance sheet of the Company and its consolidated Subsidiaries for the most recently completed fiscal quarter of the Company; 
 (iv) secured Indebtedness (hereinafter referred to as the “Permitted Other Secured Indebtedness”) created, issued, assumed, guaranteed or otherwise incurred by the Company or any Domestic Subsidiary
of the Company other than the Borrower (or any of the Borrower’s Subsidiaries) so long as no principal of 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 32

 
such Indebtedness is scheduled to mature prior to the stated maturity of the Notes; provided that at the time of creation, issuance, assumption,
guarantee or incurrence thereof and after giving effect thereto and to the application of the proceeds thereof, the ratio of (i) Consolidated Secured Indebtedness at such time to (ii) Consolidated EBITDA, as measured for the then trailing
four most recently completed fiscal quarters of the Company, shall not be in excess of 3.0 to 1.0; 
 (v) Indebtedness
(hereinafter referred to as the “Permitted Acquisition Indebtedness”) created, issued, assumed, guaranteed or otherwise incurred by the Company or any Subsidiary of the Company other than the Borrower (or any of the Borrower’s
Subsidiaries) used to finance (or assumed in connection with) the acquisition of a pharmaceutical or biotechnology product (including by way of the acquisition of stock or other similar ownership interests of the Person owning the target product);
provided that at the time of creation, issuance, assumption, guarantee or incurrence thereof and after giving effect thereto and to the application of the proceeds thereof, the aggregate outstanding principal amount of such Indebtedness
permitted by this clause (v) shall not exceed three times the lower of: 
 a. the annualized EBITDA of the Person or
product being acquired as measured for the then most recent 12 months ended; and 
 b. the lowest projected annualized EBITDA
for the Person or product being acquired, as the case may be, for any of the three years following the acquisition as determined by the Company in good faith on a pro forma basis and presented to the Company’s board of directors in connection
with the approval of such acquisition; 
 (vi) Indebtedness represented by currency swaps or letters of credit entered into or
issued, as the case may be, in the ordinary course of business of a Credit Party; and 
 (vii) Any amounts owing under the
Settlement Agreements. 
 (b) The renewal, extension, increase or refunding of any Indebtedness originally permitted to be
issued, incurred or outstanding pursuant to Section 10.1(a) shall constitute the issuance of additional Indebtedness which is, in turn, subject to the limitations of the applicable provisions of this Section 10.1. 

(c) Any Person that becomes a Subsidiary after the date hereof shall for all purposes of this Section 10.1 be deemed to
have created, assumed or incurred at the time it becomes a Subsidiary all Indebtedness of such Person existing immediately after it becomes a Subsidiary which Indebtedness, in turn, shall be subject to the limitations of this
Section 10.1 including, for the avoidance of doubt, any exceptions set forth herein. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 33

 (d) Each Credit Party, the Collateral Agent and each Purchaser acknowledges and agrees
that, notwithstanding the incurrence or assumption of any of the Indebtedness permitted to be incurred or assumed pursuant to Section 10.1(a), the Liens granted to the Collateral Agent for the benefit of the holders of Notes as
collateral security for the payment of the Obligations (including, without limitation, the Liens on the Collateral provided for in Section 3 hereof) shall remain in place as valid and enforceable Liens; provided, however,
that the Purchasers and the Collateral Agent hereby agree that, in the case of the incurrence or assumption of any Permitted Purchase Money Indebtedness, any Permitted Receivables/Inventory Indebtedness or any Permitted Acquisition Indebtedness, if
requested by the Company, the Collateral Agent shall agree, in a writing that is in form and substance reasonably acceptable thereto, with the applicable creditor or creditors holding such Permitted Purchase Money Indebtedness, such Permitted
Receivables/Inventory Indebtedness or such Permitted Acquisition Indebtedness, as the case may be, to subordinate any Liens which the Collateral Agent has or holds on the assets being acquired or financed in favor of the Liens expressly permitted to
be incurred under Sections 10.3(a)(i), 10.3(a)(ii) and 10.3(c), respectively, in connection with such acquisition. 
 Section 10.2 Mergers, Consolidations and Dispositions. 
 The Borrower will not be a party to any merger or consolidation,
unless the Borrower is the surviving entity in such merger or consolidation. The Borrower will not permit its Subsidiaries to, and the Company will not, and will not permit its Subsidiaries to, be a party to any merger or consolidation in which more
than 50% of the voting power of the Company or Subsidiary is disposed of, provided that the Company shall at all times own 100% of the voting power of the Borrower. The Borrower will not, and will not permit its Subsidiaries to, and the
Company will not, and will not permit its Subsidiaries to, sell, transfer, lease or otherwise dispose of any part of its property, including a disposition of property as part of a sale and leaseback transaction. Notwithstanding the foregoing, this
Section shall neither apply to nor operate to prevent the Company from being a party to any merger or consolidation so long as such merger or consolidation is not deemed to be a Change in Control, and shall not apply to or prevent the
Borrower, the Company or any of its Subsidiaries from: 
 (a) selling Inventory in the ordinary course of its business;

 (b) selling, transferring or otherwise disposing of worn-out, obsolete or surplus property or property no longer useful or
necessary to the operation of the business of the Company or its Subsidiaries; 
 (c) transferring or licensing rights to property of the Company or any of its Subsidiaries as part of a co-marketing, co-promotion, out-bound licensing or similar partnering arrangement (which may include product
specific financing by such co-marketer, co-promoter, licensor or partner so long as the Indebtedness represented thereby is otherwise permitted by Section 10.1) of (i) any Product of the Company or any of its Subsidiaries other than
Xyrem®, Antizol, or LUVOX® CR, or (ii) Xyrem®, solely in
connection with the licensing of rights in Xyrem® outside the United States in exchange 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 34

 
for ongoing payment of royalties and milestones (but, for the avoidance of doubt, not sales or divestitures of rights in Xyrem® or monetizations of royalty streams therein) so long as, at the time of such sale, transfer or disposition and after giving effect thereto, no Default or Event of Default shall exist (a “Permitted Product
Transfer”); 
 (d) selling, transferring or otherwise
disposing of any Product of the Borrower other than Xyrem®, Antizol, or LUVOX® CR so long as, at the time of such sale, transfer
or disposition and after giving effect thereto, no Default or Event of Default shall exist (a “Permitted Product Disposition”); 
 (e) selling, transferring or otherwise disposing of any property from the Company or any Subsidiary of the Company (other than the Borrower) to the Company or any Wholly-owned Subsidiary of the Company (other than the
Borrower) that is a Domestic Subsidiary; 
 (f) selling, transferring or otherwise disposing of any property from the Company
or any Subsidiary of the Company (other than the Borrower or a Subsidiary of the Borrower) to a Foreign Subsidiary of the Company as part of a Permitted Foreign Subsidiary Transfer; 
 (g) engaging in a transaction whereby any Subsidiary of the Company (other than the Borrower or a direct Subsidiary of the Borrower)
merges or consolidates with or into the Company or any Subsidiary that is a Domestic Subsidiary; provided that in any merger or consolidation involving the Company, the Company shall be the surviving or continuing corporation; and,

 (h) (i) engaging in licensing agreements between and among the
Borrower, the Company and the Collateral Agent according to the terms of, and in the form set forth in, Exhibit C hereto (“Xyrem License Agreement”), Exhibit D hereto (“Antizol License Agreement”), and
Exhibit E hereto (“LUVOX® CR License Agreement”, and together with the Xyrem License Agreement and the Antizol License Agreement, the “JPI Commercial License
Agreements”), (ii) selling, transferring or otherwise disposing of any property of the Borrower or any of its Subsidiaries to the Company or any of its Domestic Subsidiaries as set forth in the License Agreements; provided,
however, that the provisions of Section 10.2 (c), (e) and (f) shall not apply to the rights and property permitted to be transferred to the Company pursuant to this Section 10.2(h). 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 35

 Section 10.3 Limitation on Liens. The Borrower will not, and will not permit its Subsidiaries to,
and the Company will not, and will not permit its Subsidiaries to, create or incur, or suffer to be incurred or to exist, any Lien (except Permitted Liens) on its or their property, whether now owned or hereafter acquired, or upon any income or
profits therefrom; provided, however, that the foregoing shall neither restrict nor operate to prevent: 
 (a) Liens on
property of the Company or any Subsidiary of the Company other than the Borrower (or any of the Borrower’s direct Subsidiaries) created solely for the purpose of securing (i) Permitted Purchase Money Indebtedness so long as (x) such
Liens shall not extend to or cover property of the Company or such Subsidiary other than the property so acquired in respect of such Permitted Purchase Money Indebtedness, and (y) the principal amount of the Indebtedness secured by any such
Liens shall at no time exceed the original purchase price of such fixed assets and (ii) Permitted Receivables/Inventory Indebtedness; 
 (b) Liens on property of the Company or any Subsidiary of the Company other than the Borrower (or any of the Borrower’s direct Subsidiaries) created solely for the purpose of securing Permitted Other Secured
Indebtedness so long as such Liens do not have priority over the Liens granted in favor of the Collateral Agent for the benefit of the Purchasers under this Agreement or any other Related Documents; 
 (c) Liens on property of the Company or any Subsidiary of the Company other than the Borrower (or any of the Borrower’s direct
Subsidiaries) created solely for the purpose of securing (or assumed in connection with) Permitted Acquisition Indebtedness, so long as such Liens shall not extend to or cover property of the Company or such Subsidiary other than the property being
acquired in connection with such Permitted Acquisition Indebtedness; or 
 (d) Liens on property of the Company or any
Subsidiary of the Company created solely for the purpose of consummating a Permitted Product Transfer permitted by Section 10.2(b), so long as such Liens shall not extend to or cover property of the Company or such Subsidiary other than
the property which is the subject of such Permitted Product Transfer. 
 Section 10.4 Restricted Payments. The Borrower will not, and
will not permit its Subsidiaries to, and the Company will not, and will not permit its Subsidiaries to, except as hereinafter provided: declare or pay any dividends (other than, solely in the case of the Company, dividends payable solely in capital
stock of the Company), either in cash or property, on any shares of its capital stock of any class; directly or indirectly, or through any Subsidiary or through any Affiliate of the Company, purchase, redeem or retire any shares of its capital stock
of any class or any warrants, rights or options to purchase or acquire any shares of its capital stock (other than in connection with the repurchase of common stock by the Company from current or former employees, directors or consultants of the
Company upon the termination of their status as such); voluntarily prepay any unsecured Indebtedness permitted pursuant to Section 10.1(a)(ii) or Permitted Other Secured Indebtedness; or make any other payment or distribution, either
directly or indirectly or through any Subsidiary, in respect of its capital stock; provided, however, that the foregoing shall neither apply to nor operate to prevent any Subsidiary of the Borrower or the Company from making a dividend
or similar distribution to the Borrower, the Company or any Domestic Subsidiary thereof. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 36

 Section 10.5 Subsidiaries, Acquisitions and Investments. The Borrower will not, and will not
permit its Subsidiaries to, and the Company will not, and will not permit its Subsidiaries to, create or capitalize any Subsidiary after the date hereof, enter into any transaction or series of related transactions in which it acquires all or any
significant portion of the assets or capital stock (or other similar equity interests) of another Person or make any other Investments other than Permitted Investments; provided, however, that this Section shall neither apply to
nor operate to prevent the Company or any of its Subsidiaries from: 
 (a) creating and capitalizing a Subsidiary that is a
Domestic Subsidiary, acquiring all or a significant portion of the assets of any Person or acquiring all or a significant portion of the capital stock (or other similar equity interests) of another Person if (i) the Company and its Subsidiaries
comply with the requirements set forth in Section 9.7(a) in respect of any New Subsidiary created, (ii) any such assets or stock (or other similar equity interests) directly acquired is subject to the continuing security interests
set forth in Section 3 subject to any Liens permitted by Section 10.3, and (iii) no Default or Event of Default otherwise exists as of the time of the creation or capitalization of any such New Subsidiary; or 

(b) creating and capitalizing a Subsidiary that is a Foreign Subsidiary if the Company and its Subsidiaries comply with the
requirements set forth in Section 9.7(b) in respect of any New Subsidiary created and no Default or Event of Default otherwise exists as of the time of the creation or capitalization of such New Subsidiary. 
 For purposes of this Section 10.5, at any time when a Person becomes a Subsidiary, all Investments of such Person at such time shall be
deemed to have been made by such Person, as a Subsidiary, at such time, which Investments, in turn, shall be subject to the limitations of this Section 10.5, including, for the avoidance of doubt, any exceptions set forth herein.

 Section 10.6 Transactions with Affiliates. The Borrower will not, and will not permit its Subsidiaries to, and the Company will
not, and will not permit its Subsidiaries to, (i) enter into any transaction with Orphan, except to the extent reasonably necessary to comply with the Settlement Agreements, or (ii) enter into or be a party to any Material transaction or
arrangement not described in the immediately preceding clause (i) with any Affiliate other than the Company or any Domestic Subsidiary of the Company (including, without limitation, the purchase from, sale to or exchange of property with, or
the rendering of any service by or for, any Affiliate), except in each case described in this clause (ii) upon fair and reasonable terms not materially less favorable to the Company or such Subsidiary than would obtain in a comparable
arm’s-length transaction with a Person other than an Affiliate. 
 Section
10.7 JPI Commercial License Agreements. Except for the Orphan Asset Transfer, the Company will not, and will not permit its Subsidiaries to, and the Borrower will not, and will not permit its Subsidiaries to, enter into, or persist in, any
arrangement wherein (i) any Xyrem Contract, Antizol Contract or LUVOX® CR Contract is assigned or otherwise transferred by the Company, or any Subsidiary thereof, to any third party,
(ii) any Xyrem Contract, Antizol Contract or LUVOX® CR Contract does not permit the transfer or assignment of such contract to the Borrower irrespective of the consent, or absence
thereof, of any party to such contract, (iii) any right, title, or interest in any Xyrem Assets is transferred to any entity except as expressly permitted by the terms of the Xyrem License Agreement, or (iv) any right, title, or interest
in any Antizol Assets is transferred to any entity except as expressly permitted by the terms of the Antizol License Agreement, (v) any right, title, or interest in any LUVOX® CR
Assets is transferred to any entity except as expressly permitted by the terms of the LUVOX® CR License Agreement, or (vi) any term of any of the JPI Commercial License Agreements is
materially breached by the Company or the Borrower. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 37

 Section 10.8 Corporate Documents. Neither the Company nor the Borrower nor any other Credit Party
shall amend, supplement or otherwise modify its respective certificate of incorporation, bylaws, certificate of formation, or other constituent agreements, as applicable, as in effect on the date hereof in any manner that is materially adverse to
the interests of the holders of the Notes or the Warrants. 
 Section 10.9 Settlement Agreements. Neither the Borrower nor the
Company nor any Subsidiary thereof (including, without limitation, Orphan) shall take any action which would adversely affect the ability of such party or that of any other of the Borrower, the Company or any Subsidiary thereof to comply in all
respects with, perform, or not breach or default with respect to, any of its obligations in respect of each of the Settlement Agreements, except, solely in the case of the Corporate Integrity Agreement, for such failures to comply or perform, and
such breaches and defaults, as would not individually or collectively constitute a Material Breach or Default. 
 Section 10.10
Orphan. The Company shall cause Orphan to engage only in such activities as are reasonably necessary to comply with the Settlement Agreements. 
 SECTION 11. EVENTS OF DEFAULT. 
 An “Event of Default” shall exist if
any of the following conditions or events shall occur and be continuing: 
 (a) the Borrower defaults in the payment of any
principal on any Note when the same becomes due and payable, whether at maturity or at a date fixed for prepayment or by declaration or otherwise; or 
 (b) the Borrower defaults in the payment of any interest or Make-Whole Amount, if any, on any Note for more than one Business Day after the same becomes due and payable; or 
 (c) any of the Company, Orphan or any Credit Party or any Affiliate of any of the foregoing entities defaults in the performance of or
compliance with any provision of the Settlement Agreements (except, solely in the case of the Corporate Integrity Agreement, for such defaults as would not individually or collectively constitute a Material Breach or Default) or any Credit Party
defaults in the performance of or compliance with any term contained in Sections 2, 7.1(a), (b) and (c), 7.2 or 10; or 
 (d) any Credit Party defaults in the performance of or compliance with any term contained this Agreement (other than those referred to in paragraphs (a), (b) and (c) of this Section 11) or any
other Related Document and such default is not remedied within 15 days after the earlier of (i) the Company giving timely written notice of such default to the holders of Notes pursuant to Section 7.1(e) or (ii) if the Company
fails to give such timely notice, upon a Responsible Officer obtaining actual knowledge of such default; or 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 38

 (e) any representation or warranty made in writing by or on behalf of any Credit Party or
by any officer of a Credit Party in this Agreement, any other Related Documents or in any writing furnished in connection with the transactions contemplated hereby proves to have been false or incorrect on the date as of which made or, in the case
of any representation or warranty which is not by its terms already qualified by materiality, proves to have been materially false on the date as of which made; or 
 (f) (i) the Company or any of its Subsidiaries is in default (as principal or as guarantor or other surety) in the payment of any
principal of or premium or make-whole amount or interest on any Indebtedness that is outstanding in an aggregate principal amount of at least $2,000,000 beyond any period of grace provided with respect thereto, or (ii) the Company or any
Subsidiary is in default in the performance of or compliance with any term of any evidence of any Indebtedness in an aggregate outstanding principal amount of at least $2,000,000 or of any mortgage, indenture or other agreement relating thereto or
any other condition exists, and as a consequence of such default or condition such Indebtedness has become, or has been declared (or one or more Persons are entitled to declare such Indebtedness to be), due and payable before its stated maturity or
before its regularly scheduled dates of payment, or (iii) as a consequence of the occurrence or continuation of any event or condition (other than the passage of time or the right of the holder of Indebtedness to convert such Indebtedness into
equity interests), (1) the Company or any Subsidiary has become obligated to purchase or repay Indebtedness before its regular maturity or before its regularly scheduled dates of payment in an aggregate outstanding principal amount of at least
$2,000,000, or (2) one or more Persons have the right to require the Company or any Subsidiary so to purchase or repay such Indebtedness; or 
 (g) the Company or any Domestic Subsidiary (i) is generally not paying, or admits in writing its inability to pay, its debts as they become due, (ii) files, or consents by answer or otherwise to the filing
against it of, a petition for relief or reorganization or arrangement or any other petition in bankruptcy, for liquidation or to take advantage of any bankruptcy, insolvency, reorganization, moratorium or other similar law of any jurisdiction,
(iii) makes an assignment for the benefit of its creditors, (iv) consents to the appointment of a custodian, receiver, trustee or other officer with similar powers with respect to it or with respect to any substantial part of its property,
(v) is adjudicated as insolvent or to be liquidated, or (vi) takes corporate or limited liability company action, as the case may be, for the purpose of any of the foregoing; or 
 (h) a court or governmental authority of competent jurisdiction enters an order appointing, without consent by the Company or any of its
Domestic Subsidiaries, a custodian, receiver, trustee or other officer with similar powers with respect to it or with respect to any substantial part of its property, or constituting an order for relief or approving a petition for relief or
reorganization or any other petition in bankruptcy or for liquidation or to take advantage of any bankruptcy or insolvency law of any jurisdiction, or ordering the dissolution, winding-up or liquidation of the Company or any of its Domestic
Subsidiaries, or any such petition shall be filed against the Company or any of its Domestic Subsidiaries and such petition shall not be dismissed within 60 days; or 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 39

 (i) a final judgment or judgments for the payment of money aggregating in excess of
$4,000,000 are rendered against one or more of the Company and its Subsidiaries and which judgments are not, within 60 days after entry thereof, bonded, discharged or stayed pending appeal, or are not discharged within 60 days after the expiration
of such stay, it being understood and agreed that neither the Settlement Agreements, nor the performance of the obligations of the Company or Orphan thereunder, shall be deemed to be a Default or Event of Default under this paragraph; or 

(j) a Change in Control shall have occurred; or 
 (k) except as permitted under any Related Document, (i) any material provisions of this Agreement or any other Related Document shall
for any reason cease to be valid, binding and enforceable against the Company or any of its Subsidiaries subject to such agreements for any reason or the Company or any of its Subsidiaries shall so assert, or (ii) due to any action or inaction
of the Company or its Subsidiaries any Lien created by this Agreement or other Related Document on any asset or property having a value, individually or in the aggregate, greater than $500,000 shall at any time fail to constitute a valid and
perfected first priority Lien subject to no prior or equal Lien on any portion of the Collateral purported to be the subject of such Lien; or 
 (l) if (i) any Plan shall fail to satisfy the minimum funding standards of ERISA or the Code for any plan year or part thereof or a waiver of such standards or extension of any amortization period is sought or
granted under Section 412 of the Code, (ii) a notice of intent to terminate any Plan shall have been or is reasonably expected to be filed with the PBGC or the PBGC shall have instituted proceedings under ERISA Section 4042 to
terminate or appoint a trustee to administer any Plan or the PBGC shall have notified the Company or any ERISA Affiliate that a Plan may become a subject of any such proceedings, (iii) the aggregate “amount of unfunded benefit
liabilities” (within the meaning of Section 400l(a)(18) of ERISA) under all Plans, determined in accordance with Title IV of ERISA, shall exceed $500,000, (iv) the Company or any ERISA Affiliate shall have incurred or is reasonably
expected to incur any liability pursuant to Title I or IV of ERISA or the penalty or excise tax provisions of the Code relating to employee benefit plans, (v) the Company or any ERISA Affiliate withdraws from any Multiemployer Plan, or
(vi) the Company or any Subsidiary establishes or amends any employee welfare benefit plan that provides post-employment welfare benefits in a manner that would increase the liability of the Company or any Subsidiary thereunder; and any such
event or events described in clauses (i) through (vi) above, either individually or together with any other such event or events, could reasonably be expected to have a Material Adverse Effect. 
 As used in Section 11(l), the terms “employee benefit plan” and “employee welfare benefit plan” shall have the respective
meanings assigned to such terms in Section 3 of ERISA. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 40

 SECTION 12. REMEDIES ON DEFAULT, ETC. 
 Section 12.1 Acceleration. 
 (a) If an Event of Default with respect to the Company described in paragraph (g) or (h) of Section 11 (other than an Event of Default described in clause (i) of paragraph (g) or described in clause
(vi) of paragraph (g) by virtue of the fact that such clause encompasses clause (i) of paragraph (g)) has occurred, all the Notes then outstanding shall automatically become immediately due and payable. 
 (b) If any Event of Default other than those set forth in Section 12.1(a) has occurred and is continuing, the Majority Holders
may at any time at its or their option, by notice or notices to the Company, declare all the Notes then outstanding to be immediately due and payable. 
 (c) At any time that the Notes become due and payable under this Section 12.1, whether automatically or by declaration, each Note will forthwith mature and the entire unpaid principal amount of such Note,
plus (i) all accrued and unpaid interest thereon and (ii) in the event that the Notes have become due by reason of an Event of Default described in Sections 11(a), (b), (g), (h) or (j), the Make-Whole Amount determined in respect of
such principal amount (to the full extent permitted by applicable law), shall all be immediately due and payable, in each and every case without presentment, demand, protest or further notice, all of which are hereby waived. Each of the Company and
the Borrower acknowledges, and the parties hereto agree, that each holder of a Note has the right to maintain its investment in the Notes free from repayment by the Company (except as herein specifically provided for), and that the provision for
payment of a Make-Whole Amount by the Company in the event that the Notes are prepaid or are accelerated as a result of an Event of Default described in Sections 11(a), (b), (g), (h) or (j), is intended to provide compensation for the
deprivation of such right under such circumstances. 
 Section 12.2 Other Remedies. If any Default or Event of Default has occurred
and is continuing, and irrespective of whether any Notes have become or have been declared immediately due and payable under Section 12.1, the holder of any Note at the time outstanding may proceed to protect and enforce the rights of
such holder by an action at law, suit in equity or other appropriate proceeding, whether for the specific performance of any agreement contained herein or in any Note, or for an injunction against a violation of any of the terms hereof or thereof,
or in aid of the exercise of any power granted hereby or thereby or by law or otherwise. 
 Section 12.3 Certain Remedies as to
Collateral. If any Event of Default shall have occurred and be continuing, in addition to and not in limitation of any rights or remedies available to the holders of Notes at law or in equity, the Collateral Agent may (and shall, if so directed
by the Majority Holders) exercise in respect of the Collateral, in addition to all other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of a secured party on default under the UCC (whether or not
the UCC applies to the affected Collateral) and may also (a) notify any or all obligors on the Accounts to make all payments 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 41

 
directly to the Collateral Agent; (b) require the Borrower and the Company to, and the Borrower and the Company hereby agree that they will, at their
expense and upon request of the Collateral Agent forthwith, assemble all or part of the Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place to be designated by the Collateral Agent which is
reasonably convenient to both parties; (c) without notice or demand or legal process, enter upon any premises of the Borrower and the Company and take possession of the Collateral; and (d) without notice except as specified below, sell the
Collateral or any part thereof in one or more parcels at public or private sale, at any of the Collateral Agent’s offices or elsewhere, at such time or times, for cash, on credit or for future delivery, and at such price or prices and upon such
other terms as the Collateral Agent may deem commercially reasonable. The Borrower and the Company agree that, to the extent notice of sale shall be required by law, at least ten (10) days notice to the Borrower and the Company of the time and
place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. At any sale of the Collateral, if permitted by law, the Collateral Agent may bid (which bid may be, in whole or in part, in the
form of cancellation of indebtedness) for the purchase of the Collateral or any portion thereof for the account of the Collateral Agent and/or disclaim all warranties. The Collateral Agent shall not be obligated to make any sale of Collateral
regardless of notice of sale having been given. The Borrower and the Company shall remain liable for any deficiency. The Collateral Agent may adjourn any public or private sale from time to time by announcement at the time and place fixed thereof,
and such sale may, without further notice, be made at the time and place to which it was so adjourned. To the extent permitted by law, the Borrower and the Company hereby specifically waive all rights of redemption, stay or appraisal which they have
or may have under any law now existing or hereafter enacted. The Collateral Agent shall not be required to proceed against any Collateral but may proceed against the Borrower and the Company directly. 
 Section 12.4 Appointment of Attorney-in-Fact. Effective upon the occurrence and during the
continuation of an Event of Default, the Borrower and the Company hereby constitute and appoint the Collateral Agent as their attorney-in-fact with full authority in the place and stead of the Borrower and the Company and in their name, the
Collateral Agent or otherwise, from time to time in the Collateral Agent’s discretion to take any action and to execute any instrument that the Collateral Agent may deem necessary or advisable to accomplish the purposes of this Agreement,
including: (a) to ask, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for moneys due and to become due under or in respect of any of the Collateral; (b) to adjust, settle or compromise the amount or
payment of any Account, or release wholly or partly any customer or obligor thereunder or allow any credit or discount thereon; (c) to receive, endorse, and collect any drafts or other instruments, documents and chattel paper, in connection
with clause (a) above; (d) to file any claims or take any action or institute any proceedings that the Collateral Agent may deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of the
Collateral Agent with respect to any of the Collateral; (e) to sign and endorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, assignments, verifications and notices in connection with Accounts and other
documents relating to the Collateral; and (f) to execute on behalf of the Company the assignment of the Antizol Contracts, LUVOX® CR Contracts, and Xyrem Contracts pursuant to
Section 12.9. The appointment of the Collateral Agent as the Borrower’s and the Company’s attorney and the Collateral Agent’s rights and powers are coupled with an interest and are irrevocable until no Event of Default
shall exist or payment in full and complete performance of all of the Obligations. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 42

 Section 12.5 Limitation on Duty of the Collateral Agent with Respect to Collateral. Beyond the
safe custody thereof, the Collateral Agent shall have no duty with respect to any Collateral in its possession or control (or in the possession or control of any agent or bailee) or with respect to any income thereon or the preservation of rights
against prior parties or any other rights pertaining thereto. The Collateral Agent shall be deemed to have exercised reasonable care in the custody and preservation of the Collateral in its possession if the Collateral is accorded treatment
substantially equal to that which the Collateral Agent accords its own property. The Collateral Agent shall not be liable or responsible for any loss or damage to any of the Collateral, or for any diminution in the value thereof, by reason of the
act or omission of any warehouseman, carrier, forwarding agency, consignee or other agent or bailee selected by the Collateral Agent in good faith. 
 Section 12.6 Application of Proceeds. Upon the occurrence and during the continuance of an Event of Default, (a) the Borrower and the Company irrevocably waive the right to direct the application of any and all payments at any
time or times thereafter received by the Collateral Agent from or on behalf of the Borrower and the Company, and the Borrower and the Company hereby irrevocably agree that the Collateral Agent shall have the continuing exclusive right to apply and
to reapply any and all payments received at any time or times after the occurrence and during the continuance of an Event of Default against the Obligations in such manner as the Collateral Agent may deem advisable notwithstanding any previous entry
by the Collateral Agent upon any books and records and (b) the proceeds of any sale of, or other realization upon, all or any part of the Collateral shall be applied: first, to all fees, costs and expenses incurred by the Collateral
Agent or the Purchasers with respect to this Agreement, the other Related Documents or the Collateral; second, to accrued and unpaid interest and any Make-Whole Amount due on the Notes; and third, to the principal amounts of the
Obligations outstanding. 
 Section 12.7 License of Intellectual Property. To the extent permitted under any relevant agreement
entered into by the Company or the Borrower relating to its Intellectual Property, the Borrower and the Company hereby grant to the Collateral Agent for the benefit of the holders of Notes, effective only upon the occurrence and during the
continuance of any Event of Default hereunder, the non-exclusive limited right and license to use all Intellectual Property owned, or licensed from a third-party by, the Borrower or the Company together with any goodwill associated therewith (to the
extent owned by the Borrower or the Company), solely to the extent necessary to enable the Collateral Agent to realize on the Collateral and any successor or assign of the Collateral Agent to enjoy the benefits of the Collateral. This limited right
and license shall inure to the benefit of all successors, assigns and transferees of the Collateral Agent and its successors, assigns and transferees, whether by voluntary conveyance, operation of law, assignment, transfer, foreclosure, deed in lieu
of foreclosure or otherwise. Such right and license is granted free of charge, without requirement that any monetary payment whatsoever be made to the Borrower and the Company by the Collateral Agent. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 43

 Section 12.8 No Waivers or Election of Remedies, Expenses, Etc. No course of dealing and no delay
on the part of the Collateral Agent or any holder of any Note in exercising any right, power or remedy shall operate as a waiver thereof or otherwise prejudice the Collateral Agent’s or such holder’s rights, powers or remedies. No right,
power or remedy conferred by this Agreement or by any Note upon the Collateral Agent or any holder of a Note shall be exclusive of any other right, power or remedy referred to herein or therein or now or hereafter available at law, in equity, by
statute or otherwise. Without limiting the obligations of the Borrower and the Company under Section 15, the Company will pay to the Collateral Agent and to the holder of each Note on demand such further amount as shall be sufficient to
cover all reasonable costs and expenses of such holder incurred in any enforcement or collection under this Section 12, including, without limitation, reasonable attorneys’ fees, expenses and disbursements. 
 Section 12.9 Revocation of Jazz Commercial License Agreements. Upon the occurrence of an
Event of Default, in addition to any other rights or remedies the Collateral Agent may have, (i) the Collateral Agent may, in its discretion and upon written notice to the Company, revoke the Jazz Commercial License Agreements, and
(ii) the Company shall assign all Antizol Contracts, LUVOX® CR Contracts, and Xyrem Contracts to the Borrower upon the Collateral Agent’s written notice to the Company of its
instructions to do so. 
 SECTION 13. REGISTRATION; TRANSFER; SUBSTITUTION OF
NOTES. 
 Section 13.1 Registration of Notes. The Borrower shall keep at its principal executive office a register for
the registration and registration of transfers of Notes. The name and address of each holder of one or more Notes, each transfer thereof and the name and address of each transferee of one or more Notes shall be registered in such register. Prior to
due presentment for registration of transfer, the Person in whose name any Note shall be registered shall be deemed and treated as the owner and holder thereof for all purposes hereof, and the Borrower shall not be affected by any notice or
knowledge to the contrary. 
 Section 13.2 Transfer of Notes. Each Purchaser and any transferee (as permitted hereby) of a Purchaser
may transfer, assign or otherwise negotiate any Note (or any portion thereof) held thereby to (a) any Affiliate of such Purchaser (or permitted transferee) or (b) if such transfer is acceptable to the Borrower and the Majority Holders in
their respective discretion, any other Person (each a “Permitted Transfer”). In order to effect a Permitted Transfer, the selling Purchaser (or any selling permitted transferee) shall surrender the applicable Note at the principal
executive office of the Borrower, duly endorsed or accompanied by a written instrument of transfer duly executed by the registered holder of such Note or its attorney duly authorized in writing and accompanied by the address for notices of each
transferee of such Note or part thereof, whereupon the Borrower shall execute and deliver, at the Borrower’s expense, one or more new Notes (as requested by the holder thereof) in exchange therefor, in an aggregate principal amount equal to the
unpaid principal amount of the surrendered Note. Each such new Note shall be payable to such Person as such holder may request and shall be substantially in the form of Exhibit A. Each such new Note shall be dated and bear interest from
the date to which interest shall have been paid on the surrendered Note or dated the date of the surrendered Note if no interest shall have been paid thereon. Notes shall not be transferred in denominations of less 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 44

 
than $5,000,000 (or, in the case of any transfer to an existing holder of a Note or an Affiliate thereof, $1,000,000); provided that if necessary to
enable the registration of transfer by a holder of its entire holding of Notes, one Note may be in a denomination of less than $5,000,000. Any transferee, by its acceptance of a Note registered in its name (or the name of its nominee), shall be
deemed to have made the representations set forth in Section 6.6. 
 Section 13.3 Replacement of Notes. Upon receipt by
the Borrower of evidence reasonably satisfactory to it of the ownership of and the loss, theft, destruction or mutilation of any Note, and 
 (a) in the case of loss, theft or destruction, of indemnity reasonably satisfactory to it, or 
 (b) in the case of mutilation, upon surrender and cancellation thereof, 
 the Borrower at its own expense shall execute and deliver, in lieu
thereof, a new Note, dated and bearing interest from the date to which interest shall have been paid on such lost, stolen, destroyed or mutilated Note or dated the date of such lost, stolen, destroyed or mutilated Note if no interest shall have been
paid thereon. 
 Section 13.4 Securitization. The Borrower hereby acknowledges that the holders of Notes and their permitted
transferees may sell or securitize the Obligations (a “Securitization”) owing thereto through the pledge of the Obligations as collateral security for loans to such holders or their permitted transferees or through the sale of
the right to payment on the Obligations or the issuance of direct or indirect undivided interests in the Obligations. The Borrower shall cooperate with the holders of Notes to effect any proposed Securitization including, without limitation, by
providing such information as may be reasonably requested by the holders in connection with the rating of the Obligations by a nationally recognized ratings agency in connection with the Securitization. 
 SECTION 14. PAYMENTS ON NOTES. 
 Section 14.1 Place of Payment. Subject to Section 14.2, payments of principal, Make-Whole Amount, if any, and interest becoming due and payable on the Notes shall be made to the account or accounts
designated in writing by each holder of a Note. 
 Section 14.2 Home Office Payment. So long as a Purchaser or its nominee shall be
the holder of any Note, and notwithstanding anything contained in Section 14.1 or in such Note to the contrary, the Borrower will pay all sums becoming due on such Note for principal, Make-Whole Amount, if any, and interest by the method
and at the address specified for such purpose below the Purchaser’s name on Schedule A hereto, or by such other method or at such other address as such Purchaser shall have from time to time specified to the Borrower in writing for
such purpose, without the presentation or surrender of such Note or the making of any notation thereon, except that upon written request of the Borrower made concurrently with or reasonably promptly after payment or prepayment in full of any Note,
any holder of the Note shall surrender such Note for cancellation, reasonably promptly after any such request, to the Borrower at its 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 45

 
principal executive office or at the place of payment most recently designated by the Borrower pursuant to Section 14.1. Prior to any sale or
other disposition of any Note held by a Purchaser or its nominee such Purchaser will, at its election, either endorse thereon the amount of principal paid thereon and the last date to which interest has been paid thereon or surrender such Note to
the Borrower in exchange for a new Note or Notes pursuant to Section 13.2. The Borrower will afford the benefits of this Section 14.2 to any Purchaser that is the direct or indirect transferee of any Note purchased by such
Purchaser under this Agreement and that has made the same agreement relating to such Note as such Purchaser has made in this Section 14.2. 
 SECTION 15. EXPENSES, ETC. 
 Section 15.1 Fees; Transaction Expenses. The Borrower and the
Company will pay (a) all reasonable attorneys’ fees and disbursements of Pillsbury Winthrop Shaw Pittman LLP, special counsel to certain of the Purchasers (and to certain Purchasers under the Orphan Note Purchase Agreement) in connection
with the negotiation, execution, and delivery of this Agreement and the other Related Documents, and any Closing, and all such fees and disbursements described in Section 4.1(d); (b) all reasonable costs and expenses (including
reasonable attorneys’ fees of Pillsbury Winthrop Shaw Pittman LLP, special counsel to certain of the Purchasers) incurred by the Purchasers or holder of a Note in connection with the transactions contemplated hereby, (c) all reasonable
costs and expenses (including reasonable attorneys’ fees of a single law firm) incurred by the Collateral Agent or any holder of a Note in connection with any amendments, waivers or consents under or in respect of this Agreement, any other
Related Document including the Notes (whether or not such amendment, waiver or consent becomes effective), (d) the reasonable costs and expenses incurred by the Collateral Agent or any holder of a Note in enforcing or defending (or determining
whether or how to enforce or defend) any rights under this Agreement or the Notes or in responding to any subpoena or other legal process or informal investigative demand issued in connection with this Agreement or the Notes, or by reason of being a
holder of any Note (including reasonable attorneys’ fees for all such holders), and (e) the reasonable costs and expenses incurred by the Collateral Agent or any holder of a Note, including financial advisors’ fees, incurred in
connection with the insolvency or bankruptcy of the Company or any Subsidiary. The Borrower will pay, and will save each Purchaser and each other holder of a Note harmless from, all claims in respect of any fees, costs or expenses, if any, of
brokers and finders (other than those retained by a Purchaser). 
 Section 15.2 Survival. The obligations of the Company and the
Borrower under this Section 15 will survive the payment or transfer of any Note, the enforcement, amendment or waiver of any provision of this Agreement or the Notes, and the termination of this Agreement. 
 SECTION 16. SURVIVAL OF REPRESENTATIONS AND WARRANTIES; ENTIRE
AGREEMENT. 
 All representations and warranties contained herein shall survive the execution and delivery of this Agreement
and the other Related Documents, the purchase or transfer by a holder of any Note or Warrant of such Note or Warrant or portion thereof or interest therein and the payment of any Note or the exercise of any Warrant, and may be relied upon by any
subsequent holder of a Note, regardless of any investigation made at any time by or on behalf of any holder of a Note. All statements contained in any certificate or other instrument delivered by or on 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 46

 
behalf of the Borrower or the Company pursuant to this Agreement shall be deemed representations and warranties of the Borrower or the Company under this
Agreement. Subject to the preceding sentence, this Agreement and the other Related Documents embody the entire agreement and understanding between the Purchasers and the Company and supersede all prior agreements and understandings relating to the
subject matter hereof. 
 SECTION 17. AMENDMENT AND WAIVER. 
 Section 17.1 Requirements. This Agreement and the Notes may be amended, and the observance of any term hereof or of the Notes may be waived (either
retroactively or prospectively), with (and only with) the written consent of the Company, the Borrower and the Majority Holders, except that no such amendment or waiver may, without the written consent of the holder of each Note at the time
outstanding affected thereby, (a) change the amount or time of any prepayment or payment of principal of, or reduce the rate or change the time of payment or method of computation of interest or of the Make-Whole Amount on, the Notes,
(b) change the percentage of the principal amount of the Notes the holders of which are required to consent to any such amendment or waiver, or (c) amend any of Sections 8.1, 11(a), 12.1(a) and (b), 17.1 or 20 or the
definition of Majority Holders set forth on Schedule B. The Warrants may be amended, and the observance of any term thereof may be waived (either retroactively or prospectively) as provided therein. Notwithstanding the foregoing, the
provisions of Section 4.2 and, solely with respect to the Subsequent Closing, Section 4.3, may be amended only with the written consent of the Borrower, the Company and all of the Purchasers obligated to purchase Notes to be
issued and sold at the Subsequent Closing, and may be waived by any such Purchaser, but only to the extent applicable to such Purchaser. Notwithstanding the provisions of this Section 17.1 to the contrary, no amendment or modification to this
Agreement or the Notes that materially and adversely affects the rights of any Purchaser in a manner disproportionate to other Purchasers shall be effective with respect to such Purchaser or the Notes held by such Purchaser unless such amendment or
modification has been approved in writing by the Majority Holders and an additional Purchaser that is not an Affiliate of such approving Majority Holders. 
 Section 17.2 Solicitation of Holders of Notes. 
 (a) Solicitation. The Borrower
will provide each holder of the Notes (irrespective of the amount of Notes then owned by it) with sufficient information, sufficiently far in advance of the date a decision is required, to enable such holder to make an informed and considered
decision with respect to any proposed amendment, waiver or consent in respect of any of the provisions hereof or of the Notes. The Borrower and the Company will deliver executed or true and correct copies of each amendment, waiver or consent
effected pursuant to the provisions of this Section 17 to each holder of outstanding Notes promptly following the date on which it is executed and delivered by, or receives the consent or approval of, the requisite holders of Notes.

 (b) Payment. Neither the Borrower nor the Company will directly or indirectly pay or cause to be paid any
remuneration, whether by way of supplemental or additional interest, fee or otherwise, or grant any security, to any holder of Notes as consideration for or as an inducement to the entering into by any holder of Notes of any waiver 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 47

 
or amendment of any of the terms and provisions hereof unless such remuneration is concurrently paid, or security is concurrently granted, on the same terms,
ratably to each holder of Notes then outstanding even if such holder did not consent to such waiver or amendment. 
 Section 17.3 Binding
Effect, Etc. Any amendment or waiver consented to as provided in this Section 17 applies equally to all holders of Notes and is binding upon them and upon each future holder of any Note and upon the Borrower without regard to whether
such Note has been marked to indicate such amendment or waiver. No such amendment or waiver will extend to or affect any obligation, covenant, agreement, Default or Event of Default not expressly amended or waived or impair any right consequent
thereon. No course of dealing between the Borrower and the holder of any Note nor any delay in exercising any rights hereunder or under any Note shall operate as a waiver of any rights of any holder of such Note. As used herein, the term “this
Agreement” and references thereto shall mean this Agreement as it may from time to time be amended or supplemented. 
 Section 17.4
Notes Held by Company, Etc. Solely for the purpose of determining whether the holders of the requisite percentage of the aggregate principal amount of Notes then outstanding approved or consented to any amendment, waiver or consent to be given
under this Agreement or the Notes, or have directed the taking of any action provided herein or in the Notes to be taken upon the direction of the holders of a specified percentage of the aggregate principal amount of Notes then outstanding, Notes
directly or indirectly owned by the Company or any of its Subsidiaries shall be deemed not to be outstanding. 
 SECTION 18. NOTICES.

 All notices and communications provided for hereunder shall be in writing and sent (a) by telefacsimile if the sender on the same day
sends a confirming copy of such notice by a recognized overnight delivery service (charges prepaid), or (b) by registered or certified mail with return receipt requested (postage prepaid), or (c) by a recognized overnight delivery service
(with charges prepaid). Any such notice must be sent: 
 (i) if to a Purchaser or its nominee, to such Purchaser or its
nominee at the address specified for such communications in Schedule A hereto or at such other address as any holder of a Note or it shall have specified to the Company in writing, 
 (ii) if to any other holder of any Note, to such holder at such address as such other holder shall have specified to the Company in
writing, or 
 (iii) if to the Borrower or the Company, to the Company at 3180 Porter Drive, Palo Alto, CA 94304, to the
attention of Matthew K. Fust, Chief Financial Officer, with a copy to General Counsel, fax: (650) 496-3781, or at such other address as the Company shall have specified to the holder of each Note in writing. 
 Notices under this Section 18 will be deemed given only when actually received. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 48

 SECTION 19. REPRODUCTION OF DOCUMENTS. 
 This Agreement and all documents relating hereto, including, without limitation, (a) consents, waivers and modifications that may hereafter be
executed, (b) documents received by the Purchasers at the Closings (except the Notes and Warrants themselves), and (c) financial statements, certificates and other information previously or hereafter furnished to the Purchasers, may be
reproduced by the Purchasers by any photographic, photostatic, microfilm, microcard, miniature photographic or other similar process and any holder of a Note may destroy any original document so reproduced. Each of the Company and the Borrower
agrees and stipulates that, to the extent permitted by applicable law, any such reproduction shall be admissible in evidence as the original itself in any judicial or administrative proceeding (whether or not the original is in existence and whether
or not such reproduction was made by a holder of any Note in the regular course of business) and any enlargement, facsimile or further reproduction of such reproduction shall likewise be admissible in evidence. This Section 19 shall not
prohibit the Company and the Borrower or any other holder of Notes from contesting any such reproduction to the same extent that it could contest the original, or from introducing evidence to demonstrate the inaccuracy of any such reproduction.

 SECTION 20. CONFIDENTIAL INFORMATION. 
 For the purposes of this Section 20, “Confidential Information” means information delivered to a Purchaser by or on behalf of the Company or any Subsidiary in connection with the
transactions contemplated by or otherwise pursuant to this Agreement that is related to the business or property of the Company or its Subsidiaries or to this Agreement or the other Related Documents; provided that such term does not include
information that (a) was publicly known or otherwise known to such Purchaser without restriction prior to the time of such disclosure as evidenced by its written records, (b) subsequently becomes publicly known through no act or omission
by such Purchaser or any Person acting on its behalf, (c) otherwise becomes known to such Purchaser other than through disclosure by the Company or any Subsidiary or (d) constitutes financial statements delivered to a holder of a Note
under Section 7.1(a) or (b) that are otherwise publicly available, except in the case of clause (a), (b), or (c), to the extent such information came from a source known to such Purchaser to be bound by an obligation of
confidentiality to the Company as any of its Subsidiaries. Each Purchaser agrees to maintain the confidentiality of such Confidential Information for a period of at least 7 years in accordance with procedures adopted by such Purchaser in good faith
to protect confidential information of third parties delivered thereto, which procedures shall be at least as stringent as those used by such Purchaser with respect to its own important confidential information; provided that a Purchaser may
deliver or disclose Confidential Information to (i) its directors, trustees, officers, employees, agents, attorneys and affiliates (to the extent such disclosure reasonably relates to the administration of the investment represented by such
Purchaser’s Notes) who are bound to the terms of this Section 20 or are otherwise bound by a duty of confidentiality at least as restrictive as the terms of this Section 20, (ii) such Purchaser’s financial
advisors and other professional advisors who agree to hold confidential the Confidential Information substantially in accordance with the terms of this Section 20, (iii) any other holder of any Note, (iv) any Person who is
permitted to purchase a Note or Warrant from such Purchaser pursuant to the terms hereof or of 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 49

 
the Notes or Warrants, as the case may be (but only if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by
the provisions of this Section 20), (v) any Person from which a Purchaser offers to purchase any Note or Warrant of the Company (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound
by the provisions of this Section 20), (vi) any federal or state regulatory authority having jurisdiction over such Purchaser, (vii) any other Person to which such delivery or disclosure may be necessary or appropriate
(w) to effect compliance with any law, rule, regulation or order applicable to a Purchaser, (x) in response to any subpoena or other legal process, (y) in connection with any litigation to which such Purchaser is a party or
(z) if an Event of Default has occurred and is continuing, to the extent such Purchaser may reasonably determine such delivery and disclosure to be necessary or appropriate in the enforcement or for the protection of the rights and remedies
under any Notes and this Agreement. Each holder of a Note, by its acceptance of a Note, will be deemed to have agreed to be bound by and to be entitled to the benefits of this Section 20 as though it were a party to this Agreement. On
reasonable request by the Company in connection with the delivery to any holder of a Note of information required to be delivered to such holder under this Agreement or requested by such holder (other than a holder that is a party to this Agreement
or its nominee), such holder will enter into an agreement with the Company embodying the provisions of this Section 20. 
 SECTION 21.
THE COLLATERAL AGENT. 
 Section 21.1 Appointment; Nature of Relationship. LB I Group Inc.
is appointed by the Purchasers as the Collateral Agent hereunder and under each of the other Related Documents, and each of the Purchasers irrevocably authorizes the Collateral Agent (for so long as the Collateral Agent remains in such capacity
under this Agreement) to act as the contractual representative of such Purchaser with only the rights and duties expressly set forth herein and in the other Related Documents. The Collateral Agent agrees to act as such contractual representative
upon the express conditions contained in this Section 21. Notwithstanding the use of the defined term “Collateral Agent” it is expressly understood and agreed that the Collateral Agent shall not have any fiduciary
responsibilities to any Purchaser by reason of this Agreement and that the Collateral Agent is merely acting as the representative of the Purchasers with only those duties as are expressly set forth in this Agreement and the other Related Documents.
In its capacity as the Purchasers’ contractual representative, the Collateral Agent (i) does not assume any fiduciary duties to any of the Purchasers, (ii) is a “representative” of the Purchasers within the meaning of
Section 9-511 of the UCC and (iii) is acting as an independent contractor, the rights and duties of which are limited to those expressly set forth in this Agreement and the other Related Documents. Each of the Purchasers agrees to assert
no claim against the Collateral Agent on any agency theory or any other theory of liability for breach of fiduciary duty, all of which claims each Purchaser waives. 
 Section 21.2 Powers. The Collateral Agent shall have and may exercise such powers under the Related Documents as are specifically delegated to the Collateral Agent by the terms of each thereof, together with
such powers as are reasonably incidental thereto. The Collateral Agent shall have no implied duties or fiduciary duties to the Purchasers, or any obligation to the Purchasers to take any action hereunder or under any of the other Related Documents
except any action specifically provided by the Related Documents required to be taken by the Collateral Agent. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 50

 Section 21.3 General Immunity. Neither the Collateral Agent nor any of its directors, officers,
agents or employees shall be liable to the Company, the Borrower, any Subsidiary or Affiliate of the Company or the Borrower, or any Purchaser for any action taken or omitted to be taken by it or them hereunder or under any other Related Documents
or in connection herewith or therewith except to the extent such action or inaction is found in a final judgment by a court of competent jurisdiction to have arisen solely from (i) the gross negligence or willful misconduct of such Person or
(ii) breach of contract by such Person with respect to the Related Documents. 
 Section 21.4 No Responsibility for Loans,
Creditworthiness, Collateral, Recitals, Etc. Neither the Collateral Agent nor any of its directors, officers, Collateral Agents or employees shall be responsible for or have any duty to ascertain, inquire into, or verify (i) any statement,
warranty or representation made in connection with any Related Document or any borrowing hereunder; (ii) the performance or observance of any of the covenants or agreements of any obligor under any Related Document; (iii) the satisfaction
of any condition specified in Section 4, except receipt of items required to be delivered solely to the Collateral Agent; (iv) the existence or possible existence of any Default or Event of Default or (v) the validity,
effectiveness or genuineness of any Related Document or any other instrument or writing furnished in connection therewith. The Collateral Agent shall not be responsible to any Purchaser for any recitals, statements, representations or warranties
herein or in any of the other Related Documents, for the perfection or priority of any of the Liens on any of the Collateral, or for the execution, effectiveness, genuineness, validity, legality, enforceability, collectability, or sufficiency of
this Agreement or any of the other Related Documents or the transactions contemplated thereby, or for the financial condition of any guarantor of any or all of the Obligations, the Company or any of its Subsidiaries. 
 Section 21.5 Action on Instructions of Purchasers. The Collateral Agent shall in all cases be fully protected in acting, or in refraining from
acting, hereunder and under any other Related Document in accordance with written instructions signed by the Majority Holders (or any other percentage of Purchasers specified to be the applicable percentage in this Agreement or any other Related
Document to act on specified matters), and such instructions and any action taken or failure to act pursuant thereto shall be binding on all of the Purchasers and on all holders of Notes. The Collateral Agent shall be fully justified in failing or
refusing to take any action hereunder and under any other Related Document unless it shall first be indemnified to its satisfaction by the Purchasers pro rata against any and all liability, cost and expense that it may incur by reason of taking or
continuing to take any such action. 
 Section 21.6 Employment of Collateral Agents and Counsel. The Collateral Agent may execute any
of its duties as the Collateral Agent hereunder and under any other Related Document by or through employees, agents, and attorney-in-fact and shall not be answerable to the Purchasers, except as to money or securities received by it or its
authorized agents. The Collateral Agent shall be entitled to advice of counsel concerning the contractual arrangement between the Collateral Agent and the Purchasers and all matters pertaining to the Collateral Agent’s duties hereunder and
under any other Related Document. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 51

 Section 21.7 Reliance on Documents; Counsel. The Collateral Agent shall be entitled to rely upon
any Note, notice, consent, certificate, affidavit, letter, telegram, statement, paper or document believed by it to be genuine and correct and to have been signed or sent by the proper person or persons, and, in respect to legal matters, upon the
opinion of counsel selected by the Collateral Agent, which counsel may be employees of the Collateral Agent. 
 Section 21.8 The
Collateral Agent’s Reimbursement and Indemnification. The Purchasers agree to reimburse and indemnify the Collateral Agent ratably in proportion to the principal amount of their respective Notes outstanding from time to time (i) for
any amounts not reimbursed by the Borrower or the Company for which the Collateral Agent is entitled to reimbursement under the Related Documents, (ii) for any other expenses incurred by the Collateral Agent on behalf of the Purchasers, in
connection with the preparation, execution, delivery, administration and enforcement of the Related Documents and (iii) for any liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of
any kind and nature whatsoever which may be imposed on, incurred by or asserted against the Collateral Agent in any way relating to or arising out of the Related Documents or any other document delivered in connection therewith or the transactions
contemplated thereby, or the enforcement of any of the terms thereof or of any such other documents, provided that no Purchaser shall be liable for any of the foregoing to the extent any of the foregoing is found in a final non-appealable
judgment by a court of competent jurisdiction to have arisen solely from the gross negligence or willful misconduct of the Collateral Agent. 
 Section 21.9 Rights as a Purchaser. With respect to its Notes, the Collateral Agent shall have the same rights and powers hereunder and under any other Related Document as any Purchaser and may exercise the same as though it were not
the Collateral Agent, and the term “Purchaser” or “Purchasers” shall, unless the context otherwise indicates, include the Collateral Agent in its individual capacity. 
 Section 21.10 Successor Collateral Agent. The Collateral Agent may resign at any time by written notice to the Purchasers and the Credit Parties,
and the Collateral Agent may be removed at any time with or without cause by written notice received by the Collateral Agent from the Majority Holders. Upon any such resignation or removal, the Majority Holders shall have the right to appoint, on
behalf of the Credit Parties and the Purchasers, a successor Collateral Agent. If no successor Collateral Agent shall have been so appointed by the Majority Holders and shall have accepted such appointment within thirty days after the retiring
Collateral Agent’s giving notice of resignation, then the retiring Collateral Agent may appoint, on behalf of the Credit Parties and the Purchasers, a successor Collateral Agent. Notwithstanding anything herein to the contrary, so long as no
Default has occurred and is continuing, each such successor Collateral Agent shall be subject to approval by the Credit Parties, which approval shall not be unreasonably withheld. Upon the acceptance of any appointment as the Collateral Agent
hereunder by a successor Collateral Agent, such successor Collateral Agent shall thereupon succeed to and become vested with all the rights, powers, privileges and duties of the retiring Collateral Agent, and the retiring Collateral Agent shall be
discharged from its duties and obligations hereunder and under the other Related Documents. After any retiring Collateral Agent’s resignation hereunder as Collateral Agent, the provisions of this Section 21 shall continue in effect
for its benefit in respect of any actions taken or omitted to be taken by it while it was acting as the Collateral Agent hereunder and under the other Related Documents. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 52

 Section 21.11 Collateral Documents. 
 (a) Each Purchaser authorizes the Collateral Agent to enter into the Collateral Documents to which it is a party and to take all action
contemplated by such documents. Each Purchaser agrees that no holder of the Notes (other than the Collateral Agent) shall have the right individually to seek to realize upon the security granted by any Collateral Document, it being understood and
agreed that such rights and remedies may be exercised solely by the Collateral Agent for the benefit of the holders of the Notes upon the terms of the Collateral Documents. 
 (b) In the event that any Collateral is hereafter pledged by any Person as collateral security for the Obligations, the Collateral Agent
is hereby authorized to execute and deliver on behalf of the holders of the Notes any Related Documents necessary or appropriate to grant and perfect a Lien on such Collateral in favor of the Collateral Agent on behalf of the holders of the Notes.

 (c) The Purchasers hereby authorize the Collateral Agent, at its option and in its discretion, to (y) release any Lien
granted to or held by the Collateral Agent upon any Collateral and/or (z) release any guarantor from its obligations under any Guaranty (i) upon the satisfaction of all of the Obligations at any time arising under or in respect of this
Agreement or the Related Documents or the transactions contemplated hereby or thereby; (ii) in connection with any transaction permitted by, but only in accordance with, the terms of the applicable Related Document; or (iii) in connection
with any transaction approved, authorized or ratified in writing by the Majority Holders, unless such release is required to be approved by all of the Purchasers hereunder. Upon request by the Collateral Agent at any time, the Purchasers will
confirm in writing the Collateral Agent’s authority to release particular types or items of Collateral pursuant to this Section 21.11. 
 (d) Upon any sale or transfer of assets constituting Collateral which is permitted pursuant to the terms of any Related Document, or consented to in writing by the Majority Holders, the Collateral Agent shall (and is
hereby irrevocably authorized by the Purchasers to) execute such documents as may be necessary to evidence the release of the Liens granted to the Collateral Agent for the benefit of the holders of the Notes herein or pursuant hereto upon the
Collateral that was sold or transferred; provided, however, that (i) the Collateral Agent shall not be required to execute any such document on terms which, in the Collateral Agent’s reasonable opinion, would expose the
Collateral Agent to liability or create any obligation or entail any consequence other than the release of such Liens without recourse or warranty, and (ii) such release shall not in any manner discharge, affect or impair the Obligations or any
Liens upon (or obligations of the Company or any of its Subsidiaries in respect of) all interests retained by the Company or any of its Subsidiaries, including (without limitation) the proceeds of the sale, all of which shall continue to constitute
part of the Collateral. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 53

 SECTION 22. MISCELLANEOUS. 
 Section 22.1 Successors and Assigns. All covenants and other agreements contained in this Agreement by or on behalf of any of the parties hereto bind and inure to the benefit of their respective successors and
assigns (including, without limitation, any subsequent holder of a Note) whether so expressed or not. Neither the Borrower nor the Company shall be entitled to assign its rights hereunder without the written consent of each Purchaser and the
Collateral Agent. 
 Section 22.2 Payments Due on Non-Business Days. Anything in this Agreement or the Notes to the contrary
notwithstanding, any payment of principal of or Make-Whole Amount or interest on any Note that is due on a date other than a Business Day shall be made on the next succeeding Business Day without including the additional days elapsed in the
computation of the interest payable on such next succeeding Business Day. 
 Section 22.3 Headings. Section headings used in this
Agreement are for convenience of reference only and are not a part of this Agreement for any other purpose. 
 Section 22.4
Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining
provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall (to the full extent permitted by law) not invalidate or render unenforceable such provision in any other jurisdiction. 
 Section 22.5 Construction. Each covenant contained herein shall be construed (absent express provision to the contrary) as being independent of
each other covenant contained herein, so that compliance with any one covenant shall not (absent such an express contrary provision) be deemed to excuse compliance with any other covenant. Where any provision herein refers to action to be taken by
any Person, or which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or indirectly by such Person. 
 Section 22.6 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one instrument. Each counterpart may
consist of a number of copies hereof, each signed by less than all, but together signed by all, of the parties hereto. 
 Section 22.7
Governing Law. This Agreement shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of New York, including Section 5-1401 of the General Obligations Law of said State.

 Section 22.8 Waiver of Jury Trial. Each of the Borrower and the Company irrevocably waives, to the fullest extent permitted by law,
any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or any other Related Document or the transactions contemplated thereby. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 54

 Section 22.9 Indemnity. The Borrower and the Company further agree, jointly and severally, to
defend, protect, indemnify, and hold harmless the Collateral Agent and each and all of the holders of Notes, each of their respective Affiliates and their respective officers, directors, employees, attorneys and agents (collectively, the
“Indemnitees”) from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses of any kind or nature whatsoever (including, without limitation, the reasonable
fees and disbursements of counsel for such Indemnitees in connection with any investigative, administrative or judicial proceeding, whether or not such Indemnitees shall be designated a party thereto), imposed on, incurred by, or asserted against
such Indemnitees in any manner relating to or arising out of this Agreement, or any other Related Documents (collectively, the “Indemnified Matters”); provided, however, that neither the Borrower nor the
Company shall have any obligation to an Indemnitee hereunder with respect to Indemnified Matters caused by or resulting from (a) a dispute among the Purchasers or a dispute between any Purchaser and the Collateral Agent, or (b) the willful
misconduct or gross negligence of such Indemnitee. If the undertaking to indemnify, pay and hold harmless set forth in the preceding sentence may be unenforceable because it is violative of any law or public policy, the Borrower and the Company
shall contribute the maximum portion which it is permitted to pay and satisfy under applicable law, to the payment and satisfaction of all Indemnified Matters incurred by the Indemnitees. This Section 22.9 shall survive the full payment
of the Obligations and the termination of this Agreement or any other Related Document. 
 *    
*     *     *     * 
 If you are in agreement with the foregoing, please
sign the form of agreement on the accompanying counterpart of this Agreement and return it to the Company, whereupon the foregoing shall become a binding agreement between you and the Company and the Borrower. 
  

			
	Very truly yours,
	
	JPI COMMERCIAL, LLC
		
	By:	 	/s/ Carol A. Gamble
	Name:	 	Carol A. Gamble
	Title:	 	Authorized Person

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 55

			
	JAZZ PHARMACEUTICALS, INC.
		
	By:	 	/s/ Carol A. Gamble
	Name:	 	Carol A. Gamble
	Title:	 	Authorized Person
	
	LB I GROUP INC.
		
	By:	 	/s/ Jeffrey A. Ferrell
	Name:	 	Jeffrey A. Ferrell
	Title:	 	Vice President
	
	KKR FINANCIAL HOLDINGS III, LLC
		
	By:	 	/s/ Jamie M. Weinstein
	Name:	 	Jamie M. Weinstein
	Title:	 	Authorized Signatory

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

			
	LERNER ENTERPRISES, LLC
(FKA LERNER ENTERPRISES, LP)
		
	By:	 	Oak Hill Advisors, L.P.,
as advisor and attorney-in-fact
to Lerner Enterprises, LLC
		
	By:	 	/s/ Scott D. Krase
	Name:	 	Scott D. Krase
	Title:	 	Authorized Person
	
	OHA CAPITAL SOLUTIONS FINANCING
(OFFSHORE), LTD.
		
	By:	 	/s/ Scott D. Krase
	Name:	 	Scott D. Krase
	Title:	 	Authorized Person
	
	OHA CAPITAL SOLUTIONS FINANCING
(ONSHORE), LTD.
		
	By:	 	/s/ Scott D. Krase
	Name:	 	Scott D. Krase
	Title:	 	Authorized Person

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

			
	OAK HILL CREDIT ALPHA FINANCE I, LLC
		
	By:	 	Oak Hill Credit Alpha Fund, L.P.,
its Member
		
	By:	 	Oak Hill Credit Alpha Gen Par, L.P.,
its General Partner
		
	By:	 	 Oak Hill Credit Alpha MGP, LLC,
 its General
Partner

		
	By:	 	/s/ Scott D. Krase
	Name:	 	Scott D. Krase
	Title:	 	Authorized Person
	
	OAK HILL CREDIT ALPHA FINANCE I
(OFFSHORE), LTD.
		
	By:	 	/s/ Scott D. Krase
	Name:	 	Scott D. Krase
	Title:	 	Authorized Person
	
	OAK HILL CREDIT OPPORTUNITIES FINANCING, LTD.
		
	By:	 	/s/ Scott D. Krase
	Name:	 	Scott D. Krase
	Title:	 	Authorized Person

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

			
	CARDINAL FUND I, L.P.
		
	By:	 	Cardinal Management I, L.P.,
its General Partner
		
	By:	 	Cardinal MGP, L.L.C.,
its General Partner
		
	By:	 	/s/ Thomas W. White
	Name:	 	Thomas W. White
	Title:	 	Vice President
	
	FW JAZZ PHARMA INVESTORS, L.P.
		
	By:	 	Group VI, 31, L.L.C.,
General Partner
		
	By:	 	/s/ Thomas W. White
	Name:	 	Thomas W. White
	Title:	 	Vice President
	
	DEEP COVE MEZZANINE, LLC
		
	By:	 	/s/ Reeve Waud
	Name:	 	Reeve Waud
	Title:	 	Authorized Person
	
	GENERAL ELECTRIC PENSION TRUST
		
	By:	 	GE Asset Management Incorporated,
its Investment Manager
		
	By:	 	/s/ Daniel L. Furman
	Name:	 	Daniel L. Furman
	Title:	 	Vice President

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 SCHEDULE A 
 (to Senior Secured Note and Warrant Purchase Agreement) 
 INFORMATION RELATING TO PURCHASERS AT INITIAL
CLOSING 
  

									
	 NAME AND ADDRESS OF
PURCHASER
	  	PRINCIPAL
AMOUNT OF
TRANCHE A
NOTES TO BE
PURCHASED	  	PRINCIPAL
AMOUNT OF
TRANCHE B
NOTES TO BE
EXCHANGED	  	NUMBER OF
SHARES OF
COMMON
STOCK
SUBJECT TO
WARRANT
	 LB I Group Inc.
c/o Lehman Brothers
399 Park Avenue, 9th Floor
New York, NY 10022
Attn: Jeffrey A. Ferrell
  
 Wire Instruction:
[ * ] 
	  	$	33,500,000	  	$	56,000,000	  	470,836
	 KKR Financial Holdings III, LLC
c/o KKR Financial LLC
555 California Street
50th Floor
San Francisco, CA 94104
Jamie Weinstein
  
 Fax: (415) 391-3330
  
 Wire Instructions:
[ * ]

	  			  	$	7,143,000	  	

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

								
	 NAME AND ADDRESS OF
PURCHASER
	  	PRINCIPAL
AMOUNT OF
TRANCHE A
NOTES TO BE
PURCHASED	  	PRINCIPAL
AMOUNT OF
TRANCHE B
NOTES TO BE
EXCHANGED	  	NUMBER OF
SHARES OF
COMMON
STOCK
SUBJECT TO
WARRANT
	 Lerner Enterprises, LLC
(FKA Lerner Enterprises, L.P.)
 c/o Oak Hill Advisors, LP
1114 Avenue of the Americas
27th Floor
New York, NY 10036
Attn: Shilpa Wani
  
 Wire Instructions:
[ * ]
	  		  	$	231,000	  	
	 OHA Capital Solutions Financing
(Offshore), Ltd.
 c/o Oak Hill Advisors, LP
1114 Avenue of the Americas
27th Floor
New York, NY 10036
Attn: Shilpa Wani
  
 Wire Instructions:
[ * ]
	  		  	$	931,000	  	
	 OHA Capital Solutions Financing
(Onshore), Ltd.
 c/o Oak Hill Advisors, LP
1114 Avenue of the Americas
27th Floor
New York, NY 10036
Attn: Shilpa Wani
	  		  	$	501,000	  	

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

							
	 NAME AND ADDRESS OF
PURCHASER
	  	PRINCIPAL
AMOUNT OF
TRANCHE A
NOTES TO BE
PURCHASED	  	PRINCIPAL
AMOUNT OF
TRANCHE B
NOTES TO BE
EXCHANGED	  	NUMBER OF
SHARES OF
COMMON
STOCK
SUBJECT TO
WARRANT
	 Wire Instructions:
[ * ]
	  		  		  	
	 Oak Hill Credit Alpha Finance I, LLC
 c/o Oak Hill
Advisors, LP
1114 Avenue of the Americas
27th Floor
New York, NY 10036
Attn: Shilpa Wani
  
 Wire Instructions:
 [ * ]
	  		  	$201,000	  	
	 Oak Hill Credit Alpha Finance I
(Offshore), Ltd.
 c/o Oak Hill Advisors, LP
1114 Avenue of the Americas
27th Floor
 New York, NY 10036
Attn: Shilpa Wani
  
 Wire Instructions:
 [ * ]
	  		  	$623,000	  	

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

								
	 NAME AND ADDRESS OF
PURCHASER
	  	PRINCIPAL
AMOUNT OF
TRANCHE A
NOTES TO BE
PURCHASED	  	PRINCIPAL
AMOUNT OF
TRANCHE B
NOTES TO BE
EXCHANGED	  	NUMBER OF
SHARES OF
COMMON
STOCK
SUBJECT TO
WARRANT
	 Oak Hill Credit Opportunities Financing, Ltd.
 c/o
Oak Hill Advisors, LP
1114 Avenue of the Americas
27th Floor
New York, NY 10036
Attn: Shilpa Wani
  
 Wire Instructions:
[ * ]
	  		  	$	950,000	  	
	 CARDINAL FUND I, L.P.
 201 Main Street, Suite 1620

 Fort Worth, TX 76102
 Attn: Erin McDaniel
  
 Wire Instructions:
[ * ]
	  		  	$	280,000	  	
	 FW JAZZ PHARMA INVESTORS, L.P.
 201 Main Street,
Suite 1620
 Fort Worth, TX 76102
 Attn: Erin McDaniel

 
 Wire Instructions:
[ * ] 
	  		  	$	140,000	  	

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

									
	 NAME AND ADDRESS OF
PURCHASER
	  	PRINCIPAL
AMOUNT OF
TRANCHE A
NOTES TO BE
PURCHASED	  	PRINCIPAL
AMOUNT OF
TRANCHE B
NOTES TO BE
EXCHANGED	  	NUMBER OF
SHARES OF
COMMON
STOCK
SUBJECT TO
WARRANT
	 Deep Cove Mezzanine, LLC
560 Oakwood Avenue, Suite 203
Lake Forest, IL 60045
Attn: Mark Flower
  
 Wire Instructions:
[ * ]
	  	$	3,421,053	  	$	5,000,000	  	48,082
	 General Electric Pension Trust
c/o GE Asset Management
Incorporated
3001 Summer Street
Stamford, CT 06905
Attn: Daniel L.
Furman
Fax: (203) 326-4073
  
 Wire Instructions:
[ * ]
	  	$	3,078,947	  	$	8,000,000	  	43,274

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 INFORMATION RELATING TO PURCHASERS AT SUBSEQUENT CLOSING 
  

					
	 NAME AND ADDRESS OF
PURCHASER
	  	PRINCIPAL
AMOUNT OF
TRANCHE A
NOTES TO BE
PURCHASED	  	NUMBER OF
SHARES OF
COMMON
STOCK
SUBJECT TO
WARRANT
	 LB I Group Inc.
c/o Lehman Brothers
399 Park Avenue, 9th Floor
New York, NY 10022
Attn: Jeffrey A. Ferrell
  
 Wire Instruction:
[ * ]
	  	Up to $27,000,000
 (as determined by
the
Borrower)
	  	
	 Deep Cove Mezzanine, LLC
560 Oakwood Avenue,
Suite 203
Lake Forest, IL 60045
Attn: Mark Flower
  
 Wire Instructions:
[ * ]
	  	Up to $1,578,947
(as determined by
the Borrower)	  	

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

					
	 NAME AND ADDRESS OF
PURCHASER
	  	PRINCIPAL
AMOUNT OF
TRANCHE A
NOTES TO BE
PURCHASED	  	NUMBER OF
SHARES OF
COMMON
STOCK
SUBJECT TO
WARRANT
	 General Electric Pension Trust
c/o GE Asset Management
Incorporated
3001 Summer Street
Stamford, CT 06905
Attn: Daniel L.
Furman
Fax: (203) 326-4073
  
 Wire Instructions:
[ * ]
	  	Up to $1,421,053
(as determined
by the Borrower)	  	

  

 [Senior Note and Warrant Purchase Agreement]. 
 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 SCHEDULE B 
 (to Senior Secured Note and Warrant Purchase Agreement) 
 DEFINED TERMS 
 As used herein, the following terms have the respective meanings set forth below or set forth in the Section hereof following such term: 

“Accounts” means, with respect to any Person, all of such Person’s now existing and future: (a) accounts (as defined in the
UCC), and any and all other receivables, including, without limitation, all accounts created by, or arising from, all of such Person’s sales, leases, rentals of goods or renditions of services to its customers (whether or not they have been
earned by performance), including but not limited to, those accounts arising under any of such Person’s trade names, logos or styles, or through any of such Person’s divisions; (b) any and all instruments, documents, chattel paper
(including electronic chattel paper), contracts and contract rights (all as defined in the UCC); (c) unpaid seller’s or lessor’s rights (including rescission, replevin, reclamation, repossession and stoppage in transit) relating to
the foregoing or arising therefrom; (d) rights to any goods represented by any of the foregoing, including rights to returned, reclaimed or repossessed goods; (e) reserves and credit balances arising in connection with or pursuant to any
of the foregoing; (f) guaranties, supporting obligations, payment intangibles and letter of credit rights (all as defined in the UCC); (g) insurance policies or rights relating to any of the foregoing; (h) general intangibles
pertaining to any and all of the foregoing (including all rights to payment, including those arising in connection with bank and non-bank credit cards), and including books and records and any electronic media and software thereto; (i) notes,
deposits or property of account debtors securing the obligations of any such account debtors to such Person; and (j) cash and non-cash proceeds (as defined in the UCC) of any and all of the foregoing. 
 “Affiliate” means, at any time, and with respect to any Person, any other Person that at such time directly or indirectly through one or
more intermediaries Controls, or is Controlled by, or is under common Control with, such first Person. As used in this definition, “Control” means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. Unless the context otherwise clearly requires, any reference to an “Affiliate” is a reference to an Affiliate
of the Company. 
 “Annualized Aggregate Net Product Sales” of the Company at any time shall be an amount equal to four
times the Net Product Sales of the Company for the most recent fiscal quarter of the Company as to which financial statements have been provided pursuant to Section 7.1; provided that, if the Company shall have failed to provide
financial statements no later than five (5) Business Days after the time required by Section 7.01, then until such financial statements shall have been provided, the Annualized Aggregate Net Product Sales of the Company shall be
deemed to be $0. 
 “Antizol” means the fomepizole pharmaceutical products currently marketed under the trademarks Antizol
and Antizol Vet. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 “Antizol Assets” means Antizol Intellectual Property and Antizol Regulatory Approvals.

 “Antizol Contracts” means the contracts set forth on Exhibit F and all other contracts of any Credit Party or
Orphan and all amendments thereto, whether now existing or subsequently executed, with third parties related to the formulation, manufacture, packaging, distribution, marketing and sale of Antizol as well as the acquisition of all components
necessary for the manufacture and packaging of Antizol. 
 “Antizol Intellectual Property” means all patents, trademarks,
trade dress, copyrights, all rights therein, and any other intellectual property possessed by Orphan and/or any Credit Party and related to the making, using, selling, marketing, or distribution of Antizol. 
 “Antizol License Agreement” is defined in Section 10.2(h). 
 “Antizol Regulatory Approval” means all grants of approval and marketing exclusivity for Antizol in any jurisdiction by the competent
regulatory body for such jurisdiction. 
 “Asset Disposition” means any transaction, or series of related transactions,
pursuant to which the Company or any of its Subsidiaries sells, assigns, transfers or otherwise disposes of any property (whether now owned or hereafter acquired) yielding proceeds to any Credit Party in excess of $1,000,000 for any such transaction
or series of related transactions to any other Person (other than the Company or any Domestic Subsidiary), in each case, whether or not the consideration therefor consists of cash, securities or other assets, excluding any sales of Inventory in the
ordinary course of business on ordinary business terms; provided, however, that, notwithstanding the foregoing, any sale, assignment, transfer or other disposal of any property by the Company or any Subsidiary of the Company permitted
by Section 10.2 (a), (b) or (c) shall not be deemed to be an Asset Disposition. 
 “Bankruptcy
Code” is defined in Section 2.4. 
 “Business Day” means any day other than a Saturday, a Sunday or a day on
which commercial banks in New York City are required or authorized to be closed. 
 “Capital Lease” means, at any time, a
lease with respect to which the lessee is required concurrently to recognize the acquisition of an asset and the incurrence of a liability in accordance with GAAP. 
 “Capitalized Rentals” of any Person means as of the date of any determination thereof the amount at which the aggregate Rentals due and to become due under all Capital Leases under which such Person
is a lessee would be reflected as a liability on a consolidated balance sheet of such Person. 
 “Closing” is defined in
Section 1.3. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 2

 “Change in Control” means (i) a sale of all or substantially all of the assets of
the Company to any Person or to two or more Persons acting together as a partnership, limited partnership, syndicate or other group for the purpose of acquiring, holding or disposing of or voting securities of the Company, or a sale of all or
substantially all of the assets of the Company to any Person or Persons in which the stockholders of the Company immediately prior to such transaction do not control more than 50% of the voting power immediately following the transaction;
(ii) a transaction or series of related transactions by the Company (other than transaction(s) determined by the Board of Directors to be primarily for cash financing purposes) or by any stockholder or stockholders of the Company resulting in
more than 50% of the voting power of the Company being held by a Person or Persons other than stockholders of the Company who, immediately prior to such transaction, controlled more than 50% of the voting power of the Company; (iii) a merger or
consolidation of the Company with or into any Person or Persons, if and only if, after such merger or consolidation, directors of the Company immediately prior to such merger or consolidation do not constitute a majority of the directors of the
surviving entity or its parent. 
 “Code” means the Internal Revenue Code of 1986, as amended from time to time, and the
rules and regulations promulgated thereunder from time to time. 
 “Collateral” is defined in Section 3.1.

 “Collateral Agent” means LB I Group Inc. in its capacity as contractual representative for itself and the Purchasers
pursuant to Section 21 hereof and any successor Collateral Agent appointed pursuant Section 21. 
 “Collateral Documents” means the Pledge Agreement and all other mortgages, deeds of trust, security agreements, assignments, control account agreements, financing statements and other documents or instruments as shall from
time to time secure the Obligations. 
 “Company Guaranty” is defined in Section 2.3. 
 “Confidential Information” is defined in Section 20. 
 “Consolidated EBITDA” means, with reference to any period, the EBITDA of the Company and its Subsidiaries determined on a consolidated
basis for such period. 
 “Consolidated Secured Indebtedness” means as of the date of any determination thereof all secured
Indebtedness of the Company and its Subsidiaries determined on a consolidated basis (and without duplication but after eliminating intercompany items) in accordance with GAAP. 
 “Corporate Integrity Agreement” is defined in Section 5.23. 
 “Credit Party” means the Borrower, the Company and any Domestic Subsidiary. 
 “Default” means an event or condition the occurrence or existence of which would, with the lapse of time or the giving of notice or
both, become an Event of Default. 
 “Documents of Title” shall mean all present and future documents (as defined in the
UCC), and any and all warehouse receipts, bills of lading, shipping documents, chattel paper, instruments and similar documents, all whether negotiable or not. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 3

 “Domestic Subsidiary” means a Subsidiary of the Company formed under the laws of any
state of the United States or the District of Columbia other than Orphan. 
 “Environmental Laws” means any and all Federal,
state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the
environment or the release of any materials into the environment, including but not limited to those related to hazardous substances or wastes, air emissions and discharges to waste or public systems. 
 “Equipment” means all equipment (as defined in the UCC), including, without limitation (whether or not included in the UCC definition of
“equipment”), all furniture, furnishings, fixtures and machinery, and all parts thereof and all additions and accessions thereto and replacements therefor and all cash and non-cash proceeds (as defined in the UCC) of any and all of the
foregoing. 
 “EBITDA” for any Person during any period means Net Income of such Person for such period plus all amounts
deducted in arriving at such Net Income amount in respect of (a) Interest Expense for such period, plus (b) Federal, state and local income taxes for such period, plus (c) all amounts charged for depreciation of fixed
assets and amortization of intangible assets during such period, plus (d) all non-cash, non-recurring or extraordinary charges, expenses or losses for such period, minus (e) non-cash gains, non-recurring gains, and
extraordinary gains, all determined in accordance with GAAP. 
 “ERISA” means the Employee Retirement Income Security Act of
1974, as amended from time to time, and the rules and regulations promulgated thereunder from time to time in effect. 
 “ERISA
Affiliate” means any trade or business (whether or not incorporated) that is treated as a single employer together with the Company under Section 414 of the Code. 
 “Event of Default” is defined in Section 11. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “Fee
Letter” means the Fee Letter, dated of even date herewith, among the Company, the Borrower, and LB I Group Inc., providing for the payment by the Borrower of an arrangement fee to LB I Group Inc. in connection with the arrangement of the
transactions contemplated by this Agreement. 
 “Foreign Subsidiary” means each Subsidiary of the Company, other than
Orphan, that is not a Domestic Subsidiary. 
 “Fraudulent Conveyance” is defined in Section 2.3. 
 “GAAP” means generally accepted accounting principles as in effect from time to time in the United States of America. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 4

 “General Intangibles” means, as to any Person, all “general intangibles” as
defined in the UCC, now owned or hereafter acquired, including, without limitation (whether or not included in the UCC definition of “general intangibles”), all of such Person’s then owned or existing and future acquired or arising
general intangibles, causes in action and causes of action and all other intangible personal property of such Person of every kind and nature, including, without limitation, Intellectual Property, grants by any Governmental Authority of approval or
marketing exclusivity for any pharmaceutical product, franchises, tax refund claims, reversions or any rights thereto and any other amounts payable to such Person from any rights and claims against carriers and shippers, rights to indemnification,
and business interruption, property, casualty or any similar type of insurance and any proceeds thereof, and all cash and non-cash proceeds (as defined in the UCC) of any and all of the foregoing. 
 “Governmental Authority” means 
 (a) the government of 
 (i) the United States of America or any State or other political subdivision thereof, or 
 (ii) any jurisdiction in which the Company or any Subsidiary conducts all or any part of its business, or which asserts jurisdiction over any properties
of the Company or any Subsidiary, or 
 (b) any entity exercising executive, legislative, judicial, regulatory or administrative functions
of, or pertaining to, any such government. 
 “Guaranty” means, with respect to any Person, any obligation (except the
endorsement in the ordinary course of business of negotiable instruments for deposit or collection) of such Person guaranteeing or in effect guaranteeing any Indebtedness, dividend or other obligation of any other Person in any manner, whether
directly or indirectly, including (without limitation) obligations incurred through an agreement, contingent or otherwise, by such Person: 
 (a) to purchase such Indebtedness or obligation or any property constituting security therefor; 
 (b) to advance or supply funds
(i) for the purchase or payment of such Indebtedness or obligation, or (ii) to maintain any working capital or other balance sheet condition or any income statement condition of any other Person or otherwise to advance or make available
funds for the purchase or payment of such Indebtedness or obligation; 
 (c) to lease properties or to purchase properties or services
primarily for the purpose of assuring the owner of such Indebtedness or obligation of the ability of any other Person to make payment of the Indebtedness or obligation; or 
 (d) otherwise to assure the owner of such Indebtedness or obligation against loss in respect thereof. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 5

 In any computation of the Indebtedness or other liabilities of the obligor under any Guaranty, the
Indebtedness or other obligations that are the subject of such Guaranty shall be assumed to be direct obligations of such obligor. 
 “Hazardous Material” means any and all pollutants, toxic or hazardous wastes or any other substances that pose a hazard to health or safety, the removal of which may be required or the generation, manufacture, refining,
production, processing, treatment, storage, handling, transportation, transfer, use, disposal, release, discharge, spillage, seepage, or filtration of which is restricted, prohibited or penalized by any applicable Environmental Law (including,
without limitation, asbestos, urea formaldehyde foam insulation and polychlorinated biphenyls). 
 “holder” means, with
respect to any Note, the Person in whose name such Note is registered in the register maintained by the Company pursuant to Section 13.1. 
 “Indebtedness” with respect to any Person means, at any time, without duplication, 
 (a)
its liabilities for borrowed money and its redemption obligations in respect of mandatorily redeemable preferred stock; 
 (b) its
liabilities for the deferred purchase price of property acquired by such Person (excluding accounts payable arising in the ordinary course of business but including all liabilities created or arising under any conditional sale or other title
retention agreement with respect to any such property); 
 (c) all liabilities appearing on its balance sheet in accordance with GAAP in
respect of Capital Leases; 
 (d) all liabilities for borrowed money secured by any Lien with respect to any property owned by such Person
(whether or not it has assumed or otherwise become liable for such liabilities); 
 (e) all its liabilities in respect of letters of credit
or instruments serving a similar function issued or accepted for its account by banks and other financial institutions (whether or not representing obligations for borrowed money); 
 (f) all payment obligations of such Person with respect to interest rate swaps, currency swaps and similar obligations; and 
 (g) any Guaranty of such Person with respect to liabilities of a type described in any of clauses (a) through (f) hereof. 
 Indebtedness of any Person shall include all obligations of such Person of the character described in clauses (a) through (g) to the extent
such Person remains legally liable in respect thereof notwithstanding that any such obligation is deemed to be extinguished under GAAP. 
 “Initial Closing” is defined in Section 1.3. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 6

 “Intellectual Property” means all present and future designs, patents, patent rights and
applications therefor, trademarks and registrations or applications therefor, trade names, inventions, copyrights and all applications and registrations therefor, software or computer programs, in-bound licensed rights, trade secrets, methods,
processes, know-how, drawings, specifications, descriptions, and all memoranda, notes and records with respect to any research and development, whether now owned or hereafter acquired, and all goodwill associated with any of the foregoing.

 “Interest Expense” of the Company and its Subsidiaries for any period means all interest (including the interest
component of Rentals on Capital Leases) and all amortization of debt discount and expense on any particular Indebtedness (including, without limitation, payment-in-kind, zero coupon and other like securities) for which such calculations are being
made. Computations of Interest Expense on a pro forma basis for Indebtedness having a variable interest rate shall be calculated at the rate in effect on the date of any determination. 
 “Inventory” means, as to any Person, all “inventory” of such Person as defined in the UCC including, without limitation
(whether or not included in the UCC definition of “inventory”), all of such Person’s then owned or existing and future acquired or arising: (a) inventory, merchandise, goods and other personal property intended for sale or lease
or for display or demonstration; (b) work in process; (c) raw materials and other materials and supplies of every nature and description used or which might be used in connection with the manufacture, packing, shipping, advertising,
selling, leasing or furnishing of the foregoing or otherwise used or consumed in the conduct of business; (d) documents evidencing, and General Intangibles relating to, any of the foregoing; and (e) all cash and non-cash proceeds (as
defined in the UCC) of any and all of the foregoing. 
 “Inventories and Receivables” means, of the Company and its
consolidated Subsidiaries, as of any date of determination, an amount equal to the sum of the amount of “Inventories” of the Company and its consolidated Subsidiaries as of such date and the amount of “Accounts Receivable, net”
of the Company and its consolidated Subsidiaries as of such date, in each case as determined on a consolidated basis in accordance with GAAP. 
 “Investment Property” means a security, whether certificated or uncertificated, security entitlement, securities account, commodity contract or commodity account. 
 “Investments” means all investments, in cash or by delivery of property, made directly or indirectly in any property or assets of any
Person or in any Person, whether by acquisition of shares of capital stock, Indebtedness or other obligations or Securities or by loan, advance, capital contribution or otherwise. 
 “JPI Commercial License Agreements” is defined in Section 10.2(h). 
 “Knowledge” means, as to the Company, the actual knowledge of any officer, director or employee of the Company or any Subsidiary of the
Company after reasonable investigation. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 7

 “Lien” means, with respect to any Person, any mortgage, lien, pledge, charge, security
interest or other encumbrance, or any interest or title of any vendor, lessor, lender or other secured party to or of such Person under any conditional sale or other title retention agreement or Capital Lease, upon or with respect to any property or
asset of such Person (including in the case of stock or membership or equivalent equity interests, stockholder or member or equivalent agreements, voting trust agreements and all similar arrangements). 
 “LUVOX® CR” means the
controlled release fluvoxamine pharmaceutical product currently intended to be marketed under the trademark LUVOX® CR and the immediate release fluvoxamine pharmaceutical product previously
marketed under the trademark LUVOX®. 
 “LUVOX® CR Assets” means the LUVOX® CR Intellectual Property and LUVOX® CR Regulatory Approval. 
 “LUVOX® CR Contracts” means the contracts set forth on Exhibit G and all other contracts of any Credit Party and all amendments thereto, whether now
existing or subsequently executed, with third parties related to the formulation, manufacture, packaging, distribution, marketing and sale of LUVOX® CR as well as the acquisition of all
components necessary for the manufacture and packaging of LUVOX® CR. 
 “LUVOX® CR Intellectual
Property” means all patents, trademarks, trade dress, copyrights, all rights therein, and any other intellectual property possessed by any Credit Party and related to the making, using, selling, marketing, or distribution of LUVOX® CR. 
 “LUVOX® CR License Agreement” is defined in Section 10.2(h). 
 “LUVOX® CR Regulatory
Approval” means all grants of approval and marketing exclusivity for LUVOX® CR in the United States. 
 “Majority Holders” means, at any time, the holders of more than 50% in principal amount of the Notes at the time outstanding (exclusive of Notes then owned by the Company). 
 “Make-Whole Amount” means, with respect to any principal prepayment for which the Make-Whole Amount is applicable, an amount determined
with reference to the following formula: 
  

					
	Make-Whole Amount = pmt x (.40 – (qtr x .0167))
			
	 where:
	  		  	
			
	 pmt
	  	=    	  	the amount of the applicable principal prepayment; and
			
	 qtr
	  	=    	  	the number which is the quotient of: (x) the fewer of the number of months elapsed subsequent to June 24, 2005 and the date upon which (i) an Event of Default occurs and continues for more than
30 days notwithstanding the fact that such Event of Default is cured thereafter, or (ii) the applicable prepayment is made; divided by (y) three.

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 8

 Notwithstanding the foregoing to the contrary, so long as no Event of Default shall have occurred and be continuing, the
Make-Whole Amount for any voluntary principal prepayment on the Notes of up to an amount equal to $40,000,000 less the amount of any prepayments pursuant to Section 8.3 in the aggregate shall be equal to 10% of such principal prepayment.

 “Mandatory Prepayment Event” means, with respect to any Credit Party, the occurrence of an Asset Disposition in
connection with such Credit Party, the receipt by such Credit Party of any cash insurance proceeds for damaged or destroyed property that yields gross proceeds to such Credit Party in excess of $1,000,000, or the receipt by such Credit Party of any
cash proceeds from any judgment awards or settlements that yield gross proceeds to such Credit Party in excess of $1,000,000. 
 “Material” means material in relation to the business, operations, affairs, financial condition, assets or properties of the Company and its Subsidiaries taken as a whole. 
 “Material Adverse Effect” means a material adverse effect on (a) the business, operations, affairs, financial condition, assets or
properties of the Company and its Subsidiaries taken as a whole, or (b) the ability of the Company or the Borrower to perform its obligations under this Agreement and the Notes and Warrants, or (c) the validity or enforceability of this
Agreement or the Notes or the Warrants. 
 “Material Breach or Default” means, with respect to the Corporate Integrity
Agreement, a “material breach” or “default” as such phrases are defined therein. 
 “Minority Interests”
means, with respect to any Person, any shares of stock (or equivalent equity interests) of any class of a Subsidiary of such Person (other than directors’ qualifying shares as required by law) that are not owned by such Person and/or one or
more of its Subsidiaries. Minority Interests shall be valued by valuing Minority Interests constituting preferred stock (or equivalent equity interests) at the voluntary or involuntary liquidating value of such preferred stock (or equivalent equity
interests), whichever is greater, and by valuing Minority Interests constituting common stock (or equivalent equity interests) at the book value of capital and surplus applicable thereto adjusted, if necessary, to reflect any changes from the book
value of such common stock (or equivalent equity interests) required by the foregoing method of valuing Minority Interests in preferred stock. 
 “Multiemployer Plan” means any Plan that is a “multiemployer plan” (as such term is defined in Section 400 l(a)(3) of ERISA). 
 “Net Income” for any Person during any period means the gross revenues of such Person and its Subsidiaries for such period less all expenses and other proper charges (including taxes on income),
determined on a consolidated basis after eliminating earnings or losses attributable to outstanding Minority Interests, but excluding in any event: 
 (a) any gains or losses on the sale or other disposition of Investments or fixed or capital assets, and any taxes on such excluded gains and any tax deductions or credits on account of any such excluded losses; 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 9

 (b) the proceeds of any life insurance policy; 
 (c) net earnings and losses of any Subsidiary accrued prior to the date it became a Subsidiary; 
 (d) net earnings and losses of any corporation (other than a Subsidiary), substantially all the assets of which have been acquired in any manner by such
Person or any Subsidiary thereof, realized by such corporation prior to the date of such acquisition; 
 (e) net earnings and losses of any
corporation (other than a Subsidiary) with which such Person or any Subsidiary thereof shall have consolidated or which shall have merged into or with such Person or any Subsidiary thereof prior to the date of such consolidation or merger;

 (f) net earnings of any business entity (other than a Subsidiary) in which such Person or any Subsidiary thereof has an ownership interest
unless such net earnings shall have actually been received by such Person or any Subsidiary thereof in the form of cash distributions; 
 (g)
any portion of the net earnings of any Subsidiary which for any reason is unavailable for payment of dividends to such Person or any Subsidiary thereof; 
 (h) earnings resulting from any reappraisal, revaluation or write-up of assets; 
 (i) any deferred or other
credit representing any excess of the equity in any Subsidiary of such Person at the date of acquisition thereof over the amount invested in such Subsidiary; 
 (j) any gain arising from the acquisition of any securities of such Person or any Subsidiary thereof; 
 (k)
any reversal of any contingency reserve, except to the extent that provision for such contingency reserve shall have been made from income arising during such period; and 
 (l) any other extraordinary gain. 
 “Net Proceeds” means: 
 (a) with respect to any Asset Disposition by any Person, the amount of cash received (directly or indirectly) from time to time (whether
as initial consideration or through the payment or disposition of deferred consideration) by or on behalf of such Person in connection therewith after deducting therefrom only (i) the amount of any Indebtedness secured by any Lien which is
permitted by Section 10.3 on any property (other than any Indebtedness assumed by the purchaser of such property and Indebtedness evidenced by the Notes) which is required to be, and is, repaid in connection with such Asset Disposition,
(ii) reasonable expenses related thereto incurred by such Person in connection with the Asset Disposition, (iii) transfer taxes paid or due to be paid by such Person to any taxing authorities in connection with such Asset Disposition, and
(iv) any amount of reserves properly taken on the balance sheet of the Person making the Asset Disposition, as reasonably determined by the Board of Directors of such Person in its good faith judgment; provided that such reserves shall
be deemed part of Net Proceeds if and to the extent such reserves are not actually paid by the applicable Person and are removed from such Person’s balance sheet; 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 10

 (b) with respect to any insurance proceeds received by any Person in connection with the
damage or destruction of any property or asset, the amount of cash received (directly or indirectly) by or on behalf of such Person in connection therewith after deducting therefrom only (i) the amount of any Indebtedness secured by any Lien
which is permitted by Section 10.3 on the damaged or destroyed property or asset (other than any Indebtedness evidenced by the Notes) and (ii) reasonable expenses related thereto incurred by such Person in connection with the
collection of such insurance proceeds; 
 (c) with respect to any judgment awards or settlements received by any Person, the
amount of cash received (directly or indirectly) by or on behalf of such Person in connection therewith after deducting therefrom only reasonable expenses related thereto incurred by such Person in connection with the obtaining of such award or the
negotiation of such settlement; and 
 (d) cash received by any Person from the conversion of any non-cash proceeds received
in connection with an Asset Disposition, insurance awards or any judgments or settlements, subject to any applicable reductions noted in clauses (a), (b) and (c) above. 
 “Net Product Sales” means, for any Product for any fiscal period of the Company,
an amount equal to the excess of the amount of the proceeds of sales or royalties on sales pursuant to licensing arrangements with respect to such Product, for such fiscal period over the amount of discounts, credits, refunds, and
rebates of such Products during such fiscal period. If the term “Net Product Sales” is used in this Agreement without reference to a particular Product, then such Net Product Sales shall be determined with respect to Antizol, LUVOX® CR, Xyrem, and all other Products of the Company, if any. 
 “New
Subsidiary” is defined in Section 9.7. 
 “Notes” is defined in Section 1. 
 “Obligations” is defined in Section 2.2. 
 “Officer’s Certificate” means a certificate of a Senior Financial Officer or of any other officer of the Company whose responsibilities extend to the subject matter of such certificate.

 “Orphan” is defined in the opening recitals of this Agreement. 
 “Orphan Asset Transfer” means (i) the assignment of all right title and interest of Orphan in the Antizol Assets and the Xyrem
Assets to Borrower, (ii) the assignment of the rights and obligations of Orphan under each and every Antizol Contract and Xyrem Contract to Borrower, or to another Credit Party subject to the requirements of Section 10.7, and
(iii) repayment of all Indebtedness owed pursuant to the Orphan Note Purchase Agreement and the Orphan Notes; 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 11

 
(iv) the assignment of all right, title and interest of the Company in the LUVOX® CR Assets
to the Borrower; and (v) the assignment of the rights and obligations of the Company under each and every LUVOX® CR Contract to the Borrower or to another Credit Party subject to the
requirements of Section 10.7. 
 “Orphan Asset Transfer Agreement” means the agreement to effect the Orphan
Asset Transfer in the form set forth in Exhibit I. 
 “Orphan Merger” means the merger of
Orphan with and into the Borrower, with the Borrower being the surviving corporation, pursuant to the Orphan Merger Agreement. 
 “Orphan Merger Agreement” is the collective reference to the agreement and plan of merger, dated as of March 14, 2008, between Orphan and the Borrower and the certificate of merger in the form set forth in
Exhibit K. 
 “Orphan Note Purchase Agreement” means the Senior Secured Note and Warrant
Purchase Agreement, dated as of June 24, 2005, by and among the Purchasers (as defined therein), the Company, and Twist Merger Sub, Inc., as amended. 
 “Orphan Notes” means the “Notes”, as defined in the Orphan Note Purchase Agreement 
 “Other Collateral” means: 
 (a) all other goods and property, whether or not delivered, including,
without limitation, such other goods and property: (i) the sale or lease of which gives or purports to give rise to any Account or other Collateral, including, but not limited to, all Inventory and other merchandise returned or rejected by or
repossessed from customers; (ii) securing any Account or other Collateral, including, without limitation, all rights as a consignor, a consignee, an unpaid vendor or lienor (including, without limitation, stoppage in transit, replevin and
reclamation) with respect to such other goods and properties; or (iii) warranty claims relating to goods; 
 (b) all
substitutes and replacements for, accessories, attachments, and other additions to, any of the above and any and all products or masses into which any goods are physically united such that their identity is lost; 
 (c) all policies and certificates of insurance relating to any of the foregoing, now owned or hereafter acquired, evidencing or pertaining
to any and all items of Collateral; 
 (d) all files, correspondence, computer programs, tapes, discs and related data
processing software which contain information identifying or pertaining to any of the Collateral or any account debtor, or showing the amounts thereof or payments thereon or otherwise necessary or helpful in the realization thereon or the collection
thereof; and 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 12

 (e) any and all products and proceeds of the foregoing (including, but not limited to,
any claim to any item of Collateral and any claim against any third party for loss of, damage to or destruction of any or all of, the Collateral or for proceeds payable under, or unearned premiums with respect to, policies of insurance) in whatever
form, including, but not limited to, cash, instruments, chattel paper, security agreements and other documents. 
 “PBGC”
means the Pension Benefit Guaranty Corporation referred to and defined in ERISA or any successor thereto. 
 “Permitted Acquisition
Indebtedness” is defined in Section 10.1(a)(v). 
 “Permitted Foreign Subsidiary Transfer” means the
transfer by the Company or a Subsidiary of the Company other than the Borrower (or a Subsidiary of the Borrower) of the international rights to a Product candidate to a Foreign Subsidiary, all pursuant to documentation and on terms reasonably
acceptable to the Purchasers. 
 “Permitted Investments” means: 
 (a) Investments by the Company and its Subsidiaries in and to the Company or in or to: 
 (i) Any Domestic Subsidiary, including any Investment in a corporation which, after giving effect to such Investment, will become a
Domestic Subsidiary as permitted by Section 10.5(a); or 
 (ii) Any Foreign Subsidiary permitted to be created and
capitalized by Section 10.5(b) so long as: 
 a. such Foreign Subsidiary is established solely to carry out the
Company’s or any of its Subsidiaries’ business operations in a particular foreign jurisdictions where it is necessary or prudent, in the good faith determination of the Board of Directors of the Company, to establish a separate legal
entity under local law; 
 b. such Investment is comprised of only that amount of capital and other property as is determined
to be necessary from time to time, in the good faith discretion of the Board of Directors of the Company, to conduct the ordinary and intended business operations of such Foreign Subsidiary; and 
 c. such Investment would not be reasonably expected to have a Material Adverse Effect or otherwise materially adversely effect the value
or priority of the Collateral, taken as a whole, for the prompt and full payment of the Obligations; or 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 13

 (iii) Orphan, to the extent made prior to the date hereof. 
 (b) Investments representing loans or advances in the usual and ordinary course of business to officers, directors and employees for
expenses (including moving expenses related to a transfer) incidental to carrying on the business of the Company or any Domestic Subsidiary; 
 (c) Investments in property or assets to be used in the ordinary course of the business of the Company and its Subsidiaries as described in Section 9.6 of this Agreement; 
 (d) Investments representing travel advances in the usual and ordinary course of business to officers and employees of the Company and its
Subsidiaries incidental to carrying-on the business of the Company or any Subsidiaries; 
 (e) receivables arising from the
sale of goods and services in the ordinary course of business of the Company and its Subsidiaries; 
 (f) Investments in
commercial paper or corporate debt obligation of corporations (not constituting Securitization Entities, as hereinafter defined) organized under the laws of the United States or any state thereof maturing in 270 days or less from the date of
issuance which, at the time of acquisition by the Company or any Subsidiary, is accorded the highest rating by Standard & Poor’s Ratings Group, a division of McGraw-Hill, Inc., a New York corporation, or by Moody’s Investors
Service, Inc.; 
 (g) Investments in direct obligations of the United States of America or any agency or instrumentality of
the United States of America, the payment or guarantee of which constitutes a full faith and credit obligation of the United States of America, in either case, maturing within twelve months from the date of acquisition thereof; 
 (h) Investments in certificates of deposit and time deposits maturing within one year from the date of issuance thereof, issued by a bank
or trust company organized under the laws of the United States or any State thereof; provided that at the time of acquisition thereof by the Company or a Subsidiary, (i) the senior unsecured long-term debt of such bank or trust company
or of the holding company of such bank or trust company is rated AA or better by Standard & Poor’s Ratings Group, a division of McGraw-Hill, Inc., a New York corporation, or “Aa2” or better by Moody’s Investors Service,
Inc. or (ii) such Investments are fully insured by the Federal Depository Insurance Corporation; and 
 (i) Investments
in any money market fund which invests substantially all of its assets in obligations described in clauses (g) and (h) above. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 14

 As used herein, “Securitization Entity” means any entity the primary business of which is to own accounts,
notes or other debt instruments and related collateral, securities, or other financial assets or general intangibles. 
 “Permitted
Liens” means: 
 (a) (i) Liens in favor of the Collateral Agent for the benefit of the Purchasers pursuant to
this Agreement or any other Related Document and (ii) Liens in favor of the Collateral Agent for the benefit of the Purchasers (as defined in the Orphan Note Purchase Agreement) pursuant to the Related Documents (as defined in the Orphan Note
Purchase Agreement), but only (in the case of this clause (ii)) until the Initial Closing; 
 (b) Liens for property taxes and
assessments or governmental charges or levies and Liens securing claims or demands of mechanics and materialmen so long as the payment thereof is not at the time required by Section 9.4; 
 (c) Liens of or resulting from any judgment or award, the time for the appeal or petition for rehearing of which shall not have expired,
or in respect of which the Company or a Subsidiary thereof shall at any time in good faith be prosecuting an appeal or proceeding for a review and in respect of which a stay of execution pending such appeal or proceeding for review shall have been
secured; 
 (d) Liens incidental to the conduct of business or the ownership of properties and assets (including Liens in
connection with worker’s compensation, unemployment insurance and other like laws, warehousemen’s and attorneys’ liens and statutory landlords’ liens); provided in each case, the obligation secured is not overdue or, if
overdue, is being contested in good faith by appropriate actions or proceedings; and 
 (e) minor survey exceptions or minor
encumbrances, easements or reservations, or rights of others for rights-of-way, utilities and other similar purposes, or zoning or other restrictions as to the use of real properties, which are necessary for the conduct of the activities of the
Company and its Subsidiaries or which customarily exist on properties of corporations engaged in similar activities and similarly situated and which do not in any event materially impair their use in the operation of the business of the Company and
its Subsidiaries. 
 “Permitted Other Secured Indebtedness” is defined in Section 10.1(a)(iv). 
 “Permitted Purchase Money Indebtedness” is defined in Section 10.1(a)(iii). 
 “Permitted Receivables/Inventory Indebtedness” is defined in Section 10.1(a)(iii). 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 15

 “Person” means an individual, partnership, corporation, limited liability company,
association, trust, unincorporated organization, or a government or agency or political subdivision thereof. 
 “Plan” means
an “employee benefit plan” (as defined in Section 3(3) of ERISA) that is or, within the preceding five years, has been established or maintained, or to which contributions are or, within the preceding five years, have been made or
required to be made, by the Company or any ERISA Affiliate or with respect to which the Company or any ERISA Affiliate may have any liability. 
 “Pledge Agreement” means the Stock Pledge Agreement, dated as of the date of the Closing, executed by the Company in favor of the Collateral Agent for the benefit of the Purchasers, pursuant to which the Company shall have
pledged and collaterally assigned 100% of the capital stock of the Borrower as security for the prompt and full payment and performance of the Obligations, and each other pledge agreement executed and delivered by a Credit Party pursuant to
Section 9.7. 
 “Product” means a pharmaceutical product, drug or medication. 
 “property” or “properties” means, unless otherwise specifically limited, real or personal property of any kind,
tangible or intangible, choate or inchoate. 
 “Pro Rata Portion” means, with respect to any holder of a Note upon the
occurrence of a Mandatory Prepayment Event, the amount determined by multiplying the Net Proceeds received in connection with such Mandatory Prepayment Event by a fraction the numerator of which is the aggregate outstanding principal amount of all
Notes held by such holder at such time and the denominator of which is the aggregate outstanding principal amount of all outstanding Notes at such time. 
 “QPAM Exemption” means the Prohibited Transaction Class Exemption 84-14 issued by the United States Department of Labor. 
 “Registration Rights Agreement” means the Registration Rights Agreement, dated the date hereof, between the Company and each applicable Purchaser, in the form of Exhibit J hereto. 

“Related Documents” means this Agreement, the Notes, the Warrants, the Registration Rights Agreement, the Collateral Documents, the
Orphan Asset Transfer Agreement, and each other instrument or document to be delivered hereunder or thereunder or otherwise in connection therewith. 
 “Rentals” means and includes as of the date of any determination thereof all fixed payments (including as such all payments which the lessee is obligated to make to the lessor on termination of the
lease or surrender of the property) payable by the Company or a Subsidiary, as lessee or sublessee under a lease of real or personal property, but shall be exclusive of any amounts required to be paid by the Company or a Subsidiary (whether or not
designated as rents 

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 16

 
or additional rents) on account of maintenance, repairs, insurance, taxes and similar charges. Fixed rents under any so-called “percentage leases”
shall be computed solely on the basis of the minimum rents, if any, required to be paid by the lessee regardless of sales volume or gross revenues. 
 “Responsible Officer” means any Senior Financial Officer and any other officer of the Company with responsibility for the administration of the relevant portion of this Agreement. 
 “Securities” is defined in Section 5.13. 
 “Securities Act” means the Securities Act of 1933, as amended from time to time. 
 “Senior Financial Officer” means the chief financial officer, principal accounting officer, treasurer or controller of the Company. 
 “Settlement Agreements” is defined in Section 5.23. 
 “Subsequent
Closing” is defined in Section 1.3. 
 “Subsequent Closing Exercise Price” is defined in
Section 1.2(b). 
 “Subsidiary” means, as to any Person, any corporation, association or other business entity
in which such Person or one or more of its Subsidiaries or such Person and one or more of its Subsidiaries owns sufficient equity or voting interests to enable it or them (as a group) ordinarily, in the absence of contingencies, to elect a majority
of the directors (or Persons performing similar functions) of such entity, and any partnership or joint venture if more than a 50% interest in the profits or capital thereof is owned by such Person or one or more of its Subsidiaries or such Person
and one or more of its Subsidiaries (unless such partnership can and does ordinarily take major business actions without the prior approval of such Person or one or more of its Subsidiaries). Unless the context otherwise clearly requires, any
reference to a “Subsidiary” is a reference to a Subsidiary of the Company. For the avoidance of doubt, any reference to a Subsidiary of the Company in this Agreement shall mean and include the Borrower and each Subsidiary of the Borrower.

 “Tangible Assets” means as of the date of any determination thereof for any Person, the total amount of all assets of
such Person and its Subsidiaries (less depreciation, depletion and other properly deductible valuation reserves) after deducting, without duplication, good will, patents, trade names, trade marks, copyrights, franchises, experimental expense,
organization expense, unamortized debt discount and expense, deferred assets other than prepaid insurance and prepaid taxes, the excess of cost of shares acquired over book value of related assets and such other assets as are properly classified as
“intangible assets” in accordance with GAAP. 
 “Tranche A Notes” is defined in Section 1.1(a).

 “Tranche B Notes” is defined in Section 1.1(a). 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 17

 “Transferred Orphan Assets” has the meaning set forth in the Orphan Asset Transfer
Agreement. 
 “UCC” means the Uniform Commercial Code as in effect on the date hereof in the State of New York, as amended
from time to time, and any successor statute. 
 “Voting Stock” means Securities of any class or classes, the holders of
which are ordinarily, in the absence of contingencies, entitled to elect a majority of the corporate directors (or Persons performing similar functions). 
 “Warrants” is defined in Section 1.1(b). 
 “Wholly-owned Subsidiary”
means, at any time, any Subsidiary one hundred percent (100%) of all of the equity interests (except directors’ qualifying shares) and voting interests of which are owned by any one or more of the Company and the Company’s other
Wholly-owned Subsidiaries at such time. 
 “Xyrem” means the sodium oxybate pharmaceutical product currently marketed under
the trademark Xyrem and the sodium oxybate pharmaceutical product under development for treatment of fibromyalgia. 
 “Xyrem
Assets” means the Xyrem Intellectual Property and Xyrem Regulatory Approvals. 
 “Xyrem Contracts” means the
contracts set forth on Exhibit H and all other contracts of any Credit Party or Orphan and all amendments thereto, whether now existing or subsequently executed, with third parties related to the formulation, manufacture, packaging,
distribution, marketing and sale of Xyrem as well as the acquisition of all components necessary for the manufacture and packaging of Xyrem. 
 “Xyrem Intellectual Property” means all patents, trademarks, trade dress, copyrights, all rights therein, and any other intellectual property possessed by Orphan and/or any Credit Party and related to the making, using,
selling, marketing, or distribution of Xyrem. 
 “Xyrem License Agreement” is defined in Section 10.2(h). 

“Xyrem Regulatory Approval” means all grants of approval and marketing exclusivity for Xyrem in any jurisdiction by the competent
regulatory body for such jurisdiction. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 18

 Exhibit A-1 
 (to Senior Secured Note and Warrant Purchase Agreement) 
 FORM OF
TRANCHE A NOTE 
 THIS TRANCHE A NOTE IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT UNDER SECTIONS 1272 AND
1273 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED. THE ISSUE PRICE OF THIS TRANCHE A NOTE IS [            ]. FOR FURTHER INFORMATION REGARDING THE ISSUE PRICE, THE AMOUNT OF
ORIGINAL ISSUE DISCOUNT, THE ISSUE DATE AND THE YIELD TO MATURITY OF THE NOTE, PLEASE CONTACT [NAME AND TITLE OF CONTACT PERSON] OF THE BORROWER AT [CONTACT PERSON’S PHONE NUMBER] OR [CONTACT PERSON’S ADDRESS]. 
 THIS TRANCHE A NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND, ACCORDINGLY, MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT. COPIES OF THE AGREEMENT COVERING THE PURCHASE OF THIS TRANCHE A NOTE AND RESTRICTING ITS TRANSFER OR SALE MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD HEREOF TO THE
SECRETARY OF THE BORROWER AT ITS PRINCIPAL EXECUTIVE OFFICES. 
 JPI COMMERCIAL, LLC 
 15% Senior Secured Tranche A Note due             
        , 2011 
  

					
	No.             	 		 	Date
	$            	 		 	

 FOR VALUE RECEIVED, the undersigned, JPI
COMMERCIAL, LLC (herein called the “Borrower”), a corporation organized and existing under the laws of the State of Delaware, hereby promises to pay to
                                        
        , or registered assigns, the principal sum of
                                        
         DOLLARS on                      , 2011, with interest (computed on
the basis of a 360-day year of twelve 30-day months) on the unpaid balance thereof at the rate of 15% per annum from the date hereof, payable quarterly in arrears, on the last day of March, June, September and December in each year, commencing
with June 30, 2008, until the principal hereof shall have become due and payable; provided, however, interest on such unpaid balance shall accrue at the rate of 17% per annum during the continuance of any Event of
Default. 
 Payments of principal of, interest on and any Make-Whole Amount with respect to this Tranche A Note are to be made in lawful
money of the United States of America at such place as the holder of this Tranche A Note shall have designated by written notice to the Borrower as provided in the Note Purchase Agreement referred to below. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 This Tranche A Note is one of a series of Senior Notes (herein called the “Notes”)
issued pursuant to that certain Senior Secured Note and Warrant Purchase Agreement, dated as of March 14, 2008 (as from time to time amended, the “Note Purchase Agreement”), among the Borrower, Jazz Pharmaceuticals, Inc., LB I
Group Inc., as Collateral Agent and a Purchaser, and the other Purchasers named therein and is entitled to the benefits thereof. This Tranche A Note is secured pursuant to the provisions of the Note Purchase Agreement and other Related Documents
(defined in the Note Purchase Agreement) and is entitled to the benefit of the rights and security provided thereby. Each holder of this Tranche A Note will be deemed, by its acceptance hereof, (i) to have agreed to the confidentiality
provisions set forth in Section 20 of the Note Purchase Agreement and (ii) to have made the representations set forth in Section 6 of the Note Purchase Agreement. 
 As provided in the Note Purchase Agreement, upon surrender of this Tranche A Note for registration of transfer, duly endorsed, or accompanied by a
written instrument of transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized in writing, a new Note for a like principal amount will be issued to, and registered in the name of, the transferee. Prior
to due presentment for registration of transfer, the Borrower may treat the person in whose name this Tranche A Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Borrower will not be
affected by any notice to the contrary. 
 The Borrower will make required prepayments of principal on the dates and in the amounts specified
in the Note Purchase Agreement. This Tranche A Note is also subject to optional prepayment, in whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreement, but not otherwise. 
 If an Event of Default, as defined in the Note Purchase Agreement, occurs and is continuing, the principal of this Tranche A Note may be declared or
otherwise become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreement. 
 To the fullest extent permitted by applicable law, the Borrower waives: (a) presentment, demand and protest, and notice of presentment, dishonor, intent to accelerate, acceleration, protest, default, nonpayment,
maturity, release, compromise, settlement, extension or renewal of any or all of the obligations or liabilities under the Note Purchase Agreement or evidenced hereby, (b) all rights to notice and hearing prior to the taking of possession or
control of any collateral (including by way of attachment or replevy), and (c) the benefit of all valuation, appraisal and exemption laws. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 2

 This Tranche A Note shall be construed and enforced in accordance with, and the rights of the parties
shall be governed by, the laws of the State of New York, including Section 5-1401 of the General Obligations Law of said State. 
 BORROWER ACKNOWLEDGES THAT THE BORROWER HAS WAIVED THE RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING ON THIS TRANCHE A NOTE. 
  

			
	JPI COMMERCIAL, LLC
		
	By	 	 
	[Title]	 	

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 3

 Exhibit A-2 
 (to Senior Secured Note and Warrant Purchase Agreement) 
 FORM OF
TRANCHE B NOTE 
 THIS TRANCHE B NOTE IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT UNDER SECTIONS 1272 AND
1273 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED. FOR INFORMATION REGARDING THE ISSUE PRICE, THE AMOUNT OF ORIGINAL ISSUE DISCOUNT, THE ISSUE DATE AND THE YIELD TO MATURITY OF THE NOTE, PLEASE CONTACT [NAME AND TITLE OF CONTACT PERSON] OF THE
BORROWER AT [CONTACT PERSON’S PHONE NUMBER] OR [CONTACT PERSON’S ADDRESS]. 
 THIS TRANCHE B NOTE HAS NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AND, ACCORDINGLY, MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT. COPIES OF THE AGREEMENT COVERING THE PURCHASE OF THIS TRANCHE B NOTE AND RESTRICTING ITS TRANSFER
OR SALE MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD HEREOF TO THE SECRETARY OF THE BORROWER AT ITS PRINCIPAL EXECUTIVE OFFICES. 
 JPI COMMERCIAL, LLC 
 15% Senior Secured Tranche B Note due
                     , 2011 
  

					
	No.             	 		 	Date
	$            	 		 	

 FOR VALUE RECEIVED, the undersigned, JPI
COMMERCIAL, LLC (herein called the “Borrower”), a corporation organized and existing under the laws of the State of Delaware, hereby promises to pay to
            , or registered assigns, the principal sum of              DOLLARS on
                     , 2011, with interest (computed on the basis of a 360-day year of twelve 30-day months) on the unpaid balance
thereof at the rate of 15% per annum from the date hereof, payable quarterly in arrears, on the last day of March, June, September and December in each year, commencing with June 30, 2008, until the principal hereof shall have become
due and payable; provided, however, interest on such unpaid balance shall accrue at the rate of 17% per annum during the continuance of any Event of Default. 
 Payments of principal of, interest on and any Make-Whole Amount with respect to this Tranche B Note are to be made in lawful money of the United States
of America at such place as the holder of this Tranche B Note shall have designated by written notice to the Borrower as provided in the Note Purchase Agreement referred to below. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 

 This Tranche B Note is one of a series of Senior Notes (herein called the “Notes”)
issued pursuant to that certain Senior Secured Note and Warrant Purchase Agreement, dated as of March 14, 2008 (as from time to time amended, the “Note Purchase Agreement”), among the Borrower, Jazz Pharmaceuticals, Inc., LB I
Group Inc., as Collateral Agent and a Purchaser, and the other Purchasers named therein and is entitled to the benefits thereof. This Tranche B Note is secured pursuant to the provisions of the Note Purchase Agreement and other Related Documents
(defined in the Note Purchase Agreement) and is entitled to the benefit of the rights and security provided thereby. Each holder of this Tranche B Note will be deemed, by its acceptance hereof, (i) to have agreed to the confidentiality
provisions set forth in Section 20 of the Note Purchase Agreement and (ii) to have made the representations set forth in Section 6 of the Note Purchase Agreement. 
 As provided in the Note Purchase Agreement, upon surrender of this Tranche B Note for registration of transfer, duly endorsed, or accompanied by a
written instrument of transfer duly executed, by the registered holder hereof or such holder’s attorney duly authorized in writing, a new Note for a like principal amount will be issued to, and registered in the name of, the transferee. Prior
to due presentment for registration of transfer, the Borrower may treat the person in whose name this Tranche B Note is registered as the owner hereof for the purpose of receiving payment and for all other purposes, and the Borrower will not be
affected by any notice to the contrary. 
 The Borrower will make required prepayments of principal on the dates and in the amounts specified
in the Note Purchase Agreement. This Tranche B Note is also subject to optional prepayment, in whole or from time to time in part, at the times and on the terms specified in the Note Purchase Agreement, but not otherwise. 
 If an Event of Default, as defined in the Note Purchase Agreement, occurs and is continuing, the principal of this Tranche B Note may be declared or
otherwise become due and payable in the manner, at the price (including any applicable Make-Whole Amount) and with the effect provided in the Note Purchase Agreement. 
 To the fullest extent permitted by applicable law, the Borrower waives: (a) presentment, demand and protest, and notice of presentment, dishonor, intent to accelerate, acceleration, protest, default, nonpayment,
maturity, release, compromise, settlement, extension or renewal of any or all of the obligations or liabilities under the Note Purchase Agreement or evidenced hereby, (b) all rights to notice and hearing prior to the taking of possession or
control of any collateral (including by way of attachment or replevy), and (c) the benefit of all valuation, appraisal and exemption laws. 
  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 2

 This Tranche B Note shall be construed and enforced in accordance with, and the rights of the parties
shall be governed by, the laws of the State of New York, including Section 5-1401 of the General Obligations Law of said State. 
 BORROWER ACKNOWLEDGES THAT THE BORROWER HAS WAIVED THE RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING ON THIS TRANCHE B NOTE. 
  

			
	JPI COMMERCIAL, LLC
		
	By	 	 
	[Title]	 	

  

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended. 
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]